



Volume 30

Diagnoses of HIV Infection in the United States and Dependent Areas, 2018 (*Preliminary*)

The *HIV Surveillance Report* is published annually by the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through June 2019.

The *HIV Surveillance Report* is not copyrighted and may be used and reproduced without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. *HIV Surveillance Report, 2018 (Preliminary)*; vol. 30. <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published November 2019. Accessed [date].

On the Web: <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>

Confidential information, referrals, and educational material on HIV infection

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

Publication of this report would not have been possible without the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

This report was prepared by the following CDC staff and contractors: Shacara Johnson, André Dailey, Anna Satcher Johnson, Zanetta Gant, Xiaohong Hu, Jianmin Li, Baohua Wu, Chenchen Yu, Chan Jin, Marie Morgan, Michael Friend, Azfar Siddiqi, Angela Hernandez, the HIV Incidence and Case Surveillance Branch, and the Data Management Team of the Quantitative Sciences and Data Management Branch.

Commentary	5
Technical Notes	11
Tables	
Section 1 Diagnoses of HIV Infection and Diagnoses of Infection Classified as Stage 3 (AIDS)	
1a Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2013–2018—United States	17
1b Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2013–2018—United States and 6 dependent areas	18
2a Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2013–2018 and cumulative—United States	19
2b Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2013–2018 and cumulative—United States and 6 dependent areas	20
3a Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2018—United States	21
3b Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2018—United States and 6 dependent areas	22
4a Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2018—United States	23
4b Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2018—United States and 6 dependent areas	24
5a Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2013–2018—United States	25
5b Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2013–2018—United States and 6 dependent areas	26
6a Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2013–2018—United States	27
6b Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2013–2018—United States and 6 dependent areas	28
7a Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2013–2018—United States	29
7b Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas	33
8a Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States	37
8b Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas	41
9a Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States	45
9b Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas	49
10a Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2013–2018—United States	53
10b Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas	57
11a Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States	61
11b Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas	65
12a Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States	69
12b Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas	73
13a Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2013–2018—United States	77
13b Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2013–2018—United States and 6 dependent areas	77
14a Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2013–2018 and cumulative—United States	78
14b Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2013–2018 and cumulative—United States and 6 dependent areas	78

15	Stage 3 (AIDS) among children aged <13 years, by year of diagnosis, 1992–2018—United States and 6 dependent areas	79
16	Diagnoses of HIV infection among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2018—United States and 6 dependent areas	80
17	Stage 3 (AIDS) among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2018—United States and 6 dependent areas	81
Section 2 Deaths after a Diagnosis of HIV Infection or Stage 3 (AIDS) Classification		
18a	Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2013–2017—United States	82
18b	Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2013–2017—United States and 6 dependent areas	84
19a	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2013–2017 and cumulative—United States	86
19b	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2013–2017 and cumulative—United States and 6 dependent areas	88
20a	Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2017—United States	90
20b	Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas	92
21a	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States	94
21b	Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas	96
Section 3 Persons Living with Diagnosed HIV Infection or with Infection Ever Classified as Stage 3 (AIDS) (Prevalence)		
22a	Persons living with diagnosed HIV infection, by year and selected characteristics, 2013–2017—United States	98
22b	Persons living with diagnosed HIV infection, by year and selected characteristics, 2013–2017—United States and 6 dependent areas	100
23a	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2013–2017—United States	102
23b	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2013–2017—United States and 6 dependent areas	104
24a	Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2017—United States	106
24b	Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2017—United States and 6 dependent areas	108
25a	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2017—United States	110
25b	Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2017—United States and 6 dependent areas	112
Section 4 Data by Area of Residence		
26	Diagnoses of HIV infection, by area of residence, 2017 and 2018—United States and 6 dependent areas	114
27	Stage 3 (AIDS), by area of residence, 2017, 2018, and cumulative—United States and 6 dependent areas	115
28	Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2017—United States and 6 dependent areas	117
29	Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2017—United States and 6 dependent areas	119
30	Diagnoses of HIV infection, 2018, and persons living with diagnosed HIV infection (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico	121
31	Stage 3 (AIDS), 2018 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico	124
Web Addresses for Reports of State and Local HIV Surveillance		129

The Centers for Disease Control and Prevention (CDC) collects, analyzes, and disseminates surveillance data on HIV infection; these data are one of the nation's primary sources of information on HIV in the United States. The annual surveillance report, published by the Division of HIV/AIDS Prevention, summarizes information about diagnosed HIV infection in the United States and dependent areas. HIV surveillance data are used by CDC's public health partners in other federal agencies, health departments, nonprofit organizations, academic institutions, and the general public to help focus prevention efforts; plan services; allocate resources; develop policy; detect, monitor, and intervene in HIV clusters; and monitor trends in HIV infection.

This issue of the *HIV Surveillance Report* presents and interprets trends in diagnoses for 2013–2017 and provides preliminary data, based on a 6-month reporting delay, for 2018. Recognizing the changing needs for data, CDC will transition, beginning in 2020, to publishing the annual report earlier in the calendar year and will include data reported to CDC's National HIV Surveillance System (NHSS) through December 31 of the prior year (instead of June 30). The use of data reported to CDC through December will allow for a 12-month reporting lag, and in early 2020, CDC will release a second report of 2018 data that will present and interpret trends in HIV diagnoses through 2018 (the most recent diagnosis year provided). Future editions of the HIV Surveillance Report will be published according to the new time line.

Numbers and rates of diagnoses of HIV infection during 2013–2017 and preliminary numbers for 2018 are based on data from all 50 states, the District of Columbia, and 6 U.S. dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands).

During 2013–2017, the annual rate of diagnoses of HIV infection in the United States decreased; the annual number of diagnoses remained stable. Numbers and rates of diagnoses of HIV infection increased in some subgroups and decreased in others. Variations in trends among groups are expected and may be due to differences in testing behaviors, targeted HIV testing

initiatives, or changes in the numbers of new HIV infections (incidence) in some subgroups. (For slide sets of trends among selected populations [2010–2017], see Additional Resources.)

DEFINITIONS AND DATA SPECIFICATIONS

The term *diagnosis of HIV infection* is defined as a diagnosis of HIV infection regardless of the stage of disease (stage 0, 1, 2, 3 [AIDS], or unknown) and refers to all persons with a diagnosis of HIV infection. The term *HIV infection, stage 3 (AIDS)* and its condensed version—*stage 3 (AIDS)*—refer specifically to persons with diagnosed HIV whose infection was classified as stage 3 (AIDS) during a given year (for diagnoses) or whose infection has ever been classified as stage 3 (AIDS) (for prevalence and deaths). The 2008 surveillance case definition for HIV infection was used to classify cases diagnosed through 2013. The 2014 revised surveillance case definition was used to classify cases diagnosed after 2013. For more information on HIV surveillance case definitions and the stages of HIV infection, please review the Technical Notes.

The data on diagnoses of HIV infection reflect the date of diagnosis (diagnosed by December 31, 2018; reported to CDC as of June 30, 2019), not the date of report to CDC. Similarly, the data specific to stage 3 (AIDS) reflect the first date the criteria for stage 3 (AIDS) were met. HIV diagnoses do not necessarily reflect when a person became infected. HIV surveillance data may not be representative of all persons infected with HIV because not all infected persons have been (1) tested or (2) tested at a time when their infection could be detected and diagnosed. Because of reporting delays, the number of cases diagnosed in a given year may be lower than the numbers presented in later reports; however, fluctuations in the number of diagnoses for a calendar year typically subside after 2 to 3 years of reporting.

HIGHLIGHTS OF ANALYSES

All rates are per 100,000 population. The standard used for reporting trends in numbers and rates is an increase or a decrease of 5% or more during the spec-

ified time frame (e.g., when comparing 2013 and 2017). Exceptions to this standard were made where numbers were small (i.e., less than 12) or rates were based on small numbers. The HIV diagnosis and stage 3 (AIDS) classification data for 2018 are considered preliminary because they are based on a 6-month reporting delay and therefore should not be included when assessing trends.

Please read all table titles and footnotes carefully to ensure a complete understanding of the displayed data.

Diagnoses of HIV Infection and Diagnoses of Infection Classified as Stage 3 (AIDS)

Diagnoses of HIV infection

From 2013 through 2017, the rate of diagnoses of HIV infection in the United States decreased; the annual number of diagnoses remained stable (Table 1a). In 2018, the rate was 11.4.

- **Age group:** From 2013 through 2017, the rates for persons aged 15–19, 25–29, and 30–34 years increased. The rates for children (aged less than 13 years) and persons aged 13–14, 20–24, 40–44, 45–49, 50–54, 55–59, 60–64 years, and 65 years and older decreased. The rate for persons aged 35–39 years remained stable. In 2018, the highest rate (32.5) was for persons aged 25–29 years, followed by the rate (27.6) for persons aged 20–24 years.
- **Race/ethnicity:** From 2013 through 2017, the rates for American Indians/Alaska Natives and Native Hawaiians/other Pacific Islanders increased. The rates for blacks/African Americans, whites, and persons of multiple races decreased. The rates for Asians and Hispanics/Latinos remained stable. In 2018, the highest rate was 39.3 for blacks/African Americans, followed by 16.2 for Hispanics/Latinos, 12.4 for persons of multiple races, 11.8 for Native Hawaiians/other Pacific Islanders, 7.8 for American Indians/Alaska Natives, 4.9 for whites, and 4.7 for Asians.
- **Sex:** From 2013 through 2017, the rates for male and female adults and adolescents decreased. In 2018, males accounted for 81% of all diagnoses of HIV infection among adults and adolescents. The 2018 rate for male adults and adolescents was 22.5; the 2018 rate for females was 5.1.

- **Transmission category:** From 2013 through 2017, among male adults and adolescents, the annual number of diagnosed HIV infections attributed to male-to-male sexual contact *and* injection drug use or to heterosexual contact decreased. The number of infections attributed to male-to-male sexual contact or to injection drug use remained stable. Among female adults and adolescents, the number of infections attributed to heterosexual contact decreased. The number of infections among female adults and adolescents with infection attributed to injection drug use remained stable. In 2018, among all adults and adolescents, the diagnosed infections attributed to male-to-male sexual contact (70%, including 3% male-to-male sexual contact *and* injection drug use) and those attributed to heterosexual contact (24%) accounted for approximately 93% of diagnosed HIV infections in the United States.
- **Region:** From 2013 through 2017, the rate of diagnoses of HIV infection in the Northeast decreased. The rates in the Midwest, the South, and the West remained stable. In 2018, rates were 15.7 in the South, 10.0 in the Northeast, 9.3 in the West, and 7.2 in the Midwest.

Stage 3 (AIDS)

From 2013 through 2017, the annual number and the rate of infections classified as stage 3 (AIDS) in the United States decreased (Table 2a). In 2018, the rate of infections classified as stage 3 (AIDS) was 5.2.

- **Age group:** Because of the change in case definition in 2014, the trend among children (aged less than 13 years) was not assessed. From 2013 through 2017, the rates for age groups including persons 15 years and older decreased. In 2018, the highest rate (10.9) was for persons aged 30–34 years, followed by 10.3 for persons aged 35–39 years. Please use caution when interpreting data for children (aged less than 13 years) and persons aged 13–14 years: the numbers are small.
- **Race/ethnicity:** From 2013 through 2017, the rate for Native Hawaiians/other Pacific Islanders increased. The rates for all other race/ethnicity groups decreased. In 2018, the highest rate was 19.6 for blacks/African Americans, followed by 9.4 for persons of multiple races, 6.5 for Hispanics/Latinos, 3.4 for Native Hawaiians/other

Pacific Islanders, 2.6 for American Indians/Alaska Natives, 2.0 for whites, and 1.8 for Asians.

- **Sex:** From 2013 through 2017, the rates for male and female adults and adolescents decreased. In 2018, males accounted for 76% of all infections classified as stage 3 (AIDS) among adults and adolescents. The 2018 rate for males was 9.6; the 2018 rate for females was 2.9.
- **Transmission category:** From 2013 through 2017, the annual number of infections classified as stage 3 (AIDS) among male adults and adolescents with HIV infection attributed to male-to-male sexual contact, to injection drug use, to male-to-male sexual contact *and* injection drug use, or to heterosexual contact decreased. The number of infections classified as stage 3 (AIDS) among female adults and adolescents with HIV infection attributed to injection drug use or to heterosexual contact decreased. Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
- **Region:** From 2013 through 2017, the rates of infections classified as stage 3 (AIDS) in the 4 regions of the United States decreased. In 2018, rates were 7.2 in the South, 5.1 in the Northeast, 3.7 in the West, and 3.3 in the Midwest.

Deaths

Deaths of persons with diagnosed HIV infection

From 2013 through 2017 in the United States, the number and rate of deaths of persons with diagnosed HIV infection remained stable (Table 18a). In 2017, the rate of deaths of persons with diagnosed HIV infection was 4.9. Deaths of persons with diagnosed HIV infection may be due to any cause (i.e., may or may not be related to HIV infection).

- **Age group:** From 2013 through 2017, the rates of deaths for persons aged 60–64 and 65 years and older increased. The rates of deaths for persons aged 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, and 50–54 years decreased. The rate for persons aged 55–59 years remained stable. Please use caution when interpreting data for children (aged less than 13 years at death) and persons aged 13–14 and 15–19 years: the numbers are small.

- **Race/ethnicity:** From 2013 through 2017, the rate of deaths for Asians increased. The rates for American Indians/Alaska Natives, blacks/African Americans, and Hispanics/Latinos decreased. The rates for whites and persons of multiple races remained stable. In 2017, the highest rate of deaths was for blacks/African Americans: 17.4. Please use caution when interpreting data for Native Hawaiians/other Pacific Islanders: the numbers are small.
- **Sex and transmission category:** From 2013 through 2017, the rate of deaths for male adults and adolescents remained stable. The number of deaths among males with diagnosed HIV infection attributed to male-to-male sexual contact or to perinatal transmission increased. The number of deaths among males with infection attributed to injection drug use decreased. The numbers of deaths among males attributed to male-to-male sexual contact *and* injection drug use or to heterosexual contact remained stable. Overall, the rate of deaths for female adults and adolescents decreased. The number of deaths among female adults and adolescents with infection attributed to perinatal transmission increased. The number of deaths among females with infection attributed to injection drug use decreased. The number of deaths among females with infection attributed to heterosexual contact remained stable. Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
- **Region:** From 2013 through 2017, the rate of deaths in the Northeast decreased. The rates of deaths in the South, the West, and the Midwest remained stable. In 2017, rates were 6.5 in the Northeast, 6.4 in the South, 3.4 in the West, and 2.7 in the Midwest.

Deaths of persons with infection ever classified as stage 3 (AIDS)

From 2013 through 2017 in the United States, the annual number and rate of deaths of persons with infection ever classified as stage 3 (AIDS) remained stable (Table 19a). In 2017, the rate of deaths of persons with stage 3 (AIDS) was 3.9. Deaths of persons with stage 3 (AIDS) may be due to any cause.

- **Age group:** From 2013 through 2017, the rates of deaths among persons aged 60–64 and 65 years and older increased. Rates of deaths among persons aged 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, and 50–54 years decreased. Rates among persons aged 55–59 years remained stable. Please use caution when interpreting data for children (aged less than 13 years) and persons aged 13–14 and 15–19 years: the numbers are small.
- **Race/ethnicity:** From 2013 through 2017, the rates of deaths for American Indians/Alaska Natives, blacks/African Americans, Hispanics/Latinos, whites, and persons of multiple races decreased. The rate of deaths for Asians remained stable. In 2017, the highest death rate was for blacks/African Americans: 13.7. Please use caution when interpreting data for Native Hawaiians/other Pacific Islanders: the numbers are small.
- **Sex and transmission category:** From 2013 through 2017, the rate of deaths for male adults and adolescents remained stable. The number of deaths among males with infection attributed to perinatal transmission increased. The number of deaths among males with infection attributed to injection drug use decreased. The numbers of deaths among males with infection attributed to male-to-male sexual contact, male-to-male sexual contact *and* injection drug use, or heterosexual contact remained stable. Overall, the rate of deaths for female adults and adolescents decreased. The number of deaths among female adults and adolescents with infection attributed to perinatal transmission increased. Among female adults and adolescents with infection attributed to injection drug use or to heterosexual contact, the number of deaths decreased. Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
- **Region:** From 2013 through 2017, the rates of deaths in the Northeast and the South decreased. The rates of deaths in the Midwest and the West remained stable. In 2017, rates were 5.1 in the Northeast, 5.0 in the South, 2.8 in the West, and 2.1 in the Midwest.

Prevalence: Persons Living with Diagnosed HIV Infection and Persons Living with Infection Ever Classified as Stage 3 (AIDS)

Prevalence of diagnosed HIV infection

From 2013 through 2017, the number and rate of persons in the United States living with diagnosed HIV infection increased (Table 22a). At year-end 2017, 1,003,782 persons in the United States were living with diagnosed HIV infection. The prevalence of diagnosed HIV infection was 308.7.

- **Age group:** At year-end 2017, persons aged 50–54 years made up the largest percentage (16%) of persons living with diagnosed HIV. The highest rate (767.8) was among persons aged 50–54 years, followed by those aged 55–59 (660.6), and those aged 45–49 (625.6). From 2013 through 2017, the largest percentage increase in rates (53%) was among persons aged 65 years and older (from 115.6 in 2013 to 177.3 in 2017).
- **Race/ethnicity:** At year-end 2017, the highest rate (1,022.0) and the largest percentage (41%) were those for blacks/African Americans. Among the remaining race/ethnicity groups, the rates were 675.9 for persons of multiple races, 379.3 for Hispanics/Latinos, 152.1 for whites, 145.6 for Native Hawaiians/other Pacific Islanders, 126.2 for American Indians/Alaska Natives, and 78.1 for Asians.
- **Sex and transmission category:** At year-end 2017, the rates were 574.4 for male adults and adolescents, 169.9 for female adults and adolescents, and 3.9 for children (aged less than 13 years at year-end 2017). Among a total of 765,129 males (aged 13 years and older at year-end 2017), 72% of infections were attributed to male-to-male sexual contact, 10% to heterosexual contact, 9% to injection drug use, 7% to male-to-male sexual contact *and* injection drug use, and 1% to perinatal transmission. Among a total of 236,589 females (aged 13 years and older at year-end 2017), 76% of infections were attributed to heterosexual contact, 21% to injection drug use, and 2% to perinatal transmission. Among a total of 2,064 children (aged less than 13 years at year-end 2017), 81% of infections were attributed to perinatal transmission.

- **Region:** From 2013 through 2017, the rates of persons living with HIV in the 4 regions of the United States increased: the largest percentage increase in the rate (11%) was in the Midwest (from 159.1 in 2013 to 176.0 in 2017). At year-end 2017, the rate was highest in the Northeast at 417.2, followed by 365.5 in the South, 256.2 in the West, and 176.0 in the Midwest.

Prevalence of stage 3 (AIDS)

From 2013 through 2017, the number and rate of persons living with infection ever classified as stage 3 (AIDS) remained stable (Table 23a). At year-end 2017, 524,904 persons in the United States were living with infection ever classified as stage 3 (AIDS). The prevalence of infections classified as stage 3 (AIDS) was 161.4.

- **Age group:** At year-end 2017, the highest rate (469.0) and the largest percentage (19%) were those for persons aged 50–54 years, followed by persons aged 55–59 (421.7 and 18%, respectively). From 2013 through 2017, the largest percentage increase in rates (51%) was among persons aged 65 years and older (from 77.5 in 2013 to 116.9 in 2017).
- **Race/ethnicity:** At year-end 2017, the highest rate (530.6) and the largest percentage (41%) were those for blacks/African Americans. Among the remaining race/ethnicity groups, the rates were 390.7 for persons of multiple races, 205.8 for Hispanics/Latinos, 77.6 for whites, 70.4 for Native Hawaiians/other Pacific Islanders, 61.4 for American Indians/Alaska Natives, and 35.3 for Asians.
- **Sex and transmission category:** At year-end 2017, the rates were 300.4 for male adults and adolescents, 89.4 for female adults and adolescents, and 0.5 for children (aged less than 13 years at year-end 2017). Among a total of 400,084 males (aged 13 years and older at year-end 2017), 67% of infections were attributed to male-to-male sexual contact, 12% to heterosexual contact, 12% to injection drug use, 9% to male-to-male sexual contact *and* injection drug use, and 1% to perinatal transmission. Among a total of 124,538 females (aged 13 years and older at year-end 2017), 73% of infections were attributed to heterosexual contact, 24% to injection

drug use, and 2% to perinatal transmission. Among a total of 282 children (aged less than 13 years at year-end 2017), 86% of infections were attributed to perinatal transmission.

- **Region:** At year-end 2017, the rate was highest in the Northeast at 233.8, followed by 185.9 in the South, 135.3 in the West, and 87.1 in the Midwest.

ADDITIONAL RESOURCES

The following were prepared by using HIV surveillance data:

- *MMWR* articles (selected): <http://www.cdc.gov/hiv/library/reports/mmwr.html>
- Other surveillance reports: <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>
- Public-use slides updated annually: <http://www.cdc.gov/hiv/library/slidesets/>
- NCHHSTP AtlasPlus [interactive tool for accessing HIV/AIDS, STD, TB, and hepatitis data]: <http://www.cdc.gov/nchhstp/atlas/>

SUGGESTED READINGS

- CDC. Establishing a holistic framework to reduce inequities in HIV, viral hepatitis, STDs, and tuberculosis in the United States. <http://stacks.cdc.gov/view/cdc/11585>. Published October 2010. Accessed October 7, 2019.
- CDC. Estimated HIV incidence and prevalence in the United States, 2010–2016. *HIV Surveillance Supplemental Report* 2019;24(No. 1). <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published February 2019. Accessed October 7, 2019.
- CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2017. *HIV Surveillance Supplemental Report* 2019; 24(No. 3). <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published June 2019. Accessed October 7, 2019.

CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case definition for HIV infection—United States, 2014. *MMWR* 2014;63(RR-03):1–10. http://www.cdc.gov/mmwr/indrr_2014.html. Accessed October 7, 2019.

CDC [Schneider E, Whitmore S, Glynn MK, Dominguez K, Mitsch A, McKenna MT]. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. *MMWR* 2008;57(RR-10):1–12. http://www.cdc.gov/mmwr/indrr_2008.html. Accessed October 7, 2019.

CDC [Dailey AF, Hoots BE, Hall HI, et al]. Vital Signs: Human immunodeficiency virus testing and diagnosis delays—United States. *MMWR* 2017;66(47):1300–1306. <http://www.cdc.gov/mmwr/volumes/66/wr/mm6647e1.htm>. Accessed October 7, 2019.

Cohen SM, Gray KM, Ocfemia MC, Johnson AS, Hall HI. The status of the National HIV Surveillance System, United States, 2013. *Public Health Rep* 2014;129(4):335–341. doi:10.1177/003335491412900408.

Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic: a plan for the United States [editorial]. *JAMA* 2019;321(9):844–845. doi:10.1001/jama.2019.1343.

Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. *Ann Epidemiol* 2018;28(12):850–857. doi:10.1016/j.annepidem.2018.05.003.

SURVEILLANCE OF HIV INFECTION

This report includes case report data from 50 states, the District of Columbia, and 6 U.S. dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands) in which laws or regulations require confidential reporting to the jurisdiction (not to CDC), by name, for adults, adolescents, and children with confirmed diagnoses of HIV infection. After the removal of personally identifiable information, data from these reports were submitted to CDC. Although AIDS cases have been reported to CDC since 1981, the date of implementation of HIV infection reporting has differed from jurisdiction to jurisdiction. All states, the District of Columbia, and 6 U.S. dependent areas had fully implemented name-based HIV infection reporting by April 2008.

Please use caution when interpreting data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection. In addition, testing patterns are influenced by many factors, including the extent to which testing is routinely offered to specific groups and the availability of, and access to, medical care and testing services. The data presented in this report provide minimum counts of persons for whom HIV infection has been diagnosed and reported to the surveillance system. Although all jurisdictions use a uniform case report form, surveillance practices in data collection and updating of case records may differ among jurisdictions. Agreements between CDC and state/local HIV surveillance programs regarding the release of data require the suppression of small numbers to ensure the confidentiality of personally identifiable information.

Based on annual standard evaluation results, the completeness of reporting of HIV infection, as of December 2018, is estimated to be at least 85% in all but 3 jurisdictions [1].

STAGES OF HIV INFECTION

Both the 2008 and 2014 HIV case definitions were used to classify HIV infection among adults and adolescents and among children [2, 3]. In the following lists, some bulleted items are paraphrases, not quotations from the published surveillance case definitions. The intention is to emphasize the differences between the 2008 and 2014 case definitions.

The 2008 case definition was used to classify cases diagnosed through 2013. For adults and adolescents, this definition incorporates an HIV infection staging system that includes AIDS (HIV infection, stage 3). The 2008 stages of HIV infection are defined as follows:

- **HIV infection, stage 1:** No AIDS-defining opportunistic illness (OI) and either CD4+ T-lymphocyte (CD4 lymphocyte) count of ≥ 500 cells/ μ L or CD4 percentage of total lymphocytes of ≥ 29 .
- **HIV infection, stage 2:** No AIDS-defining OI and either CD4 lymphocyte count of 200–499 cells/ μ L or CD4 percentage of total lymphocytes of 14–28.
- **HIV infection, stage 3 (AIDS):** Documentation of an AIDS-defining OI or either a CD4 lymphocyte count of < 200 cells/ μ L or CD4 percentage of total lymphocytes of < 14 . Documentation of an AIDS-defining OI supersedes a CD4 lymphocyte count or percentage that would not, by itself, be the basis for a stage 3 (AIDS) classification.
- **HIV infection, stage unknown:** No reported information on AIDS-defining OIs and no information available on CD4 lymphocyte count or percentage.

The 2014 case definition was used to classify cases diagnosed in 2014 and later. It is similar to the 2008 case definition except for the following:

1. inclusion of criteria for stage 0
2. inclusion of CD4 lymphocyte testing criteria for stage 3 in children
3. changes in the cutoffs for CD4 percentage of total lymphocytes used for classification of stages 1 and 2 in persons aged 6 years and older [3]

The stages of HIV infection in the 2014 case definition are based on age-specific CD4 lymphocyte counts or percentages of total lymphocytes and are defined as follows:

- **HIV infection, stage 0:** Negative (nonreactive) or indeterminate HIV-1 test result within 180 days before the first positive HIV-1 test result, or the presence of HIV-specific viral markers (e.g., p24 antigen or nucleic acid [RNA or DNA]) 0–180 days before or after an antibody test that had a negative or an indeterminate result. Although the stage of disease at diagnosis does not change, if 180 days elapse after the stage was 0 at diagnosis and the current stage of disease has not been reclassified to 1, 2, or 3 because of further testing (i.e., CD4+ T-lymphocyte test results) or because of an opportunistic illness diagnosed >180 days after the HIV infection diagnosis, the current stage of disease is classified as unknown.
- **HIV infection, stages 1, 2, and 3:** Documentation of an AIDS-defining OI (excluding stage 0 as described above) is stage 3. Otherwise, the stage is determined by the lowest CD4 lymphocyte test result [3, p 7].
- **HIV infection, stage unknown:** No reported information on AIDS-defining OIs and no information available on CD4 lymphocyte count or percentage.

The transition to CD4 lymphocyte–based criteria for stage 3 (AIDS) among children has resulted in an increase in the number of annual stage 3 (AIDS) classifications among pediatric cases diagnosed after 2013. Before implementation of the 2014 revised case definition, an OI diagnosis was required for a pediatric case to meet the criteria for stage 3 classification.

In this report, the term *diagnosis of HIV infection* is defined as a diagnosis of HIV infection regardless of the stage of disease (stage 0, 1, 2, 3 [AIDS], or unknown) and refers to all persons with a diagnosis of HIV infection. The term HIV infection, *stage 3 (AIDS)* and its condensed version—*stage 3 (AIDS)*—refer specifically to persons with diagnosed HIV whose infection was classified as stage 3 (AIDS) during a given year (for diagnoses) or whose infection has ever been classified as stage 3 (AIDS) (for prevalence and deaths).

TABULATION AND PRESENTATION OF DATA

The data in this report include information received by CDC through June 30, 2019. The data are organized into 4 sections.

- Section 1 (Tables 1a/b–17): numbers and rates of diagnoses of HIV infection (any stage) and diagnoses of infection classified as stage 3 (AIDS)
- Section 2 (Tables 18a/b–21a/b): numbers and rates of deaths among persons with diagnosed HIV infection (any stage) and persons with infection ever classified as stage 3 (AIDS)
- Section 3 (Tables 22a/b–25a/b): numbers and rates of persons living with diagnosed HIV infection (any stage) and persons living with infection ever classified as stage 3 (AIDS) (i.e., prevalence)
- Section 4 (Tables 26–31): numbers and rates of diagnoses and prevalence of HIV infection (any stage) and diagnoses and prevalence of infection classified as stage 3 (AIDS), presented by state and metropolitan statistical area (MSA)

Many tables in the 2018 report present data in 2 formats. Tables in the first format—labeled “a”—exclude data from the dependent areas (American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands). Tables in the second format—labeled “b”—include data from the dependent areas.

Please use caution when interpreting numbers less than 12, and rates and trends based on these numbers.

Numbers of diagnoses for the most recent year (2018) are considered preliminary. Please use caution when interpreting these numbers, and do not include them when assessing trends.

Diagnoses of HIV Infection and Classifications of Stage 3 (AIDS)

This report is based on diagnoses of HIV infection that the 50 states, the District of Columbia, and 6 U.S. dependent areas reported to CDC as of June 30, 2019. The data reflect numbers and rates of diagnoses of HIV infection (Tables 1a/b, 3a/b, 5a/b, 7a/b–9a/b, 13a/b, and 26) and classifications of stage 3 (AIDS) (Tables 2a/b, 4a/b, 6a/b, 10a/b–12a/b, 14a/b, 15, and 27), by selected characteristics and area of residence. For tables presenting diagnosis data, region or area of residence reflects the address at the time of HIV diagnosis or at the time of stage 3 (AIDS) classification,

with the exception of Tables 16 and 17, which present numbers and percentages of diagnoses of HIV infection (Table 16) and classifications of stage 3 (AIDS) (Table 17) among Hispanics/Latinos by transmission category and place of birth.

Deaths

Persons reported to the National HIV Surveillance System are assumed alive unless their deaths have been reported to CDC. Death data include deaths of persons with diagnosed HIV infection (Tables 18a/b and 20a/b) or with infection ever classified as stage 3 (AIDS) (Tables 19a/b and 21a/b) regardless of the cause of death. Because of delays in the reporting of deaths, only 5 years (2013–2017) of death data are displayed. The exclusion of data from the most recent year allowed at least 18 months for deaths to be reported to CDC. For the death tables, region or area of residence is based on residence at death. When information on residence at death is not available, the state where a person's death occurred is used.

Prevalence: Persons Living with Diagnosed HIV Infection and Persons Living with Infection Ever Classified as Stage 3 (AIDS)

Because of delays in the reporting of deaths, only 5 years of prevalence data are displayed. The data reflect persons living with diagnosed HIV infection, regardless of stage of disease (Tables 22a/b, 24a/b, 28, and 30), and persons living with infection ever classified as stage 3 (AIDS) (Tables 23a/b, 25a/b, 29, and 31) at the end of a given year during 2013–2017. The exclusion of data from the most recent year allowed at least 18 months for deaths to be reported and for these deaths to be factored into calculations of prevalence. For tables presenting prevalence data, region or area of residence is based on most recent known address as of the end of the specified year.

Age

The designation “adults and adolescents” refers to persons aged 13 years and older; the designation “children” refers to persons aged less than 13 years. For presentations of data on persons living with diagnosed HIV infection (Tables 22a/b, 24a/b, and 28) and presentations of data on persons living with infection classified as stage 3 (AIDS) (Tables 23a/b, 25a/b,

and 29), the age-group assignment (e.g., 20–24 years) or the age designation (e.g., “adults and adolescents”) is based on the person's age as of December 31 of the specified year. For presentations of data on deaths of persons with diagnosed HIV infection (Tables 18a/b and 20a/b) and deaths of persons with infection classified as stage 3 (AIDS) (Tables 19a/b and 21a/b), age-group assignment is determined by the person's age at the time of death. For all other tables, the age designation or the specific age-group assignment is based on the person's age at the time of HIV diagnosis or at the time of stage 3 (AIDS) classification.

Age-group designations for transmission categories in tables displaying data on prevalence and on deaths are based on a person's age at the end of the specified year or age at death, respectively. The transmission categories among “adults and adolescents” in these tables include persons who were children at the time of diagnosis but who were aged 13 years and older during the specified year or at death.

Sex

Sex designations in this report are based on a person's sex at birth. *Transgender* is an umbrella term that is used to identify persons whose sex assigned at birth does not match current gender identity or expression. Data for transgender persons are not presented in this report because information on gender identity (a person's internal understanding of his or her gender or the gender with which a person identifies) is not consistently collected or documented in the data sources used by HIV reporting jurisdictions. HIV surveillance personnel collect data on gender identity, when available, from sources such as case report forms submitted by health care or HIV testing providers and medical records, or by matching with other health department databases (e.g., Ryan White program data). In May 2012, CDC issued guidance to state and local programs on methods for collecting data on transgender persons and working with transgender-specific data. However, characterization of HIV infection among transgender persons may require supplemental data from special studies.

Race and Ethnicity

In the *Federal Register* [4] for October 30, 1997, the Office of Management and Budget (OMB) announced the Revisions to the Standards for the Classification of

Federal Data on Race and Ethnicity. Implementation by January 1, 2003, was mandated. At a minimum, data on the following race categories should be collected:

- American Indian or Alaska Native
- Asian
- black or African American
- Native Hawaiian or other Pacific Islander
- white

Additionally, systems must be able to retain information when multiple race categories are reported. In addition to data on race, data on 2 categories of ethnicity should be collected:

- Hispanic or Latino
- not Hispanic or Latino

The Asian or Pacific Islander category displayed in annual surveillance reports published prior to the 2007 surveillance report was split into 2 categories:

(1) Asian and (2) Native Hawaiian or other Pacific Islander. The Asian category (in tables where footnoted) includes the cases in Asians/Pacific Islanders (referred to as legacy cases) that were reported before the implementation of the new race categories in 2003 (e.g., cases of HIV infection that were diagnosed and reported to CDC before 2003 but that were classified as stage 3 [AIDS] after 2003) and a small percentage of cases that were reported after 2003 but that were reported according to the old race category (Asian/Pacific Islander). In tables of diagnoses of HIV infection during 2013–2018, the Asian category does not include Asian/Pacific Islander cases because these cases were diagnosed after 2003 and were reported to CDC in accordance with OMB's Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity [4].

This report also presents data for persons for whom multiple race categories are reported. In this report, persons categorized by race were not Hispanic or Latino. The number of persons reported in each race category may, however, include persons whose ethnicity was not reported.

Geographic Designations

For tables that present number of diagnoses (Tables 1a/b–17, 26, 27, 30, 31), residence is based on address at the time of diagnosis of HIV infection or at the time of classification of stage 3 (AIDS). For tables present-

ing prevalence data (22a/b–25a/b, 28–31), residence is based on most recent known address as of the end of the specified year. For the death tables (18a/b–21a/b), residence is based on residence at death. When information on residence at death is not available, the state where a person's death occurred is used.

The 4 regions of residence used in this report are defined by the U.S. Census Bureau as follows:

Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont

Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin

South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia

West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming

U.S. dependent areas: American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the U.S. Virgin Islands

Metropolitan Statistical Areas

In the *Federal Register* for June 28, 2010, OMB published revised standards for defining MSAs in federal statistical activities [5]. These standards, which provided for the identification of MSAs in the United States and Puerto Rico, replaced the 2000 standards. The adoption of the new standards was effective as of June 28, 2010. On August 15, 2017, OMB announced updated MSA delineations based on the Census 2010 data [6]. Tables 30 (data on diagnosed HIV infection) and 31 (data on stage 3 [AIDS]) present numbers and rates of diagnoses and prevalence, by MSA, for areas with populations of 500,000 or more. The MSAs listed in these tables were defined according to OMB's update (August 2017) of statistical areas [6].

Transmission Categories

Transmission category is the term for the classification of cases that summarizes a person's possible HIV risk factors; the summary classification results from selecting, from the presumed hierarchical order of probability, the 1 (single) risk factor most likely to

have been responsible for transmission. For surveillance purposes, a diagnosis of HIV infection is counted only once in the hierarchy of transmission categories. Persons with more than 1 reported risk factor for HIV infection are classified in the transmission category listed first in the hierarchy. The exception is men who had sexual contact with other men and injected drugs; this group makes up a separate transmission category.

Persons whose transmission category is classified as male-to-male sexual contact include men who have ever had sexual contact with other men (i.e., homosexual contact) and men who have ever had sexual contact with both men and women (i.e., bisexual contact). Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

Tables of prevalence data and tables of death data include a separate transmission category of adults and adolescents with HIV infection attributed to perinatal transmission. The category includes persons infected through perinatal transmission but aged 13 years and older during the specified year or at death.

Cases of HIV infection reported without a risk factor listed in the hierarchy of transmission categories are classified as “no identified risk (NIR).” Cases classified as NIR include cases that are being followed up by local health department staff; cases in persons whose risk-factor information is missing because they died, declined to be interviewed, or were lost to follow-up; and cases in persons who were interviewed or for whom other follow-up information was available but for whom no risk factor was identified.

Because a substantial proportion of cases of HIV infection are reported to CDC without an identified risk factor, multiple imputation is used to assign a transmission category [7]. Multiple imputation is a statistical approach in which each missing transmission category is replaced with a set of plausible values that represent the uncertainty about the true, but missing, value [8]. Each resulting data set containing the plausible values is analyzed by using standard procedures, and the results from these analyses are then combined to produce the final results. In tables displaying transmission categories, multiple imputation was used for

adults and adolescents, but not for children, because the number of cases in children is small.

Rates

Rates per 100,000 population were calculated for (1) the numbers of diagnoses of HIV infection and the numbers of infections classified as stage 3 (AIDS), (2) the numbers of deaths of persons with diagnosed HIV infection and deaths of persons with infection ever classified as stage 3 (AIDS), and (3) the numbers of persons living with diagnosed HIV infection and persons living with infection ever classified as stage 3 (AIDS).

The population denominators used to compute the rates for the 50 states, the District of Columbia, and Puerto Rico were based on the Vintage 2018 postcensal estimates file (for years 2013–2018) from the U.S. Census Bureau [9]. The population denominators for American Samoa, Guam, the Northern Mariana Islands, the Republic of Palau, and the U.S. Virgin Islands were based on estimates and projections from the U.S. Census Bureau’s International Data Base [10]. Each rate was calculated by dividing the total number of diagnoses (or deaths or prevalence) for the calendar year by the population for that calendar year and then multiplying the result by 100,000. The denominators used for calculating the rates specific to age, sex, and race/ethnicity were computed by applying the appropriate vintage estimates for age, sex, and race/ethnicity for the 50 states and the District of Columbia [9]. The same method was used to calculate the denominators for Puerto Rico, with the exception of race/ethnicity estimates; these data are not available for Puerto Rico (see next paragraph). For the other 5 U.S. dependent areas, estimates from the U.S. Census Bureau’s International Data Base were used for age- and sex-specific population denominators [10].

CDC currently does not provide subpopulation rates by race/ethnicity for the 6 U.S. dependent areas because the U.S. Census Bureau does not collect information from all dependent areas. Rates for transmission categories are not provided in this report because of the absence of denominator data from the U.S. Census Bureau, the source of data used for calculating all rates in this report.

REFERENCES

1. Karch DL, Chen M, Tang T. Evaluation of the National Human Immunodeficiency Virus Surveillance System for the 2011 diagnosis year. *J Public Health Manag Pract* 2014;20(6):598–607. doi: 10.1097/PHH.0000000000000033.
2. CDC [Schneider E, Whitmore S, Glynn MK, Dominguez K, Mitsch A, McKenna MT]. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. *MMWR* 2008;57(RR-10):1–12.
3. CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case definition for HIV infection—United States, 2014. *MMWR* 2014;63(RR-03):1–10.
4. Office of Management and Budget. Revisions to the standards for the classification of federal data on race and ethnicity. *Federal Register* 1997;62:58782–58790. <http://go.usa.gov/xPg4F>. Accessed October 7, 2019.
5. Office of Management and Budget. 2010 Standards for delineating metropolitan and micropolitan statistical areas. *Federal Register* 2010;75(123):37246–39052. <https://go.usa.gov/xn43u>. Accessed October 7, 2019.
6. Office of Management and Budget. Revised delineations of metropolitan statistical areas, micropolitan statistical areas, and combined statistical areas, and guidance on uses of the delineations of these areas. OMB Bulletin 17-01. <https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2017/b-17-01.pdf>. Published August 15, 2017. Accessed October 7, 2019.
7. Harrison KM, Kajese T, Hall HI, Song R. Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach. *Public Health Rep* 2008;123(5):618–627.
8. Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. New York: John Wiley & Sons Inc; 1987.
9. U.S. Census Bureau. Population and Housing Unit Estimates Datasets. <https://go.usa.gov/xn4cc>. Accessed October 7, 2019.
10. U.S. Census Bureau. International Data Base. <https://www.census.gov/data-tools/demo/idb/>. Updated September 2018. Accessed October 7, 2019.

Table 1a. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2013–2018—United States

	2013		2014		2015		2016		2017		2018	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at diagnosis (yr)												
<13	184	0.3	181	0.3	143	0.3	127	0.2	103	0.2	91	0.2
13–14	40	0.5	32	0.4	25	0.3	26	0.3	28	0.3	19	0.2
15–19	1,693	8.0	1,730	8.2	1,757	8.3	1,703	8.1	1,763	8.4	1,688	8.0
20–24	7,026	30.8	7,363	32.2	7,279	32.1	6,911	30.9	6,454	29.2	6,027	27.6
25–29	6,634	30.8	7,193	32.8	7,584	33.8	7,949	34.7	7,709	33.0	7,653	32.5
30–34	5,187	24.4	5,430	25.2	5,455	25.2	5,643	25.9	5,637	25.7	5,669	25.6
35–39	3,950	20.1	4,223	21.2	4,256	20.9	4,239	20.4	4,274	20.2	4,186	19.4
40–44	3,923	18.8	3,778	18.4	3,407	16.9	3,264	16.6	2,971	15.2	2,972	15.1
45–49	3,905	18.4	3,610	17.3	3,313	15.9	3,090	14.8	2,945	14.1	2,831	13.6
50–54	2,950	13.1	2,886	12.8	2,997	13.5	2,878	13.2	2,649	12.4	2,451	11.7
55–59	2,000	9.4	1,920	8.9	1,876	8.6	1,883	8.6	1,862	8.5	1,872	8.5
60–64	1,066	5.9	968	5.2	997	5.2	1,080	5.5	1,075	5.4	1,038	5.1
≥65	856	1.9	830	1.8	850	1.8	854	1.7	859	1.7	880	1.7
Race/ethnicity												
American Indian/Alaska Native	144	6.2	178	7.6	185	7.8	222	9.3	212	8.8	189	7.8
Asian	788	4.9	905	5.4	925	5.4	960	5.4	936	5.1	874	4.7
Black/African American	17,050	43.6	17,314	43.8	17,270	43.3	17,110	42.5	16,491	40.6	16,067	39.3
Hispanic/Latino ^b	9,077	16.8	9,651	17.5	9,756	17.3	9,990	17.4	9,716	16.5	9,673	16.2
Native Hawaiian/Other Pacific Islander	45	8.4	43	7.9	72	13.0	41	7.2	54	9.4	69	11.8
White	10,484	5.3	10,451	5.3	10,275	5.2	10,009	5.1	9,822	5.0	9,620	4.9
Multiple races	1,826	29.5	1,602	25.1	1,456	22.2	1,315	19.5	1,098	15.8	885	12.4
Transmission category^c												
Male adult or adolescent												
Male-to-male sexual contact	25,467	—	26,428	—	26,387	—	26,090	—	25,404	—	24,650	—
Injection drug use	1,334	—	1,255	—	1,304	—	1,204	—	1,308	—	1,430	—
Male-to-male sexual contact and injection drug use	1,432	—	1,395	—	1,432	—	1,409	—	1,347	—	1,305	—
Heterosexual contact ^d	3,350	—	3,271	—	3,248	—	3,293	—	2,850	—	2,727	—
Other ^e	42	—	34	—	37	—	27	—	33	—	35	—
Subtotal	31,624	24.6	32,383	24.9	32,407	24.7	32,023	24.2	30,942	23.2	30,147	22.5
Female adult or adolescent												
Injection drug use	999	—	966	—	1,025	—	988	—	1,035	—	1,048	—
Heterosexual contact ^d	6,562	—	6,582	—	6,336	—	6,465	—	6,206	—	6,051	—
Other ^e	45	—	32	—	29	—	43	—	43	—	41	—
Subtotal	7,606	5.6	7,580	5.6	7,389	5.4	7,497	5.4	7,284	5.2	7,139	5.1
Child (<13 yrs at diagnosis)												
Perinatal	125	—	138	—	111	—	103	—	84	—	66	—
Other ^f	59	—	43	—	32	—	24	—	19	—	25	—
Subtotal	184	0.3	181	0.3	143	0.3	127	0.2	103	0.2	91	0.2
Region of residence^g												
Northeast	6,937	12.4	6,919	12.4	6,476	11.6	6,225	11.1	5,988	10.7	5,588	10.0
Midwest	5,287	7.8	5,121	7.6	5,243	7.7	5,183	7.6	5,094	7.5	4,933	7.2
South	19,900	16.8	20,248	16.9	20,395	16.9	20,263	16.6	19,721	16.0	19,585	15.7
West	7,290	9.8	7,856	10.5	7,825	10.3	7,976	10.4	7,526	9.7	7,271	9.3
Total	39,414	12.5	40,144	12.6	39,939	12.5	39,647	12.3	38,329	11.8	37,377	11.4

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Data for the year 2018 should not be used when assessing trends.

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^b Hispanics/Latinos can be of any race.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2013–2018—United States and 6 dependent areas

	2013		2014		2015		2016		2017		2018	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at diagnosis (yr)												
<13	184	0.3	181	0.3	143	0.3	127	0.2	103	0.2	91	0.2
13–14	41	0.5	32	0.4	25	0.3	26	0.3	28	0.3	19	0.2
15–19	1,712	8.0	1,755	8.2	1,763	8.3	1,716	8.0	1,775	8.3	1,703	8.0
20–24	7,114	30.8	7,481	32.3	7,360	32.1	6,986	30.9	6,517	29.2	6,085	27.5
25–29	6,718	30.8	7,287	32.8	7,679	33.9	8,020	34.6	7,773	33.0	7,734	32.5
30–34	5,277	24.5	5,492	25.3	5,514	25.2	5,708	25.9	5,700	25.7	5,724	25.6
35–39	4,016	20.2	4,295	21.3	4,325	21.0	4,310	20.5	4,326	20.2	4,218	19.4
40–44	3,989	18.9	3,854	18.5	3,470	17.0	3,321	16.7	3,008	15.2	3,019	15.1
45–49	3,989	18.6	3,669	17.4	3,379	16.1	3,148	14.9	2,988	14.1	2,873	13.7
50–54	3,022	13.2	2,932	12.9	3,054	13.6	2,924	13.2	2,700	12.5	2,504	11.9
55–59	2,044	9.5	1,965	9.0	1,908	8.7	1,933	8.7	1,896	8.5	1,902	8.6
60–64	1,101	6.0	996	5.3	1,014	5.3	1,104	5.6	1,095	5.4	1,058	5.1
≥65	884	2.0	857	1.8	880	1.8	878	1.8	880	1.7	902	1.7
Race/ethnicity												
American Indian/Alaska Native	144	—	178	—	185	—	222	—	212	—	189	—
Asian	788	—	907	—	929	—	961	—	939	—	878	—
Black/African American	17,066	—	17,331	—	17,279	—	17,116	—	16,494	—	16,076	—
Hispanic/Latino ^b	9,733	—	10,273	—	10,312	—	10,529	—	10,163	—	10,106	—
Native Hawaiian/Other Pacific Islander	46	—	46	—	75	—	47	—	57	—	71	—
White	10,488	—	10,458	—	10,277	—	10,011	—	9,825	—	9,626	—
Multiple races	1,826	—	1,603	—	1,457	—	1,315	—	1,099	—	886	—
Transmission category^c												
Male adult or adolescent												
Male-to-male sexual contact	25,760	—	26,761	—	26,693	—	26,386	—	25,641	—	24,909	—
Injection drug use	1,413	—	1,315	—	1,357	—	1,242	—	1,340	—	1,462	—
Male-to-male sexual contact and injection drug use	1,454	—	1,403	—	1,453	—	1,420	—	1,358	—	1,316	—
Heterosexual contact ^d	3,468	—	3,376	—	3,331	—	3,399	—	2,937	—	2,799	—
Other ^e	42	—	34	—	37	—	27	—	33	—	35	—
Subtotal	32,137	24.7	32,889	25.0	32,872	24.8	32,475	24.3	31,309	23.2	30,521	22.5
Female adult or adolescent												
Injection drug use	1,025	—	981	—	1,033	—	998	—	1,043	—	1,049	—
Heterosexual contact ^d	6,700	—	6,713	—	6,437	—	6,558	—	6,290	—	6,130	—
Other ^e	45	—	32	—	29	—	43	—	43	—	41	—
Subtotal	7,770	5.7	7,726	5.6	7,499	5.4	7,599	5.4	7,377	5.2	7,220	5.1
Child (<13 yrs at diagnosis)												
Perinatal	125	—	138	—	111	—	103	—	84	—	66	—
Other ^f	59	—	43	—	32	—	24	—	19	—	25	—
Subtotal	184	0.3	181	0.3	143	0.3	127	0.2	103	0.2	91	0.2
Region of residence^g												
Northeast	6,937	12.4	6,919	12.4	6,476	11.6	6,225	11.1	5,988	10.7	5,588	10.0
Midwest	5,287	7.8	5,121	7.6	5,243	7.7	5,183	7.6	5,094	7.5	4,933	7.2
South	19,900	16.8	20,248	16.9	20,395	16.9	20,263	16.6	19,721	16.0	19,585	15.7
West	7,290	9.8	7,856	10.5	7,825	10.3	7,976	10.4	7,526	9.7	7,271	9.3
U.S. dependent areas	677	16.9	652	16.6	575	14.8	554	14.6	460	12.3	455	12.7
Total	40,091	12.5	40,796	12.7	40,514	12.5	40,201	12.3	38,789	11.8	37,832	11.4

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Data for the year 2018 should not be used when assessing trends.

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^b Hispanics/Latinos can be of any race.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 2a. Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2013–2018 and cumulative—United States

	2013		2014		2015		2016		2017		2018		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Age at diagnosis (yr)													
<13 ^c	9	0.0	70	0.1	40	0.1	39	0.1	34	0.1	42	0.1	9,581
13–14	29	0.3	15	0.2	7	0.1	14	0.2	7	0.1	3	0.0	1,482
15–19	400	1.9	184	0.9	192	0.9	213	1.0	208	1.0	177	0.8	9,666
20–24	2,007	8.8	1,358	5.9	1,312	5.8	1,269	5.7	1,154	5.2	1,072	4.9	55,881
25–29	2,786	12.9	2,342	10.7	2,390	10.7	2,472	10.8	2,322	10.0	2,300	9.8	148,753
30–34	2,920	13.7	2,415	11.2	2,438	11.3	2,406	11.0	2,453	11.2	2,413	10.9	231,147
35–39	2,821	14.4	2,392	12.0	2,257	11.1	2,357	11.3	2,232	10.5	2,216	10.3	248,335
40–44	3,068	14.7	2,478	12.1	2,231	11.1	2,071	10.5	1,919	9.8	1,790	9.1	208,756
45–49	3,300	15.6	2,668	12.8	2,413	11.6	2,161	10.3	2,066	9.9	1,901	9.2	146,155
50–54	2,757	12.2	2,290	10.2	2,294	10.3	2,205	10.1	2,036	9.5	1,933	9.3	90,846
55–59	1,776	8.4	1,572	7.3	1,475	6.8	1,516	6.9	1,571	7.2	1,460	6.7	51,986
60–64	1,027	5.7	854	4.6	847	4.5	912	4.7	926	4.6	898	4.4	28,142
≥65	760	1.7	733	1.6	732	1.5	756	1.5	794	1.6	827	1.6	23,846
Race/ethnicity													
American Indian/Alaska Native	84	3.6	80	3.4	89	3.8	96	4.0	74	3.1	64	2.6	3,557
Asian ^d	338	2.1	306	1.8	314	1.8	332	1.9	335	1.8	342	1.8	10,411
Black/African American	11,033	28.2	8,950	22.7	8,618	21.6	8,496	21.1	8,292	20.4	8,035	19.6	517,490
Hispanic/Latino ^e	5,031	9.3	4,194	7.6	4,067	7.2	4,177	7.3	3,958	6.7	3,887	6.5	234,609
Native Hawaiian/ Other Pacific Islander	21	3.9	17	3.1	22	4.0	15	2.7	25	4.3	20	3.4	815
White	5,824	2.9	4,798	2.4	4,614	2.3	4,442	2.2	4,267	2.2	4,018	2.0	442,774
Multiple races	1,329	21.5	1,026	16.1	904	13.8	833	12.3	771	11.1	666	9.4	44,838
Transmission category^f													
Male adult or adolescent													
Male-to-male sexual contact	12,918	—	10,360	—	10,112	—	10,083	—	9,730	—	9,473	—	611,167
Injection drug use	1,300	—	1,119	—	975	—	910	—	938	—	894	—	183,449
Male-to-male sexual contact and injection drug use	1,069	—	840	—	853	—	846	—	792	—	717	—	90,787
Heterosexual contact ^g	2,561	—	2,187	—	2,039	—	2,127	—	1,890	—	1,716	—	90,209
Other ^h	125	—	76	—	95	—	78	—	70	—	84	—	11,738
Subtotal	17,974	14.0	14,582	11.2	14,074	10.7	14,044	10.6	13,420	10.1	12,884	9.6	987,349
Female adult or adolescent													
Injection drug use	1,018	—	840	—	801	—	741	—	744	—	730	—	91,516
Heterosexual contact ^g	4,525	—	3,793	—	3,630	—	3,459	—	3,438	—	3,295	—	159,946
Other ^h	134	—	86	—	83	—	109	—	86	—	81	—	6,184
Subtotal	5,677	4.2	4,719	3.5	4,514	3.3	4,308	3.1	4,268	3.1	4,106	2.9	257,646
Child (<13 yrs at diagnosis)													
Perinatal	8	—	60	—	31	—	32	—	27	—	30	—	8,701
Other ⁱ	1	—	10	—	9	—	7	—	7	—	12	—	880
Subtotal	9	0.0	70	0.1	40	0.1	39	0.1	34	0.1	42	0.1	9,581
Region of residence^j													
Northeast	4,295	7.7	3,497	6.2	3,304	5.9	3,161	5.6	2,979	5.3	2,841	5.1	355,353
Midwest	2,954	4.4	2,480	3.7	2,434	3.6	2,498	3.7	2,269	3.3	2,244	3.3	135,760
South	12,479	10.5	10,095	8.4	9,761	8.1	9,567	7.8	9,421	7.6	9,034	7.2	514,949
West	3,932	5.3	3,299	4.4	3,129	4.1	3,165	4.1	3,053	3.9	2,913	3.7	248,514
Total^k	23,660	7.5	19,371	6.1	18,628	5.8	18,391	5.7	17,722	5.5	17,032	5.2	1,254,576

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2018.

^b Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^c The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^e Hispanics/Latinos can be of any race.

^f Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^g Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^h Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

ⁱ Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^j Data are based on residence at time of stage 3 (AIDS) classification.

^k Cumulative total includes persons whose race/ethnicity is unknown.

Table 2b. Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2013–2018 and cumulative—United States and 6 dependent areas

	2013		2014		2015		2016		2017		2018		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Age at diagnosis (yr)													
<13 ^c	9	0.0	70	0.1	40	0.1	40	0.1	34	0.1	42	0.1	10,011
13–14	30	0.4	15	0.2	7	0.1	14	0.2	7	0.1	3	0.0	1,540
15–19	405	1.9	189	0.9	193	0.9	216	1.0	209	1.0	177	0.8	9,908
20–24	2,027	8.8	1,376	5.9	1,325	5.8	1,285	5.7	1,165	5.2	1,082	4.9	57,339
25–29	2,815	12.9	2,363	10.6	2,411	10.6	2,486	10.7	2,333	9.9	2,315	9.7	153,006
30–34	2,968	13.8	2,456	11.3	2,465	11.3	2,433	11.0	2,480	11.2	2,429	10.9	238,102
35–39	2,872	14.5	2,441	12.1	2,289	11.1	2,401	11.4	2,259	10.5	2,233	10.3	255,580
40–44	3,123	14.8	2,535	12.2	2,266	11.1	2,104	10.6	1,945	9.8	1,812	9.1	214,594
45–49	3,372	15.7	2,720	12.9	2,453	11.7	2,208	10.4	2,091	9.9	1,930	9.2	150,169
50–54	2,823	12.4	2,336	10.3	2,343	10.4	2,241	10.2	2,076	9.6	1,971	9.3	93,316
55–59	1,824	8.5	1,612	7.4	1,498	6.8	1,549	7.0	1,592	7.2	1,481	6.7	53,484
60–64	1,053	5.7	876	4.7	856	4.4	928	4.7	937	4.6	913	4.4	28,988
≥65	783	1.7	750	1.6	750	1.6	776	1.6	809	1.6	840	1.6	24,865
Race/ethnicity													
American Indian/Alaska Native	84	—	80	—	89	—	96	—	74	—	64	—	3,559
Asian ^d	338	—	308	—	314	—	333	—	338	—	342	—	10,479
Black/African American	11,038	—	8,959	—	8,627	—	8,501	—	8,295	—	8,041	—	517,982
Hispanic/Latino ^e	5,469	—	4,547	—	4,322	—	4,455	—	4,163	—	4,073	—	270,193
Native Hawaiian/ Other Pacific Islander	21	—	19	—	24	—	19	—	28	—	23	—	851
White	5,825	—	4,800	—	4,616	—	4,443	—	4,268	—	4,019	—	442,893
Multiple races	1,329	—	1,026	—	904	—	834	—	771	—	666	—	44,863
Transmission category^f													
Male adult or adolescent													
Male-to-male sexual contact	13,051	—	10,460	—	10,203	—	10,174	—	9,805	—	9,549	—	617,605
Injection drug use	1,375	—	1,191	—	1,022	—	961	—	966	—	925	—	196,870
Male-to-male sexual contact and injection drug use	1,086	—	851	—	869	—	866	—	796	—	728	—	93,495
Heterosexual contact ^g	2,650	—	2,257	—	2,090	—	2,191	—	1,930	—	1,749	—	94,349
Other ^h	127	—	77	—	97	—	80	—	70	—	86	—	11,942
Subtotal	18,288	14.0	14,836	11.3	14,281	10.8	14,272	10.7	13,567	10.1	13,037	9.6	1,014,260
Female adult or adolescent													
Injection drug use	1,047	—	868	—	810	—	755	—	750	—	736	—	94,639
Heterosexual contact ^g	4,624	—	3,874	—	3,681	—	3,504	—	3,497	—	3,331	—	165,656
Other ^h	136	—	91	—	85	—	110	—	89	—	82	—	6,336
Subtotal	5,807	4.3	4,833	3.5	4,575	3.3	4,369	3.1	4,336	3.1	4,149	2.9	266,631
Child (<13 yrs at diagnosis)													
Perinatal	8	—	60	—	31	—	33	—	27	—	30	—	9,105
Other ⁱ	1	—	10	—	9	—	7	—	7	—	12	—	906
Subtotal	9	0.0	70	0.1	40	0.1	40	0.1	34	0.1	42	0.1	10,011
Region of residence^j													
Northeast	4,295	7.7	3,497	6.2	3,304	5.9	3,161	5.6	2,979	5.3	2,841	5.1	355,353
Midwest	2,954	4.4	2,480	3.7	2,434	3.6	2,498	3.7	2,269	3.3	2,244	3.3	135,760
South	12,479	10.5	10,095	8.4	9,761	8.1	9,567	7.8	9,421	7.6	9,034	7.2	514,949
West	3,932	5.3	3,299	4.4	3,129	4.1	3,165	4.1	3,053	3.9	2,913	3.7	248,514
U.S. dependent areas	444	11.1	368	9.3	268	6.9	290	7.6	215	5.8	196	5.5	36,326
Total^k	24,104	7.5	19,739	6.1	18,896	5.8	18,681	5.7	17,937	5.5	17,228	5.2	1,290,902

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2018.

^b Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^c The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^e Hispanics/Latinos can be of any race.

^f Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^g Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^h Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

ⁱ Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^j Data are based on residence at time of stage 3 (AIDS) classification.

^k Cumulative total includes persons whose race/ethnicity is unknown.

Table 3a. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2018—United States

	American Indian/ Alaska Native		Asian		Black/African American		Hispanic/ Latino ^a		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total	
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b
Age at diagnosis (yr)																
<13	0	0.0	5	0.2	59	0.8	9	0.1	0	0.0	14	0.1	4	0.2	91	0.2
13–14	0	0.0	1	0.2	11	1.0	5	0.2	0	0.0	2	0.0	0	0.0	19	0.2
15–19	10	5.6	21	1.9	1,010	34.5	363	7.3	4	9.8	233	2.1	47	6.4	1,688	8.0
20–24	31	16.8	126	9.7	3,052	97.6	1,535	31.7	9	20.5	1,098	9.4	176	26.8	6,027	27.6
25–29	35	17.5	196	12.2	3,448	99.2	2,057	42.2	13	25.3	1,704	13.3	200	35.9	7,653	32.5
30–34	35	20.5	151	9.2	2,184	74.9	1,634	35.9	18	35.5	1,505	12.1	142	33.7	5,669	25.6
35–39	20	12.8	91	5.8	1,572	56.8	1,232	27.5	8	16.8	1,158	9.5	105	28.6	4,186	19.4
40–44	14	9.9	90	6.3	1,150	46.2	801	19.5	3	7.6	862	7.7	52	17.5	2,972	15.1
45–49	12	8.3	71	5.1	1,033	39.9	766	20.4	4	10.8	891	7.1	54	19.9	2,831	13.6
50–54	16	10.7	42	3.5	950	36.7	571	17.5	3	8.6	822	6.1	47	19.9	2,451	11.7
55–59	9	5.7	32	2.9	775	29.7	355	12.9	5	14.9	675	4.5	21	9.0	1,872	8.5
60–64	3	2.2	24	2.4	446	19.5	185	8.6	1	3.6	361	2.5	18	9.1	1,038	5.1
≥65	4	1.4	24	1.0	377	7.9	160	3.6	1	1.8	295	0.7	19	4.7	880	1.7
Transmission category^c																
Male adult or adolescent																
Male-to-male sexual contact	121	—	683	—	9,496	—	7,298	—	54	—	6,418	—	580	—	24,650	—
Injection drug use	7	—	12	—	448	—	332	—	2	—	592	—	37	—	1,430	—
Male-to-male sexual contact and injection drug use	20	—	13	—	257	—	311	—	5	—	647	—	51	—	1,305	—
Heterosexual contact ^d	9	—	55	—	1,674	—	532	—	3	—	417	—	37	—	2,728	—
Other ^e	0	—	3	—	19	—	8	—	0	—	5	—	0	—	35	—
Subtotal	157	16.3	766	10.1	11,894	74.8	8,481	36.4	64	26.6	8,080	9.6	705	30.9	30,147	22.5
Female adult or adolescent																
Injection drug use	14	—	6	—	320	—	147	—	0	—	522	—	39	—	1,047	—
Heterosexual contact ^d	18	—	96	—	3,768	—	1,029	—	5	—	999	—	136	—	6,051	—
Other ^e	0	—	1	—	26	—	7	—	0	—	6	—	2	—	41	—
Subtotal	32	3.2	103	1.2	4,114	23.1	1,183	5.2	5	2.1	1,526	1.7	176	7.3	7,139	5.1
Child (<13 yrs at diagnosis)																
Perinatal	0	—	3	—	44	—	6	—	0	—	9	—	4	—	66	—
Other ^f	0	—	2	—	15	—	3	—	0	—	5	—	0	—	25	—
Subtotal	0	0.0	5	0.2	59	0.8	9	0.1	0	0.0	14	0.1	4	0.2	91	0.2
Region of residence^g																
Northeast	7	5.5	186	4.9	2,239	35.3	1,720	20.8	4	18.3	1,270	3.5	162	16.8	5,588	10.0
Midwest	27	6.5	78	3.3	2,346	32.8	646	11.8	3	8.6	1,708	3.3	125	9.2	4,933	7.2
South	43	5.4	244	5.5	10,178	42.7	4,272	18.8	17	18.2	4,422	6.3	409	17.3	19,585	15.7
West	112	10.4	366	4.5	1,304	36.5	3,035	12.9	45	10.3	2,220	5.7	189	7.8	7,271	9.3
Total	189	7.8	874	4.7	16,067	39.3	9,673	16.2	69	11.8	9,620	4.9	885	12.4	37,377	11.4

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Hispanics/Latinos can be of any race.

^b Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2018—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian	Black/African American	Hispanic/ Latino ^a	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Age at diagnosis (yr)								
<13	0	5	59	9	0	14	4	91
13–14	0	1	11	5	0	2	0	19
15–19	10	21	1,010	377	4	234	47	1,703
20–24	31	126	3,052	1,592	9	1,099	176	6,085
25–29	35	197	3,451	2,134	13	1,704	200	7,734
30–34	35	153	2,185	1,686	18	1,505	142	5,724
35–39	20	91	1,572	1,262	9	1,158	106	4,218
40–44	14	91	1,151	845	3	863	52	3,019
45–49	12	71	1,034	807	4	891	54	2,873
50–54	16	42	951	622	3	823	47	2,504
55–59	9	32	776	381	6	677	21	1,902
60–64	3	24	447	204	1	361	18	1,058
≥65	4	24	377	182	1	295	19	902
Transmission category^b								
Male adult or adolescent								
Male-to-male sexual contact	121	687	9,499	7,543	55	6,423	580	24,909
Injection drug use	7	12	450	362	2	593	37	1,462
Male-to-male sexual contact and injection drug use	20	13	257	323	5	647	51	1,316
Heterosexual contact ^c	9	56	1,678	597	4	417	38	2,799
Other ^d	0	3	19	8	0	5	0	35
Subtotal	157	770	11,903	8,833	66	8,086	706	30,521
Female adult or adolescent								
Injection drug use	14	6	320	149	0	522	39	1,049
Heterosexual contact ^c	18	96	3,768	1,109	5	999	136	6,130
Other ^d	0	1	26	7	0	6	2	41
Subtotal	32	103	4,114	1,264	5	1,526	176	7,220
Child (<13 yrs at diagnosis)								
Perinatal	0	3	44	6	0	9	4	66
Other ^e	0	2	15	3	0	5	0	25
Subtotal	0	5	59	9	0	14	4	91
Region of residence^f								
Northeast	7	186	2,239	1,720	4	1,270	162	5,588
Midwest	27	78	2,346	646	3	1,708	125	4,933
South	43	244	10,178	4,272	17	4,422	409	19,585
West	112	366	1,304	3,035	45	2,220	189	7,271
U.S. dependent areas	0	4	9	433	2	6	1	455
Total	189	878	16,076	10,106	71	9,626	886	37,832

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12 should be interpreted with caution.

^a Hispanics/Latinos can be of any race.

^b Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^e Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^f Data are based on residence at time of diagnosis of HIV infection.

Table 4a. Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2018—United States

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total	
	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c
Age at diagnosis (yr)																
<13	0	0.0	0	0.0	29	0.4	6	0.0	0	0.0	2	0.0	5	0.2	42	0.1
13–14	0	0.0	1	0.2	1	0.1	1	0.0	0	0.0	0	0.0	0	0.0	3	0.0
15–19	0	0.0	2	0.2	107	3.7	43	0.9	0	0.0	16	0.1	9	1.2	177	0.8
20–24	1	0.5	25	1.9	591	18.9	265	5.5	2	4.6	152	1.3	36	5.5	1,072	4.9
25–29	19	9.5	53	3.3	1,243	35.7	562	11.5	2	3.9	353	2.8	68	12.2	2,300	9.8
30–34	5	2.9	57	3.5	1,208	41.4	582	12.8	3	5.9	450	3.6	108	25.6	2,413	10.9
35–39	6	3.8	44	2.8	949	34.3	613	13.7	4	8.4	514	4.2	86	23.5	2,216	10.3
40–44	11	7.8	52	3.6	785	31.5	437	10.6	3	7.6	428	3.8	74	24.9	1,790	9.1
45–49	5	3.5	35	2.5	821	31.7	443	11.8	2	5.4	526	4.2	69	25.4	1,901	9.2
50–54	10	6.7	27	2.3	846	32.6	408	12.5	0	0.0	568	4.2	74	31.3	1,933	9.3
55–59	5	3.2	22	2.0	666	25.5	247	9.0	2	6.0	464	3.1	54	23.3	1,460	6.7
60–64	0	0.0	12	1.2	434	19.0	145	6.8	1	3.6	269	1.8	37	18.8	898	4.4
≥65	2	0.7	12	0.5	355	7.4	135	3.1	1	1.8	276	0.7	46	11.4	827	1.6
Transmission category^d																
Male adult or adolescent																
Male-to-male sexual contact	34	0.0	239	0.0	3,794	0.0	2,540	0.0	18	0.0	2,488	0.0	360	0.0	9,473	0.0
Injection drug use	7	0.0	7	0.0	380	0.0	219	0.0	0	0.0	243	0.0	37	0.0	894	0.0
Male-to-male sexual contact and injection drug use	3	0.0	5	0.0	203	0.0	186	0.0	1	0.0	274	0.0	44	0.0	717	0.0
Heterosexual contact ^e	5	0.0	33	0.0	1,090	0.0	295	0.0	1	0.0	250	0.0	42	0.0	1,716	0.0
Other ^f	0	0.0	1	0.0	47	0.0	17	0.0	0	0.0	16	0.0	3	0.0	84	0.0
Subtotal	49	5.1	285	3.8	5,514	34.7	3,256	14.0	20	8.3	3,273	3.9	487	21.4	12,884	9.6
Female adult or adolescent																
Injection drug use	5	0.0	4	0.0	298	0.0	120	0.0	0	0.0	255	0.0	47	0.0	730	0.0
Heterosexual contact ^e	10	0.0	51	0.0	2,146	0.0	488	0.0	0	0.0	475	0.0	125	0.0	3,295	0.0
Other ^f	0	0.0	2	0.0	48	0.0	16	0.0	0	0.0	13	0.0	2	0.0	81	0.0
Subtotal	15	1.5	57	0.7	2,492	14.0	625	2.7	0	0.0	743	0.8	174	7.2	4,106	2.9
Child (<13 yrs at diagnosis)																
Perinatal	0	0.0	0	0.0	21	0.0	4	0.0	0	0.0	1	0.0	4	0.0	30	0.0
Other ^g	0	0.0	0	0.0	8	0.0	2	0.0	0	0.0	1	0.0	1	0.0	12	0.0
Subtotal	0	0.0	0	0.0	29	0.4	6	0.0	0	0.0	2	0.0	5	0.2	42	0.1
Region of residence^h																
Northeast	1	0.8	88	2.3	1,234	19.4	844	10.2	1	4.6	532	1.5	141	14.6	2,841	5.1
Midwest	10	2.4	25	1.1	1,097	15.3	263	4.8	2	5.7	770	1.5	77	5.7	2,244	3.3
South	12	1.5	88	2.0	5,167	21.7	1,608	7.1	5	5.4	1,829	2.6	325	13.7	9,034	7.2
West	41	3.8	141	1.7	537	15.0	1,172	5.0	12	2.8	887	2.3	123	5.1	2,913	3.7
Total	64	2.6	342	1.8	8,035	19.6	3,887	6.5	20	3.4	4,018	2.0	666	9.4	17,032	5.2

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on residence at time of stage 3 (AIDS) classification.

Table 4b. Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2018—United States and 6 dependent areas

	American Indian/ Alaska Native No.	Asian ^a No.	Black/African American No.	Hispanic/ Latino ^b No.	Native Hawaiian/ Other Pacific Islander No.	White No.	Multiple races No.	Total No.
Age at diagnosis (yr)								
<13	0	0	29	6	0	2	5	42
13–14	0	1	1	1	0	0	0	3
15–19	0	2	107	43	0	16	9	177
20–24	1	25	592	273	3	152	36	1,082
25–29	19	53	1,243	577	2	353	68	2,315
30–34	5	57	1,209	597	3	450	108	2,429
35–39	6	44	949	629	5	514	86	2,233
40–44	11	52	786	458	3	428	74	1,812
45–49	5	35	822	471	2	526	69	1,930
50–54	10	27	848	443	0	569	74	1,971
55–59	5	22	666	267	3	464	54	1,481
60–64	0	12	434	160	1	269	37	913
≥65	2	12	355	148	1	276	46	840
Transmission category^c								
Male adult or adolescent								
Male-to-male sexual contact	34	239	3,797	2,612	18	2,489	360	9,549
Injection drug use	7	7	380	249	0	243	37	925
Male-to-male sexual contact and injection drug use	3	5	203	197	1	274	44	728
Heterosexual contact ^d	5	33	1,091	325	3	250	42	1,749
Other ^e	0	1	47	18	0	16	3	86
Subtotal	49	285	5,518	3,401	23	3,274	487	13,037
Female adult or adolescent								
Injection drug use	5	4	298	126	0	255	47	736
Heterosexual contact ^d	10	51	2,148	522	0	475	125	3,331
Other ^e	0	2	48	17	0	13	2	82
Subtotal	15	57	2,494	666	0	743	174	4,149
Child (<13 yrs at diagnosis)								
Perinatal	0	0	21	4	0	1	4	30
Other ^f	0	0	8	2	0	1	1	12
Subtotal	0	0	29	6	0	2	5	42
Region of residence^g								
Northeast	1	88	1,234	844	1	532	141	2,841
Midwest	10	25	1,097	263	2	770	77	2,244
South	12	88	5,167	1,608	5	1,829	325	9,034
West	41	141	537	1,172	12	887	123	2,913
U.S. dependent areas	0	0	6	186	3	1	0	196
Total	64	342	8,041	4,073	23	4,019	666	17,228

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at time of stage 3 (AIDS) classification.

Table 5a. Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2013–2018—United States

	2013		2014		2015		2016		2017		2018	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Male adult or adolescent												
Age at diagnosis (yr)												
13–14	20	0.5	17	0.4	11	0.3	9	0.2	14	0.3	10	0.2
15–19	1,388	12.8	1,415	13.1	1,505	14.0	1,453	13.4	1,511	14.0	1,438	13.3
20–24	6,230	53.3	6,514	55.5	6,448	55.4	6,170	53.7	5,676	50.1	5,320	47.5
25–29	5,655	51.7	6,198	55.6	6,599	57.9	6,884	59.0	6,740	56.7	6,690	55.7
30–34	4,195	39.3	4,419	40.9	4,469	41.1	4,602	41.9	4,624	41.8	4,707	42.1
35–39	3,057	31.3	3,237	32.6	3,302	32.5	3,278	31.6	3,339	31.5	3,260	30.2
40–44	3,061	29.6	2,908	28.5	2,601	26.0	2,489	25.5	2,234	23.0	2,181	22.3
45–49	3,009	28.7	2,820	27.3	2,554	24.8	2,313	22.3	2,181	21.1	2,092	20.4
50–54	2,170	19.6	2,193	19.8	2,253	20.6	2,146	20.0	1,989	19.0	1,796	17.5
55–59	1,426	13.9	1,334	12.8	1,344	12.7	1,319	12.4	1,301	12.2	1,314	12.3
60–64	772	8.9	699	7.9	696	7.7	735	7.9	741	7.8	718	7.4
≥65	641	3.3	629	3.1	625	3.0	625	2.9	592	2.6	621	2.7
Race/ethnicity												
American Indian/Alaska Native	114	12.4	142	15.3	135	14.4	180	19.0	165	17.2	157	16.3
Asian	644	10.0	768	11.5	790	11.5	806	11.3	813	11.1	766	10.1
Black/African American	12,271	81.7	12,634	83.1	12,776	83.0	12,577	80.8	12,104	76.9	11,894	74.8
Hispanic/Latino ^b	7,879	38.1	8,375	39.6	8,566	39.5	8,798	39.6	8,555	37.6	8,481	36.4
Native Hawaiian/Other Pacific Islander	36	16.6	34	15.4	65	28.7	33	14.3	44	18.6	64	26.6
White	9,195	11.0	9,129	10.9	8,863	10.6	8,544	10.2	8,363	10.0	8,080	9.6
Multiple races	1,485	77.9	1,301	65.8	1,212	59.1	1,085	51.1	898	40.8	705	30.9
Region of residence^c												
Northeast	5,401	23.6	5,348	23.3	5,035	21.9	4,802	20.8	4,642	20.1	4,335	18.7
Midwest	4,306	15.6	4,228	15.3	4,263	15.4	4,211	15.1	4,130	14.8	4,006	14.3
South	15,509	32.5	15,942	33.0	16,197	33.1	16,070	32.4	15,574	31.1	15,478	30.5
West	6,408	21.1	6,865	22.3	6,912	22.2	6,940	22.0	6,596	20.6	6,328	19.6
Subtotal	31,624	24.6	32,383	24.9	32,407	24.7	32,023	24.2	30,942	23.2	30,147	22.5
Female adult or adolescent												
Age at diagnosis (yr)												
13–14	20	0.5	15	0.4	14	0.3	17	0.4	14	0.3	9	0.2
15–19	305	3.0	315	3.1	252	2.4	250	2.4	252	2.4	250	2.4
20–24	796	7.2	849	7.6	831	7.5	741	6.8	778	7.2	707	6.6
25–29	979	9.2	995	9.2	985	8.9	1,065	9.5	969	8.5	963	8.3
30–34	992	9.4	1,011	9.4	986	9.2	1,041	9.6	1,013	9.3	962	8.8
35–39	893	9.1	986	9.9	954	9.4	961	9.2	935	8.8	926	8.6
40–44	862	8.2	870	8.4	806	7.9	775	7.8	737	7.5	791	8.0
45–49	896	8.4	790	7.5	759	7.2	777	7.4	764	7.2	739	7.0
50–54	780	6.8	693	6.0	744	6.6	732	6.6	660	6.1	655	6.2
55–59	574	5.3	586	5.3	532	4.8	564	5.0	561	5.0	558	5.0
60–64	294	3.1	269	2.8	301	3.0	345	3.4	334	3.2	320	3.0
≥65	215	0.9	201	0.8	225	0.8	229	0.8	267	0.9	259	0.9
Race/ethnicity												
American Indian/Alaska Native	30	3.1	33	3.4	48	4.9	42	4.2	47	4.7	32	3.2
Asian	128	1.8	128	1.7	125	1.6	145	1.8	119	1.4	103	1.2
Black/African American	4,661	27.6	4,570	26.8	4,403	25.5	4,456	25.6	4,328	24.6	4,114	23.1
Hispanic/Latino ^b	1,188	5.9	1,257	6.0	1,177	5.5	1,174	5.4	1,143	5.1	1,183	5.2
Native Hawaiian/Other Pacific Islander	9	4.2	8	3.7	7	3.1	8	3.5	9	3.8	5	2.1
White	1,265	1.5	1,294	1.5	1,395	1.6	1,449	1.7	1,445	1.7	1,526	1.7
Multiple races	325	15.8	290	13.6	234	10.7	223	9.8	193	8.2	176	7.3
Region of residence^c												
Northeast	1,508	6.1	1,554	6.3	1,415	5.7	1,410	5.7	1,339	5.4	1,243	5.0
Midwest	944	3.3	854	3.0	953	3.3	942	3.2	946	3.3	910	3.1
South	4,313	8.5	4,213	8.2	4,133	8.0	4,129	7.9	4,083	7.7	4,060	7.6
West	841	2.7	959	3.1	888	2.8	1,016	3.2	916	2.8	926	2.8
Subtotal	7,606	5.6	7,580	5.6	7,389	5.4	7,497	5.4	7,284	5.2	7,139	5.1
Total	39,230	14.9	39,963	15.0	39,796	14.8	39,520	14.6	38,226	14.0	37,286	13.6

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.

^b Hispanics/Latinos can be of any race.

^c Data are based on residence at time of diagnosis of HIV infection.

Table 5b. Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2013–2018—United States and 6 dependent areas

	2013		2014		2015		2016		2017		2018	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Male adult or adolescent												
Age at diagnosis (yr)												
13–14	20	0.5	17	0.4	11	0.3	9	0.2	14	0.3	10	0.2
15–19	1,404	12.8	1,432	13.1	1,509	13.8	1,463	13.4	1,520	13.9	1,449	13.3
20–24	6,306	53.3	6,620	55.8	6,519	55.3	6,239	53.7	5,734	50.1	5,370	47.4
25–29	5,727	51.8	6,284	55.8	6,682	58.0	6,949	59.0	6,792	56.6	6,765	55.7
30–34	4,271	39.6	4,464	40.9	4,521	41.2	4,658	42.0	4,680	41.9	4,756	42.1
35–39	3,100	31.3	3,287	32.7	3,360	32.7	3,331	31.7	3,378	31.6	3,288	30.2
40–44	3,112	29.7	2,962	28.7	2,648	26.2	2,531	25.6	2,264	23.0	2,219	22.4
45–49	3,066	28.9	2,861	27.4	2,605	25.0	2,357	22.5	2,209	21.1	2,120	20.4
50–54	2,218	19.8	2,226	19.9	2,295	20.8	2,184	20.2	2,028	19.1	1,837	17.7
55–59	1,452	14.0	1,365	13.0	1,365	12.8	1,355	12.6	1,324	12.3	1,336	12.4
60–64	798	9.1	723	8.1	712	7.7	753	8.0	757	7.9	734	7.5
≥65	663	3.3	648	3.1	645	3.0	646	2.9	609	2.7	637	2.7
Race/ethnicity												
American Indian/Alaska Native	114	—	142	—	135	—	180	—	165	—	157	—
Asian	644	—	770	—	794	—	807	—	816	—	770	—
Black/African American	12,280	—	12,645	—	12,781	—	12,583	—	12,105	—	11,903	—
Hispanic/Latino ^b	8,379	—	8,859	—	9,017	—	9,235	—	8,913	—	8,833	—
Native Hawaiian/Other Pacific Islander	37	—	36	—	68	—	39	—	47	—	66	—
White	9,198	—	9,135	—	8,865	—	8,546	—	8,364	—	8,086	—
Multiple races	1,485	—	1,302	—	1,212	—	1,085	—	899	—	706	—
Region of residence^c												
Northeast	5,401	23.6	5,348	23.3	5,035	21.9	4,802	20.8	4,642	20.1	4,335	18.7
Midwest	4,306	15.6	4,228	15.3	4,263	15.4	4,211	15.1	4,130	14.8	4,006	14.3
South	15,509	32.5	15,942	33.0	16,197	33.1	16,070	32.4	15,574	31.1	15,478	30.5
West	6,408	21.1	6,865	22.3	6,912	22.2	6,940	22.0	6,596	20.6	6,328	19.6
U.S. dependent areas	513	32.2	506	32.1	465	29.8	452	29.4	367	24.3	374	25.4
Subtotal	32,137	24.7	32,889	25.0	32,872	24.8	32,475	24.3	31,309	23.2	30,521	22.5
Female adult or adolescent												
Age at diagnosis (yr)												
13–14	21	0.5	15	0.4	14	0.3	17	0.4	14	0.3	9	0.2
15–19	308	2.9	323	3.1	254	2.4	253	2.4	255	2.4	254	2.4
20–24	808	7.2	861	7.6	841	7.5	747	6.8	783	7.2	715	6.6
25–29	991	9.2	1,003	9.2	997	8.9	1,071	9.4	981	8.5	969	8.3
30–34	1,006	9.4	1,028	9.5	993	9.1	1,050	9.6	1,020	9.3	968	8.8
35–39	916	9.2	1,008	10.0	965	9.4	979	9.3	948	8.8	930	8.5
40–44	877	8.2	892	8.5	822	8.0	790	7.9	744	7.5	800	8.0
45–49	923	8.5	808	7.6	774	7.3	791	7.4	779	7.3	753	7.1
50–54	804	6.9	706	6.1	759	6.6	740	6.6	672	6.1	667	6.2
55–59	592	5.4	600	5.4	543	4.8	578	5.1	572	5.0	566	5.0
60–64	303	3.2	273	2.8	302	3.0	351	3.4	338	3.2	324	3.0
≥65	221	0.9	209	0.8	235	0.9	232	0.8	271	0.9	265	0.9
Race/ethnicity												
American Indian/Alaska Native	30	—	33	—	48	—	42	—	47	—	32	—
Asian	128	—	128	—	125	—	145	—	119	—	103	—
Black/African American	4,668	—	4,576	—	4,407	—	4,456	—	4,330	—	4,114	—
Hispanic/Latino ^b	1,344	—	1,395	—	1,282	—	1,276	—	1,232	—	1,264	—
Native Hawaiian/Other Pacific Islander	9	—	9	—	7	—	8	—	9	—	5	—
White	1,266	—	1,295	—	1,395	—	1,449	—	1,447	—	1,526	—
Multiple races	325	—	290	—	235	—	223	—	193	—	176	—
Region of residence^c												
Northeast	1,508	6.1	1,554	6.3	1,415	5.7	1,410	5.7	1,339	5.4	1,243	5.0
Midwest	944	3.3	854	3.0	953	3.3	942	3.2	946	3.3	910	3.1
South	4,313	8.5	4,213	8.2	4,133	8.0	4,129	7.9	4,083	7.7	4,060	7.6
West	841	2.7	959	3.1	888	2.8	1,016	3.2	916	2.8	926	2.8
U.S. dependent areas	164	9.3	146	8.4	110	6.4	102	6.0	93	5.5	81	4.9
Subtotal	7,770	5.7	7,726	5.6	7,499	5.4	7,599	5.4	7,377	5.2	7,220	5.1
Total	39,907	15.0	40,615	15.1	40,371	14.9	40,074	14.6	38,686	14.0	37,741	13.6

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

^b Hispanics/Latinos can be of any race.

^c Data are based on residence at time of diagnosis of HIV infection.

Table 6a. Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2013–2018—United States

	2013		2014		2015		2016		2017		2018	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Male adult or adolescent												
Age at diagnosis (yr)												
13–14	12	0.3	7	0.2	3	0.1	7	0.2	3	0.1	2	0.0
15–19	293	2.7	130	1.2	144	1.3	160	1.5	164	1.5	134	1.2
20–24	1,701	14.6	1,141	9.7	1,101	9.5	1,053	9.2	964	8.5	912	8.1
25–29	2,304	21.1	1,933	17.3	1,974	17.3	2,079	17.8	1,948	16.4	1,979	16.5
30–34	2,251	21.1	1,856	17.2	1,885	17.3	1,902	17.3	1,948	17.6	1,925	17.2
35–39	2,063	21.1	1,726	17.4	1,627	16.0	1,704	16.4	1,619	15.3	1,635	15.2
40–44	2,255	21.8	1,787	17.5	1,612	16.1	1,501	15.4	1,363	14.0	1,274	13.0
45–49	2,444	23.3	1,999	19.4	1,778	17.3	1,624	15.7	1,499	14.5	1,351	13.2
50–54	2,056	18.6	1,695	15.3	1,734	15.9	1,681	15.7	1,503	14.3	1,419	13.8
55–59	1,278	12.4	1,137	10.9	1,083	10.3	1,103	10.3	1,157	10.8	1,037	9.7
60–64	742	8.6	625	7.1	603	6.6	665	7.1	653	6.8	612	6.3
≥65	575	2.9	546	2.7	530	2.5	565	2.6	599	2.7	604	2.6
Race/ethnicity												
American Indian/Alaska Native	65	7.1	59	6.4	55	5.9	71	7.5	52	5.4	49	5.1
Asian ^b	290	4.5	250	3.8	262	3.8	271	3.8	280	3.8	285	3.8
Black/African American	7,470	49.8	5,941	39.1	5,819	37.8	5,858	37.6	5,659	36.0	5,514	34.7
Hispanic/Latino ^c	4,173	20.2	3,473	16.4	3,392	15.7	3,483	15.7	3,313	14.6	3,256	14.0
Native Hawaiian/Other Pacific Islander	16	7.4	14	6.3	20	8.8	11	4.8	17	7.2	20	8.3
White	4,993	6.0	4,066	4.9	3,859	4.6	3,728	4.4	3,526	4.2	3,273	3.9
Multiple races	967	50.7	779	39.4	667	32.5	622	29.3	573	26.0	487	21.4
Region of residence^d												
Northeast	3,069	13.4	2,468	10.7	2,399	10.4	2,284	9.9	2,121	9.2	2,037	8.8
Midwest	2,387	8.7	1,934	7.0	1,952	7.0	1,953	7.0	1,726	6.2	1,759	6.3
South	9,066	19.0	7,348	15.2	7,066	14.4	7,098	14.3	6,939	13.8	6,645	13.1
West	3,452	11.4	2,832	9.2	2,657	8.5	2,709	8.6	2,634	8.2	2,443	7.6
Subtotal	17,974	14.0	14,582	11.2	14,074	10.7	14,044	10.6	13,420	10.1	12,884	9.6
Female adult or adolescent												
Age at diagnosis (yr)												
13–14	17	0.4	8	0.2	4	0.1	7	0.2	4	0.1	1	0.0
15–19	107	1.0	54	0.5	48	0.5	53	0.5	44	0.4	43	0.4
20–24	306	2.7	217	1.9	211	1.9	216	2.0	190	1.8	160	1.5
25–29	482	4.5	409	3.8	416	3.8	393	3.5	374	3.3	321	2.8
30–34	669	6.3	559	5.2	553	5.1	504	4.7	505	4.6	488	4.5
35–39	758	7.7	666	6.7	630	6.2	653	6.3	613	5.8	581	5.4
40–44	813	7.7	691	6.7	619	6.1	570	5.7	556	5.6	516	5.2
45–49	856	8.0	669	6.4	635	6.1	537	5.1	567	5.4	550	5.2
50–54	701	6.1	595	5.2	560	4.9	524	4.7	533	4.9	514	4.8
55–59	498	4.6	435	3.9	392	3.5	413	3.7	414	3.7	423	3.8
60–64	285	3.0	229	2.4	244	2.5	247	2.4	273	2.6	286	2.7
≥65	185	0.7	187	0.7	202	0.8	191	0.7	195	0.7	223	0.8
Race/ethnicity												
American Indian/Alaska Native	19	2.0	20	2.1	34	3.5	24	2.4	20	2.0	15	1.5
Asian ^b	48	0.7	56	0.7	50	0.6	61	0.8	55	0.7	57	0.7
Black/African American	3,558	21.1	2,962	17.3	2,770	16.0	2,612	15.0	2,609	14.8	2,492	14.0
Hispanic/Latino ^c	856	4.2	708	3.4	670	3.1	692	3.2	639	2.9	625	2.7
Native Hawaiian/Other Pacific Islander	5	2.3	3	1.4	2	0.9	4	1.7	7	3.0	—	—
White	831	1.0	726	0.8	752	0.9	709	0.8	741	0.8	743	0.8
Multiple races	360	17.5	244	11.5	236	10.8	206	9.1	197	8.4	174	7.2
Region of residence^d												
Northeast	1,224	5.0	1,023	4.2	895	3.6	871	3.5	853	3.5	795	3.2
Midwest	566	2.0	532	1.8	473	1.6	537	1.9	537	1.8	480	1.6
South	3,408	6.7	2,704	5.3	2,676	5.2	2,451	4.7	2,463	4.6	2,368	4.4
West	479	1.5	460	1.5	470	1.5	449	1.4	415	1.3	463	1.4
Subtotal	5,677	4.2	4,719	3.5	4,514	3.3	4,308	3.1	4,268	3.1	4,106	2.9
Total	23,651	9.0	19,301	7.3	18,588	6.9	18,352	6.8	17,688	6.5	16,990	6.2

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data are based on residence at time of stage 3 (AIDS) classification.

Table 6b. Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2013–2018—United States and 6 dependent areas

	2013		2014		2015		2016		2017		2018	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Male adult or adolescent												
Age at diagnosis (yr)												
13–14	13	0.3	7	0.2	3	0.1	7	0.2	3	0.1	2	0.0
15–19	295	2.7	132	1.2	144	1.3	163	1.5	164	1.5	134	1.2
20–24	1,720	14.5	1,155	9.7	1,113	9.4	1,066	9.2	969	8.5	920	8.1
25–29	2,328	21.1	1,948	17.3	1,993	17.3	2,090	17.7	1,956	16.3	1,993	16.4
30–34	2,289	21.2	1,877	17.2	1,905	17.3	1,926	17.4	1,967	17.6	1,939	17.2
35–39	2,098	21.2	1,762	17.6	1,651	16.1	1,737	16.5	1,639	15.3	1,647	15.1
40–44	2,294	21.9	1,824	17.7	1,638	16.2	1,528	15.5	1,381	14.0	1,289	13.0
45–49	2,484	23.4	2,041	19.5	1,807	17.3	1,660	15.8	1,512	14.4	1,372	13.2
50–54	2,103	18.8	1,726	15.4	1,774	16.1	1,711	15.8	1,532	14.4	1,447	13.9
55–59	1,309	12.6	1,162	11.0	1,102	10.3	1,125	10.4	1,171	10.9	1,053	9.8
60–64	763	8.7	644	7.2	611	6.6	676	7.2	663	6.9	626	6.4
≥65	592	3.0	558	2.7	540	2.5	583	2.6	610	2.7	615	2.6
Race/ethnicity												
American Indian/Alaska Native	65	—	59	—	55	—	71	—	52	—	49	—
Asian ^b	290	—	252	—	262	—	272	—	283	—	285	—
Black/African American	7,472	—	5,947	—	5,825	—	5,860	—	5,659	—	5,518	—
Hispanic/Latino ^c	4,484	—	3,716	—	3,589	—	3,704	—	3,455	—	3,401	—
Native Hawaiian/Other Pacific Islander	16	—	16	—	22	—	14	—	19	—	23	—
White	4,994	—	4,067	—	3,861	—	3,729	—	3,526	—	3,274	—
Multiple races	967	—	779	—	667	—	622	—	573	—	487	—
Region of residence^d												
Northeast	3,069	13.4	2,468	10.7	2,399	10.4	2,284	9.9	2,121	9.2	2,037	8.8
Midwest	2,387	8.7	1,934	7.0	1,952	7.0	1,953	7.0	1,726	6.2	1,759	6.3
South	9,066	19.0	7,348	15.2	7,066	14.4	7,098	14.3	6,939	13.8	6,645	13.1
West	3,452	11.4	2,832	9.2	2,657	8.5	2,709	8.6	2,634	8.2	2,443	7.6
U.S. dependent areas	314	19.7	254	16.1	207	13.3	228	14.8	147	9.7	153	10.4
Subtotal	18,288	14.0	14,836	11.3	14,281	10.8	14,272	10.7	13,567	10.1	13,037	9.6
Female adult or adolescent												
Age at diagnosis (yr)												
13–14	17	0.4	8	0.2	4	0.1	7	0.2	4	0.1	1	0.0
15–19	110	1.1	57	0.5	49	0.5	53	0.5	45	0.4	43	0.4
20–24	307	2.7	221	2.0	212	1.9	219	2.0	196	1.8	162	1.5
25–29	487	4.5	415	3.8	418	3.7	396	3.5	377	3.3	322	2.8
30–34	679	6.3	579	5.3	560	5.1	507	4.6	513	4.7	490	4.4
35–39	774	7.8	679	6.7	638	6.2	664	6.3	620	5.8	586	5.4
40–44	829	7.8	711	6.8	628	6.1	576	5.7	564	5.6	523	5.2
45–49	888	8.2	679	6.4	646	6.1	548	5.1	579	5.4	558	5.3
50–54	720	6.2	610	5.3	569	5.0	530	4.7	544	5.0	524	4.9
55–59	515	4.7	450	4.0	396	3.5	424	3.7	421	3.7	428	3.8
60–64	290	3.0	232	2.4	245	2.4	252	2.5	274	2.6	287	2.7
≥65	191	0.8	192	0.7	210	0.8	193	0.7	199	0.7	225	0.8
Race/ethnicity												
American Indian/Alaska Native	19	—	20	—	34	—	24	—	20	—	15	—
Asian ^b	48	—	56	—	50	—	61	—	55	—	57	—
Black/African American	3,561	—	2,965	—	2,773	—	2,614	—	2,612	—	2,494	—
Hispanic/Latino ^c	983	—	818	—	728	—	749	—	702	—	666	—
Native Hawaiian/Other Pacific Islander	5	—	3	—	2	—	5	—	8	—	—	—
White	831	—	727	—	752	—	709	—	742	—	743	—
Multiple races	360	—	244	—	236	—	207	—	197	—	174	—
Region of residence^d												
Northeast	1,224	5.0	1,023	4.2	895	3.6	871	3.5	853	3.5	795	3.2
Midwest	566	2.0	532	1.8	473	1.6	537	1.9	537	1.8	480	1.6
South	3,408	6.7	2,704	5.3	2,676	5.2	2,451	4.7	2,463	4.6	2,368	4.4
West	479	1.5	460	1.5	470	1.5	449	1.4	415	1.3	463	1.4
U.S. dependent areas	130	7.4	114	6.5	61	3.5	61	3.6	68	4.0	43	2.6
Subtotal	5,807	4.3	4,833	3.5	4,575	3.3	4,369	3.1	4,336	3.1	4,149	2.9
Total	24,095	9.0	19,669	7.3	18,856	7.0	18,641	6.8	17,903	6.5	17,186	6.2

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data are based on residence at time of stage 3 (AIDS) classification.

Table 7a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	4	5	2	2	8	0	0	1	0	0	0
20–24	17	28	30	25	18	27	1	1	3	4	3	2
25–29	23	27	23	39	33	26	1	1	1	7	8	5
30–34	10	19	17	29	20	20	2	0	0	3	5	5
35–39	7	6	14	12	15	12	1	0	3	2	1	2
40–44	7	10	6	14	13	9	0	1	0	0	2	1
45–49	7	10	6	6	6	5	1	2	0	0	1	3
50–54	6	7	5	5	8	8	2	3	0	1	0	1
55–59	0	2	3	3	2	4	0	0	0	0	0	0
60–64	1	0	0	3	2	1	0	0	0	0	1	0
≥65	2	0	0	1	0	2	0	0	0	0	1	0
Region of residence^a												
Northeast	1	5	3	7	2	6	0	0	0	0	0	0
Midwest	6	9	9	13	13	16	1	3	1	2	4	4
South	19	24	32	35	27	22	2	1	2	6	11	5
West	54	75	64	82	75	77	5	4	7	10	8	12
Total	80	113	108	137	117	121	8	8	10	18	23	20
Asian												
Age at diagnosis (yr)												
13–14	0	0	1	0	0	1	0	0	0	0	0	0
15–19	6	14	23	20	24	20	0	1	0	1	0	0
20–24	93	127	120	113	153	111	2	2	4	4	2	1
25–29	107	144	167	164	155	176	2	2	4	0	3	4
30–34	97	112	103	127	112	119	0	2	3	3	6	2
35–39	78	93	74	84	89	71	1	3	3	1	2	3
40–44	89	73	79	86	74	65	2	5	3	0	0	2
45–49	51	60	62	52	67	53	1	1	1	1	3	0
50–54	20	31	35	32	34	25	0	1	1	1	1	0
55–59	11	10	14	20	20	20	0	0	0	0	0	0
60–64	6	7	4	9	8	12	0	1	0	0	0	0
≥65	4	8	5	10	7	10	0	0	0	1	0	0
Region of residence^a												
Northeast	90	117	110	139	133	136	5	2	2	3	2	3
Midwest	48	53	81	67	80	67	0	5	2	4	1	0
South	133	135	154	153	154	182	2	3	6	1	1	2
West	291	373	344	358	375	298	3	9	9	6	14	9
Total	562	679	689	717	743	683	10	19	20	14	17	13

Table 7a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	10	3	8	4	5	7	1	0	0	0	0	0
15–19	778	801	864	807	851	805	16	11	15	15	10	10
20–24	2,992	3,130	2,998	2,873	2,573	2,445	82	55	59	53	36	44
25–29	2,023	2,303	2,474	2,595	2,548	2,572	66	51	48	65	61	72
30–34	1,036	1,178	1,210	1,225	1,351	1,339	41	41	37	45	45	45
35–39	652	675	733	741	778	771	23	26	33	31	37	24
40–44	581	509	490	454	442	463	23	27	18	17	17	16
45–49	515	480	466	393	371	384	27	15	17	17	12	12
50–54	369	330	361	361	338	323	22	22	14	13	23	16
55–59	189	224	206	217	209	197	17	15	13	8	10	10
60–64	93	103	86	100	107	110	8	9	5	8	6	6
≥65	62	80	82	70	67	80	4	4	4	4	4	3
Region of residence^a												
Northeast	1,220	1,282	1,238	1,158	1,192	1,123	49	48	30	33	38	40
Midwest	1,567	1,599	1,576	1,628	1,525	1,489	53	45	37	57	41	49
South	5,776	6,153	6,325	6,158	6,085	6,054	185	142	159	148	131	132
West	735	784	840	894	837	830	42	42	37	39	50	37
Total	9,299	9,818	9,979	9,839	9,639	9,496	329	276	263	276	260	257
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	2	5	1	1	5	1	0	0	0	0	0	0
15–19	277	283	303	307	326	301	11	18	14	12	8	10
20–24	1,276	1,457	1,509	1,459	1,340	1,312	68	52	71	71	63	62
25–29	1,386	1,490	1,585	1,781	1,716	1,735	81	61	81	75	87	81
30–34	1,118	1,209	1,197	1,309	1,310	1,299	62	69	69	71	58	52
35–39	766	871	921	939	913	900	41	43	38	42	44	41
40–44	650	667	604	630	585	561	37	33	31	33	24	22
45–49	519	547	542	477	520	504	18	28	22	12	19	18
50–54	303	293	354	353	339	336	15	11	11	17	15	15
55–59	153	136	171	160	169	196	7	8	5	6	8	5
60–64	60	77	60	76	73	87	1	3	1	4	3	4
≥65	49	54	59	51	71	65	3	2	2	2	2	2
Region of residence^a												
Northeast	1,259	1,294	1,278	1,219	1,255	1,148	74	52	53	48	38	50
Midwest	485	506	489	480	499	514	26	19	29	29	24	24
South	2,609	2,829	3,053	3,228	3,155	3,190	120	119	126	133	120	97
West	2,206	2,460	2,487	2,615	2,457	2,446	124	138	137	136	151	140
Total	6,559	7,088	7,305	7,542	7,366	7,298	345	328	346	346	332	311

Table 7a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	1	2	1	1	3	0	0	0	0	0	0
20–24	2	5	9	1	9	7	0	0	0	0	0	2
25–29	9	3	12	7	10	12	1	0	0	2	0	1
30–34	8	6	10	3	9	12	1	1	0	2	0	1
35–39	4	7	7	6	2	8	0	0	1	0	1	0
40–44	3	3	3	4	5	3	0	0	0	0	0	0
45–49	4	3	6	1	1	3	0	0	0	0	0	0
50–54	2	1	5	2	1	2	0	0	0	0	0	0
55–59	0	0	2	0	0	4	0	0	0	0	0	0
60–64	0	1	0	0	0	1	0	0	0	0	0	0
≥65	0	1	0	1	0	1	0	0	0	1	0	0
Region of residence^a												
Northeast	1	0	2	3	3	2	1	0	0	1	0	0
Midwest	2	1	1	2	2	3	0	0	0	0	0	0
South	2	7	18	4	6	14	0	0	1	0	0	0
West	28	23	35	17	27	36	1	1	0	4	1	5
Total	33	31	55	25	38	54	2	1	1	5	1	5
White												
Age at diagnosis (yr)												
13–14	1	3	0	0	1	0	0	0	0	0	0	0
15–19	134	141	148	156	169	171	10	9	15	18	12	11
20–24	956	969	947	898	955	835	103	84	103	93	81	63
25–29	1,096	1,273	1,252	1,227	1,261	1,175	135	149	160	148	160	160
30–34	1,016	1,000	1,013	980	909	965	103	118	125	122	118	132
35–39	773	808	744	691	755	680	74	86	99	83	93	106
40–44	930	808	702	624	502	541	75	81	53	67	57	45
45–49	1,031	936	764	729	632	587	51	64	48	55	56	49
50–54	754	801	801	740	691	544	40	50	60	40	36	42
55–59	512	452	425	456	436	458	26	21	32	30	25	26
60–64	295	235	249	236	244	248	12	9	12	12	16	8
≥65	221	205	193	201	182	212	9	4	4	9	9	6
Region of residence^a												
Northeast	1,203	1,176	1,035	976	873	803	72	63	71	60	73	72
Midwest	1,373	1,320	1,259	1,216	1,238	1,122	81	113	125	128	106	122
South	3,259	3,239	3,037	3,003	2,930	2,931	261	267	290	259	286	258
West	1,884	1,895	1,908	1,744	1,697	1,562	224	229	226	229	199	196
Total	7,720	7,630	7,239	6,939	6,737	6,418	638	673	712	676	664	647

Table 7a. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States (cont)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	83	70	57	51	51	29	8	6	2	3	1	2
20–24	335	270	258	225	169	145	26	23	15	16	10	6
25–29	253	231	254	216	194	135	18	18	22	18	12	18
30–34	157	148	138	132	120	97	16	10	21	14	4	8
35–39	109	104	90	69	66	69	10	9	6	8	8	8
40–44	82	76	60	56	48	33	5	9	5	1	3	1
45–49	89	70	55	50	37	26	7	8	5	7	4	5
50–54	44	54	45	37	43	24	8	5	1	4	4	3
55–59	33	26	26	30	20	9	1	2	2	2	3	0
60–64	19	9	16	17	11	6	0	1	1	1	1	0
≥65	12	10	13	8	6	6	2	0	0	0	0	0
Region of residence^a												
Northeast	294	231	226	186	149	107	19	18	16	14	7	4
Midwest	156	135	124	102	115	78	12	12	10	14	6	10
South	541	491	441	408	348	271	46	33	25	28	25	21
West	223	212	220	196	151	124	25	28	30	18	12	16
Total	1,214	1,069	1,011	891	764	580	101	90	81	73	50	51
Total												
Age at diagnosis (yr)												
13–14	13	11	10	5	10	9	1	0	0	0	0	0
15–19	1,279	1,315	1,402	1,344	1,423	1,336	46	45	48	49	32	33
20–24	5,671	5,985	5,871	5,593	5,217	4,882	282	218	256	240	195	179
25–29	4,898	5,472	5,766	6,029	5,916	5,830	304	281	315	315	331	343
30–34	3,441	3,673	3,688	3,805	3,831	3,851	226	241	255	259	236	245
35–39	2,389	2,563	2,584	2,541	2,617	2,511	151	167	184	168	186	183
40–44	2,342	2,147	1,943	1,867	1,669	1,675	142	155	110	118	104	87
45–49	2,214	2,105	1,901	1,709	1,633	1,563	105	117	93	93	95	86
50–54	1,499	1,518	1,607	1,530	1,453	1,262	87	92	88	77	79	78
55–59	897	849	846	885	856	888	51	47	52	47	46	41
60–64	474	431	416	441	445	465	21	22	20	26	27	19
≥65	350	358	353	343	333	377	17	10	11	17	16	11
Region of residence^a												
Northeast	4,068	4,106	3,891	3,688	3,607	3,323	219	184	172	158	157	169
Midwest	3,638	3,622	3,537	3,508	3,473	3,289	173	196	203	233	182	208
South	12,339	12,878	13,061	12,989	12,705	12,664	615	565	610	575	573	514
West	5,421	5,821	5,898	5,905	5,619	5,374	424	450	447	442	435	414
Total	25,467	26,428	26,387	26,090	25,404	24,650	1,432	1,395	1,432	1,409	1,347	1,305

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	4	5	2	2	8	0	0	1	0	0	0
20–24	17	28	30	25	18	27	1	1	3	4	3	2
25–29	23	27	23	39	33	26	1	1	1	7	8	5
30–34	10	19	17	29	20	20	2	0	0	3	5	5
35–39	7	6	14	12	15	12	1	0	3	2	1	2
40–44	7	10	6	14	13	9	0	1	0	0	2	1
45–49	7	10	6	6	6	5	1	2	0	0	1	3
50–54	6	7	5	5	8	8	2	3	0	1	0	1
55–59	0	2	3	3	2	4	0	0	0	0	0	0
60–64	1	0	0	3	2	1	0	0	0	0	1	0
≥65	2	0	0	1	0	2	0	0	0	0	1	0
Region of residence^a												
Northeast	1	5	3	7	2	6	0	0	0	0	0	0
Midwest	6	9	9	13	13	16	1	3	1	2	4	4
South	19	24	32	35	27	22	2	1	2	6	11	5
West	54	75	64	82	75	77	5	4	7	10	8	12
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	80	113	108	137	117	121	8	8	10	18	23	20
Asian												
Age at diagnosis (yr)												
13–14	0	0	1	0	0	1	0	0	0	0	0	0
15–19	6	14	23	20	24	20	0	1	0	1	0	0
20–24	93	127	120	113	153	111	2	2	4	4	2	1
25–29	107	145	168	164	155	177	2	2	4	0	3	4
30–34	97	112	104	127	114	121	0	2	3	3	6	2
35–39	78	93	75	84	90	71	1	3	3	1	2	3
40–44	89	73	79	86	74	66	2	5	3	0	0	2
45–49	51	60	62	52	67	53	1	1	1	1	3	0
50–54	20	32	35	32	34	25	0	1	1	1	1	0
55–59	11	10	14	20	20	20	0	0	0	0	0	0
60–64	6	7	4	9	8	12	0	1	0	0	0	0
≥65	4	8	5	10	7	10	0	0	0	1	0	0
Region of residence^a												
Northeast	90	117	110	139	133	136	5	2	2	3	2	3
Midwest	48	53	81	67	80	67	0	5	2	4	1	0
South	133	135	154	153	154	182	2	3	6	1	1	2
West	291	373	344	358	375	298	3	9	9	6	14	9
U.S. dependent areas	0	2	3	1	3	3	0	0	0	0	0	0
Total	562	681	691	718	746	687	10	19	20	14	17	13

Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	10	3	8	4	5	7	1	0	0	0	0	0
15–19	778	801	864	807	851	805	16	11	15	15	10	10
20–24	2,993	3,130	2,999	2,874	2,573	2,445	82	55	59	53	36	44
25–29	2,024	2,303	2,475	2,595	2,548	2,574	66	51	48	65	61	72
30–34	1,036	1,179	1,210	1,226	1,351	1,340	41	41	37	45	45	45
35–39	652	676	734	741	778	771	24	26	33	31	37	24
40–44	582	510	491	455	443	463	23	27	18	17	17	16
45–49	515	481	467	393	371	385	27	15	17	17	12	12
50–54	369	331	361	361	338	323	22	22	14	13	23	16
55–59	189	225	206	217	209	197	17	15	13	8	10	10
60–64	93	103	86	100	107	110	8	9	5	8	6	6
≥65	62	80	82	70	67	80	4	4	4	4	4	3
Region of residence^a												
Northeast	1,220	1,282	1,238	1,158	1,192	1,123	49	48	30	33	38	40
Midwest	1,567	1,599	1,576	1,628	1,525	1,489	53	45	37	57	41	49
South	5,776	6,153	6,325	6,158	6,085	6,054	185	142	159	148	131	132
West	735	784	840	894	837	830	42	42	37	39	50	37
U.S. dependent areas	3	4	5	3	1	4	0	0	0	0	0	0
Total	9,302	9,821	9,984	9,842	9,640	9,499	329	276	263	276	260	257
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	2	5	1	1	5	1	0	0	0	0	0	0
15–19	291	299	306	316	334	311	11	18	14	12	8	10
20–24	1,341	1,549	1,566	1,521	1,389	1,357	71	55	75	71	64	63
25–29	1,442	1,554	1,651	1,837	1,757	1,789	82	62	84	77	92	85
30–34	1,169	1,242	1,234	1,351	1,350	1,332	70	69	70	73	60	55
35–39	788	904	957	972	936	921	41	45	41	46	47	42
40–44	679	701	633	650	602	585	41	34	36	35	25	22
45–49	537	566	568	496	535	524	20	28	24	13	21	18
50–54	317	304	371	376	360	353	20	11	12	18	15	16
55–59	158	142	179	178	179	208	7	8	5	6	8	6
60–64	68	81	69	79	77	94	1	3	1	4	3	5
≥65	53	59	66	52	74	68	3	3	4	2	2	2
Region of residence^a												
Northeast	1,259	1,294	1,278	1,219	1,255	1,148	74	52	53	48	38	50
Midwest	485	506	489	480	499	514	26	19	29	29	24	24
South	2,609	2,829	3,053	3,228	3,155	3,190	120	119	126	133	120	97
West	2,206	2,460	2,487	2,615	2,457	2,446	124	138	137	136	151	140
U.S. dependent areas	287	319	296	286	230	245	22	8	21	11	11	11
Total	6,846	7,407	7,601	7,828	7,596	7,543	367	336	367	357	343	323

Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	1	2	1	1	3	0	0	0	0	0	0
20–24	2	5	10	3	9	7	0	0	0	0	0	2
25–29	9	4	13	7	10	12	1	0	0	3	0	1
30–34	9	6	10	5	9	12	1	1	0	2	0	1
35–39	4	7	7	6	2	9	0	0	1	0	1	0
40–44	3	4	3	4	5	3	0	0	0	0	0	0
45–49	4	3	6	1	1	3	0	0	0	0	0	0
50–54	2	1	5	2	2	2	0	0	0	0	0	0
55–59	0	0	2	0	1	4	0	0	0	0	0	0
60–64	0	1	0	0	0	1	0	0	0	0	0	0
≥65	0	1	0	1	0	1	0	0	0	1	0	0
Region of residence^a												
Northeast	1	0	2	3	3	2	1	0	0	1	0	0
Midwest	2	1	1	2	2	3	0	0	0	0	0	0
South	2	7	18	4	6	14	0	0	1	0	0	0
West	28	23	35	17	27	36	1	1	0	4	1	5
U.S. dependent areas	1	2	3	4	2	1	0	0	0	1	0	0
Total	34	33	58	29	40	55	2	1	1	6	1	5
White												
Age at diagnosis (yr)												
13–14	1	3	0	0	1	0	0	0	0	0	0	0
15–19	134	141	148	156	169	172	10	9	15	18	12	11
20–24	956	970	947	899	955	836	103	84	103	93	81	63
25–29	1,097	1,274	1,252	1,227	1,261	1,175	135	149	160	148	160	160
30–34	1,017	1,001	1,013	981	909	965	103	118	125	122	118	132
35–39	773	808	744	691	756	680	74	86	99	83	93	106
40–44	930	810	702	624	502	542	75	81	53	67	57	45
45–49	1,031	936	764	729	632	587	51	64	48	55	56	49
50–54	754	801	803	740	691	545	40	50	60	40	36	42
55–59	512	453	425	456	436	460	26	21	32	30	25	26
60–64	295	235	249	236	244	248	12	9	12	12	16	8
≥65	221	205	193	201	182	212	9	4	4	9	9	6
Region of residence^a												
Northeast	1,203	1,176	1,035	976	873	803	72	63	71	60	73	72
Midwest	1,373	1,320	1,259	1,216	1,238	1,122	81	113	125	128	106	122
South	3,259	3,239	3,037	3,003	2,930	2,931	261	267	290	259	286	258
West	1,884	1,895	1,908	1,744	1,697	1,562	224	229	226	229	199	196
U.S. dependent areas	2	6	1	2	1	6	0	0	0	0	0	0
Total	7,722	7,636	7,240	6,941	6,738	6,423	638	673	712	676	664	647

Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	83	71	57	51	51	29	8	6	2	3	1	2
20–24	335	270	258	225	169	145	26	23	15	16	10	6
25–29	253	231	254	216	194	135	18	18	22	18	12	18
30–34	157	148	138	132	120	97	16	10	21	14	4	8
35–39	109	104	90	69	67	69	10	9	6	8	8	8
40–44	82	76	60	56	48	33	5	9	5	1	3	1
45–49	89	70	55	50	37	26	7	8	5	7	4	5
50–54	44	54	45	37	43	24	8	5	1	4	4	3
55–59	33	26	26	30	20	9	1	2	2	2	3	0
60–64	19	9	16	17	11	6	0	1	1	1	1	0
≥65	12	10	13	8	6	6	2	0	0	0	0	0
Region of residence^a												
Northeast	294	231	226	186	149	107	19	18	16	14	7	4
Midwest	156	135	124	102	115	78	12	12	10	14	6	10
South	541	491	441	408	348	271	46	33	25	28	25	21
West	223	212	220	196	151	124	25	28	30	18	12	16
U.S. dependent areas	0	1	0	0	1	0	0	0	0	0	0	0
Total	1,214	1,070	1,011	891	765	580	101	90	81	73	50	51
Total												
Age at diagnosis (yr)												
13–14	13	11	10	5	10	9	1	0	0	0	0	0
15–19	1,293	1,332	1,405	1,353	1,431	1,347	46	45	48	49	32	33
20–24	5,737	6,079	5,930	5,659	5,266	4,928	285	221	260	240	196	180
25–29	4,956	5,539	5,836	6,084	5,958	5,887	305	282	318	318	335	346
30–34	3,494	3,708	3,726	3,851	3,872	3,888	234	241	256	261	238	248
35–39	2,411	2,597	2,622	2,575	2,643	2,532	151	169	187	171	188	184
40–44	2,372	2,183	1,973	1,888	1,687	1,701	146	156	115	120	104	87
45–49	2,233	2,125	1,928	1,728	1,649	1,583	107	117	95	94	97	86
50–54	1,513	1,530	1,626	1,553	1,475	1,281	91	92	89	77	79	78
55–59	902	857	854	903	867	902	51	47	52	47	46	42
60–64	482	436	425	444	448	472	21	22	20	26	27	20
≥65	354	363	359	344	336	380	17	11	13	17	16	11
Region of residence^a												
Northeast	4,068	4,106	3,891	3,688	3,607	3,323	219	184	172	158	157	169
Midwest	3,638	3,622	3,537	3,508	3,473	3,289	173	196	203	233	182	208
South	12,339	12,878	13,061	12,989	12,705	12,664	615	565	610	575	573	514
West	5,421	5,821	5,898	5,905	5,619	5,374	424	450	447	442	435	414
U.S. dependent areas	294	333	307	296	238	259	22	8	21	12	11	11
Total	25,760	26,761	26,693	26,386	25,641	24,909	1,454	1,403	1,453	1,420	1,358	1,316

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States

	Male						Female					
	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	1	0	0	0	0	1	0
20–24	2	1	0	3	1	0	1	0	1	1	1	0
25–29	1	2	2	4	6	0	0	2	2	2	3	2
30–34	3	0	2	0	4	2	2	2	2	1	1	4
35–39	0	0	1	1	0	0	0	1	1	2	2	3
40–44	2	3	0	2	1	0	3	2	2	1	2	0
45–49	3	1	0	2	0	1	1	1	3	1	2	2
50–54	1	3	1	0	3	1	2	0	0	5	3	1
55–59	1	0	1	2	0	0	0	0	2	0	1	0
60–64	0	0	0	0	1	1	1	1	1	1	0	1
≥65	1	0	0	0	1	0	0	0	0	0	1	0
Region of residence^a												
Northeast	0	0	0	0	1	1	0	0	0	1	1	0
Midwest	1	1	0	1	2	1	3	2	1	1	1	2
South	4	4	2	3	2	1	2	3	4	1	4	5
West	10	6	5	12	12	4	5	5	9	11	10	7
Total	15	11	8	16	18	7	10	10	13	13	17	14
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	0	0	0	0	0	0
20–24	2	1	0	0	0	1	0	1	1	1	1	0
25–29	2	1	1	1	0	1	1	0	0	1	2	0
30–34	3	3	7	1	1	3	1	1	1	1	0	2
35–39	3	4	0	3	3	0	1	1	1	2	1	1
40–44	5	3	4	1	2	1	0	0	1	0	0	0
45–49	3	2	1	2	3	2	2	0	0	1	0	0
50–54	1	2	2	2	2	1	1	0	0	0	1	1
55–59	1	1	1	1	0	0	1	1	0	1	0	0
60–64	1	0	1	0	0	1	0	0	2	0	0	0
≥65	1	1	1	1	0	1	0	0	0	0	0	1
Region of residence^a	7	5	7	3	4	5	1	2	1	2	1	1
Northeast												
Midwest	2	1	0	2	0	1	2	1	1	0	0	0
South	6	8	2	3	2	5	1	1	2	2	1	2
West	7	4	8	7	6	1	3	2	2	3	3	3
Total	22	19	19	14	12	12	7	6	5	8	6	6

Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States (*cont*)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	0	0	1	0	1	0	2	1	0	0
15–19	8	5	5	3	6	6	10	10	7	6	10	8
20–24	26	33	28	19	20	27	28	31	28	19	29	23
25–29	39	36	35	34	38	51	28	35	43	42	40	32
30–34	41	37	41	33	57	51	42	38	32	38	38	37
35–39	51	36	43	49	45	62	35	39	33	30	39	38
40–44	47	50	47	44	33	41	49	41	34	28	37	31
45–49	87	69	44	45	47	46	60	52	43	33	41	36
50–54	90	64	68	57	49	48	54	48	42	54	36	36
55–59	81	78	62	44	57	51	62	48	36	40	31	38
60–64	44	41	31	36	35	31	24	20	25	28	26	22
≥65	30	38	29	29	29	35	14	16	15	15	15	19
Region of residence^a												
Northeast	178	158	126	110	137	136	93	107	95	74	96	83
Midwest	59	47	48	52	64	61	61	46	50	50	56	43
South	266	251	214	183	183	208	220	189	158	169	159	164
West	41	31	44	49	31	43	30	36	35	43	32	31
Total	544	487	432	394	415	448	405	377	338	335	343	320
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	2	1	2	5	3	4	6	4	4	4	3
20–24	19	17	22	20	18	23	14	19	26	13	16	20
25–29	35	32	38	32	38	35	23	18	13	31	16	18
30–34	48	40	43	51	58	63	22	22	17	26	28	22
35–39	42	35	47	43	41	43	17	21	18	12	21	22
40–44	48	50	39	25	43	33	22	27	18	17	15	12
45–49	56	48	34	32	39	43	18	16	17	14	14	18
50–54	30	35	37	39	37	39	20	16	16	14	12	13
55–59	36	25	28	25	24	25	10	16	9	13	6	7
60–64	9	15	10	11	14	15	7	7	3	7	5	8
≥65	12	7	13	13	13	11	5	5	6	5	4	4
Region of residence^a												
Northeast	128	95	106	101	114	112	70	63	50	53	44	49
Midwest	19	11	17	13	15	13	12	12	7	9	8	8
South	100	92	93	85	93	103	43	50	51	51	43	50
West	91	108	94	94	107	104	36	48	39	43	46	41
Total	338	306	311	292	330	332	161	174	147	156	140	147

Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States (*cont*)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	1	0	0	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	0	0	1	0	0	0	0	0	0	0	0	0
40–44	0	0	1	0	0	0	0	0	0	0	0	0
45–49	1	0	0	0	0	1	0	0	0	0	0	0
50–54	0	0	0	0	1	0	0	0	0	2	0	0
55–59	0	0	0	0	0	0	0	0	0	0	0	0
60–64	0	1	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	1	1	0	0	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	0	0	0
West	1	0	1	0	1	1	0	0	1	2	0	0
Total	1	1	2	0	1	2	0	1	1	2	0	0
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	0	1	0	0	0
15–19	2	2	1	4	4	5	9	13	9	6	9	9
20–24	26	25	43	30	36	36	37	40	51	42	50	50
25–29	36	41	81	81	85	101	51	54	90	91	89	78
30–34	47	54	79	60	91	110	59	63	88	68	93	102
35–39	37	44	53	70	78	111	34	47	54	59	81	88
40–44	42	57	55	46	48	63	47	37	60	43	52	68
45–49	59	52	66	51	57	52	50	38	49	42	37	43
50–54	46	53	56	49	37	49	42	27	41	41	39	41
55–59	38	28	31	28	38	35	23	20	23	21	29	27
60–64	17	19	21	19	19	19	13	6	11	13	9	8
≥65	13	13	9	16	15	10	4	5	6	8	4	6
Region of residence^a												
Northeast	58	64	73	82	97	121	69	59	76	87	92	96
Midwest	55	51	142	87	93	123	63	41	134	85	90	110
South	147	146	157	164	202	212	164	168	195	181	220	216
West	103	125	123	121	114	136	73	81	77	82	90	99
Total	363	387	495	453	507	592	369	349	482	435	492	522

Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	1	0	1	1	2	2	1	2	3
20–24	2	2	2	2	0	3	4	4	1	3	5	5
25–29	5	9	6	5	6	8	6	4	3	6	5	9
30–34	6	7	8	0	4	5	4	8	8	2	4	4
35–39	4	5	1	6	4	4	6	7	3	8	5	5
40–44	10	4	2	5	4	3	7	6	3	5	5	4
45–49	8	5	3	2	4	2	4	6	5	6	4	2
50–54	10	6	4	8	2	6	5	8	4	4	5	3
55–59	3	4	4	3	3	5	4	4	8	4	2	1
60–64	3	3	2	2	1	1	4	1	1	1	0	2
≥65	2	1	4	1	0	0	1	2	1	0	0	3
Region of residence^a												
Northeast	14	11	10	7	6	5	13	13	7	8	12	11
Midwest	3	10	8	3	5	8	6	4	7	5	4	5
South	22	14	15	12	8	11	19	25	14	16	13	13
West	13	10	5	13	8	14	8	9	10	9	8	10
Total	52	45	38	34	27	37	46	51	39	39	37	39
Total												
Age at diagnosis (yr)												
13–14	0	0	0	0	1	0	1	0	3	2	0	0
15–19	12	10	8	10	14	16	25	32	22	16	26	23
20–24	78	79	95	75	75	91	83	94	108	81	102	99
25–29	118	121	163	157	172	196	107	112	151	173	154	140
30–34	148	140	180	145	215	233	131	133	148	137	165	170
35–39	136	124	146	173	170	221	93	117	109	113	149	157
40–44	155	167	148	121	131	141	129	112	116	94	113	115
45–49	217	176	148	134	149	147	135	113	117	96	96	101
50–54	178	162	168	155	130	145	124	99	102	119	95	95
55–59	160	135	126	103	121	116	100	89	78	79	70	74
60–64	74	79	65	68	70	68	48	36	42	49	40	41
≥65	58	60	56	61	58	56	24	28	28	29	25	33
Region of residence^a												
Northeast	384	335	323	302	360	380	246	243	229	224	245	239
Midwest	139	120	216	156	179	209	147	106	199	150	160	168
South	545	516	484	450	491	539	450	435	424	420	441	450
West	266	284	281	296	278	302	156	183	173	194	189	189
Total	1,334	1,255	1,304	1,204	1,308	1,430	999	966	1,025	988	1,035	1,048

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	1	0	0	0	0	1	0
20–24	2	1	0	3	1	0	1	0	1	1	1	0
25–29	1	2	2	4	6	0	0	2	2	2	3	2
30–34	3	0	2	0	4	2	2	2	2	1	1	4
35–39	0	0	1	1	0	0	0	1	1	2	2	3
40–44	2	3	0	2	1	0	3	2	2	1	2	0
45–49	3	1	0	2	0	1	1	1	3	1	2	2
50–54	1	3	1	0	3	1	2	0	0	5	3	1
55–59	1	0	1	2	0	0	0	0	2	0	1	0
60–64	0	0	0	0	1	1	1	1	1	1	0	1
≥65	1	0	0	0	1	0	0	0	0	0	1	0
Region of residence^a												
Northeast	0	0	0	0	1	1	0	0	0	1	1	0
Midwest	1	1	0	1	2	1	3	2	1	1	1	2
South	4	4	2	3	2	1	2	3	4	1	4	5
West	10	6	5	12	12	4	5	5	9	11	10	7
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	15	11	8	16	18	7	10	10	13	13	17	14
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	0	0	0	0	0	0
20–24	2	1	0	0	0	1	0	1	1	1	1	0
25–29	2	1	1	1	0	1	1	0	0	1	2	0
30–34	3	3	7	1	1	3	1	1	1	1	0	2
35–39	3	4	2	3	3	0	1	1	1	2	1	1
40–44	5	3	4	1	2	2	0	0	1	0	0	0
45–49	3	2	1	2	3	2	2	0	0	1	0	0
50–54	1	2	2	2	2	1	1	0	0	0	1	1
55–59	1	1	1	1	0	0	1	1	0	1	0	0
60–64	1	0	1	0	0	1	0	0	2	0	0	0
≥65	1	1	1	1	0	1	0	0	0	0	0	1
Region of residence^a												
Northeast	7	5	7	3	4	5	1	2	1	2	1	1
Midwest	2	1	0	2	0	1	2	1	1	0	0	0
South	6	8	2	3	2	5	1	1	2	2	1	2
West	7	4	8	7	6	1	3	2	2	3	3	3
U.S. dependent areas	0	0	1	0	0	0	0	0	0	0	0	0
Total	22	19	20	14	12	12	7	6	5	8	6	6

Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	0	0	1	0	1	0	2	1	0	0
15–19	8	5	5	3	6	6	10	10	7	6	10	8
20–24	26	33	28	19	20	27	28	31	28	19	29	23
25–29	39	36	35	34	38	51	28	35	43	42	40	32
30–34	41	37	41	33	57	51	42	38	32	38	38	37
35–39	51	36	43	49	45	62	35	40	33	30	39	38
40–44	47	50	47	44	33	41	49	41	34	28	37	31
45–49	87	69	44	45	47	47	60	52	43	33	41	36
50–54	91	64	68	57	49	48	54	48	42	54	36	36
55–59	81	78	62	44	57	52	62	48	36	40	31	38
60–64	44	43	31	36	35	31	24	20	25	28	26	22
≥65	30	38	29	29	29	35	14	16	15	15	15	19
Region of residence^a												
Northeast	178	158	126	110	137	136	93	107	95	74	96	83
Midwest	59	47	48	52	64	61	61	46	50	50	56	43
South	266	251	214	183	183	208	220	189	158	169	159	164
West	41	31	44	49	31	43	30	36	35	43	32	31
U.S. dependent areas	1	3	0	1	0	2	0	0	0	0	0	0
Total	545	490	432	394	415	450	405	378	338	335	343	320
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	2	2	3	5	3	4	7	5	4	4	3
20–24	20	21	23	22	18	24	14	20	27	14	16	20
25–29	39	39	41	33	40	38	25	18	14	32	16	18
30–34	54	43	49	52	62	66	24	25	18	27	28	23
35–39	52	42	53	50	41	44	23	25	20	14	23	22
40–44	55	53	45	29	44	39	24	29	19	18	15	12
45–49	71	59	41	37	42	46	24	17	17	15	17	18
50–54	42	41	45	42	47	46	23	17	17	15	13	13
55–59	48	34	35	31	28	26	11	17	9	13	7	7
60–64	16	20	13	14	17	16	9	7	4	8	6	8
≥65	16	9	15	17	17	13	6	6	6	5	4	4
Region of residence^a												
Northeast	128	95	106	101	114	112	70	63	50	53	44	49
Midwest	19	11	17	13	15	13	12	12	7	9	8	8
South	100	92	93	85	93	103	43	50	51	51	43	50
West	91	108	94	94	107	104	36	48	39	43	46	41
U.S. dependent areas	78	57	51	37	31	30	25	15	8	10	9	2
Total	416	363	362	330	361	362	187	188	155	166	149	149

Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	1	0	0	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	0	0	1	0	0	0	0	0	0	0	0	0
40–44	0	0	1	0	0	0	0	0	0	0	0	0
45–49	1	0	0	0	0	1	0	0	0	0	0	0
50–54	0	0	0	0	1	0	0	0	0	2	0	0
55–59	0	0	0	1	0	0	0	0	0	0	0	0
60–64	0	1	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	1	1	0	0	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	0	0	0
West	1	0	1	0	1	1	0	0	1	2	0	0
U.S. dependent areas	0	0	0	1	0	0	0	0	0	0	0	0
Total	1	1	3	1	1	2	0	1	1	2	0	0
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	0	1	0	0	0
15–19	2	2	1	4	4	5	9	13	9	6	9	9
20–24	26	25	43	30	36	36	37	40	51	42	50	50
25–29	36	41	81	81	85	101	51	54	90	91	89	78
30–34	47	54	79	60	91	110	59	63	88	68	93	102
35–39	37	44	53	70	78	111	34	47	54	59	81	88
40–44	42	57	55	46	48	63	47	37	60	43	52	68
45–49	60	52	66	51	57	52	50	38	49	42	37	43
50–54	46	53	57	49	37	49	42	27	41	41	39	41
55–59	38	28	31	28	38	35	23	20	23	21	29	27
60–64	17	19	21	19	19	19	13	6	11	13	9	8
≥65	13	13	9	16	15	10	4	5	6	8	4	6
Region of residence^a												
Northeast	58	64	73	82	97	121	69	59	76	87	92	96
Midwest	55	51	142	87	93	123	63	41	134	85	90	110
South	147	146	157	164	202	212	164	168	195	181	220	216
West	103	125	123	121	114	136	73	81	77	82	90	99
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	363	387	496	453	507	593	369	349	482	435	492	522

Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	1	0	1	1	2	2	1	2	3
20–24	2	2	2	2	0	3	4	4	1	3	5	5
25–29	5	9	6	5	6	8	6	4	3	6	5	9
30–34	6	7	8	0	4	5	4	8	8	2	4	4
35–39	4	5	1	6	4	4	6	7	3	8	5	5
40–44	10	4	2	5	4	3	7	6	3	5	5	4
45–49	8	5	3	2	4	2	4	6	5	6	4	2
50–54	10	6	4	8	2	6	5	8	4	4	5	3
55–59	3	4	4	3	3	5	4	4	8	4	2	1
60–64	3	3	2	2	1	1	4	1	1	1	0	2
≥65	2	1	4	1	0	0	1	2	1	0	0	3
Region of residence^a												
Northeast	14	11	10	7	6	5	13	13	7	8	12	11
Midwest	3	10	8	3	5	8	6	4	7	5	4	5
South	22	14	15	12	8	11	19	25	14	16	13	13
West	13	10	5	13	8	14	8	9	10	9	8	10
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	52	45	38	34	27	37	46	51	39	39	37	39
Total												
Age at diagnosis (yr)												
13–14	0	0	0	0	1	0	1	0	3	2	0	0
15–19	12	11	9	11	14	16	25	33	22	16	26	23
20–24	79	82	97	77	75	91	83	95	109	82	102	99
25–29	122	128	166	158	174	199	109	112	152	174	154	140
30–34	154	143	187	147	218	236	133	136	149	138	165	171
35–39	146	131	153	179	171	222	99	121	111	115	151	157
40–44	162	171	153	126	132	148	131	114	117	95	113	115
45–49	232	188	154	139	153	151	141	114	117	98	99	101
50–54	190	169	177	158	140	152	127	100	103	120	96	95
55–59	172	145	133	110	125	118	101	90	78	79	71	74
60–64	80	85	68	72	73	70	50	36	43	50	41	41
≥65	63	62	58	65	62	59	25	29	28	29	25	33
Region of residence^a												
Northeast	384	335	323	302	360	380	246	243	229	224	245	239
Midwest	139	120	216	156	179	209	147	106	199	150	160	168
South	545	516	484	450	491	539	450	435	424	420	441	450
West	266	284	281	296	278	302	156	183	173	194	189	189
U.S. dependent areas	79	60	54	39	32	32	25	15	8	10	9	2
Total	1,413	1,315	1,357	1,242	1,340	1,462	1,025	981	1,033	998	1,043	1,049

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States

	Male						Female					
	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	1	2	1	0	0	1
20–24	1	0	1	0	0	1	3	1	2	0	2	1
25–29	2	0	0	1	1	0	1	6	7	5	5	2
30–34	3	3	1	1	2	1	2	1	6	3	2	2
35–39	1	1	1	1	3	1	2	3	5	6	4	2
40–44	0	1	0	1	0	0	2	2	4	6	5	4
45–49	3	3	3	1	1	0	1	1	3	4	5	1
50–54	0	0	2	1	0	2	5	5	4	2	4	3
55–59	0	1	1	0	1	2	1	3	3	2	1	3
60–64	0	0	0	1	0	0	0	0	0	1	2	0
≥65	0	0	0	2	0	1	2	0	1	1	0	0
Region of residence^a												
Northeast	3	2	2	0	0	0	0	0	1	4	0	0
Midwest	5	1	1	1	0	2	5	3	6	1	4	2
South	1	1	2	2	4	2	5	7	14	8	6	8
West	2	7	4	6	4	4	10	13	13	16	21	9
Total	11	10	10	9	8	9	20	23	35	29	30	18
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	0	0	1	0	0
15–19	0	1	0	0	0	0	2	1	3	0	1	0
20–24	1	1	0	3	2	5	8	9	13	9	6	7
25–29	6	6	6	3	4	1	18	19	17	19	19	13
30–34	6	13	4	10	4	8	22	17	20	33	8	17
35–39	4	6	18	13	9	7	22	24	19	24	25	10
40–44	11	5	10	5	3	10	16	21	15	15	10	12
45–49	9	4	9	7	6	6	12	10	10	10	12	11
50–54	5	8	6	4	2	6	7	8	8	10	13	8
55–59	4	3	4	4	2	2	7	8	4	7	7	9
60–64	2	1	1	4	4	6	2	5	6	4	7	5
≥65	1	5	4	6	4	5	3	1	5	5	5	6
Region of residence^a												
Northeast	11	15	10	10	9	13	20	24	21	33	18	28
Midwest	6	6	7	9	4	3	19	14	16	13	20	5
South	16	15	24	24	12	24	37	32	42	43	31	28
West	17	15	20	16	15	17	44	52	39	47	44	36
Total	50	51	61	59	40	55	120	121	119	135	112	96

Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	2	1	0	0	0	5	5	7	6	5	2
15–19	34	29	31	39	24	31	183	184	151	143	142	136
20–24	134	160	164	163	132	111	460	466	469	409	416	395
25–29	192	204	245	255	205	209	563	560	535	570	519	505
30–34	225	210	211	235	205	224	559	530	530	544	549	485
35–39	226	222	222	231	218	204	506	546	549	557	498	472
40–44	239	270	255	229	187	162	478	476	428	428	414	436
45–49	299	246	256	234	183	170	479	434	396	436	398	384
50–54	265	259	258	236	202	194	413	365	390	383	346	331
55–59	199	200	211	185	186	167	317	325	283	303	298	311
60–64	134	112	128	126	123	100	142	154	175	190	199	176
≥65	132	122	104	123	109	102	120	127	134	122	171	136
Region of residence^a												
Northeast	412	418	383	358	292	251	689	766	711	677	657	593
Midwest	216	174	191	193	188	192	521	480	496	506	517	487
South	1,371	1,353	1,420	1,413	1,232	1,159	2,793	2,683	2,575	2,603	2,540	2,414
West	80	90	93	93	61	72	222	244	265	303	241	275
Total	2,079	2,035	2,087	2,055	1,773	1,674	4,225	4,173	4,047	4,090	3,954	3,768
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	2	1	0	2	2	3
15–19	7	5	4	5	7	7	44	44	39	30	38	33
20–24	35	41	33	52	30	28	92	128	120	102	114	89
25–29	78	66	51	74	59	51	146	131	133	135	133	136
30–34	102	90	87	89	72	73	130	161	133	154	132	126
35–39	96	104	101	86	77	84	129	153	141	121	124	142
40–44	79	96	80	82	78	67	115	124	122	121	100	106
45–49	78	84	69	77	56	71	120	112	105	103	121	112
50–54	64	71	64	57	52	57	116	91	110	102	87	110
55–59	48	43	46	36	34	44	60	73	58	68	71	77
60–64	21	22	26	30	29	20	38	36	37	40	41	50
≥65	24	25	36	25	27	30	30	24	27	39	37	46
Region of residence^a												
Northeast	163	163	151	163	126	119	326	310	274	301	256	238
Midwest	43	35	39	41	27	32	61	73	51	59	60	52
South	320	348	321	303	274	306	409	421	475	427	459	514
West	106	99	86	106	94	75	226	273	226	228	224	225
Total	631	646	596	614	521	532	1,022	1,078	1,026	1,015	999	1,029

Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States (*cont*)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	1	1	0	0	1
20–24	0	0	0	0	0	0	3	1	2	1	0	0
25–29	0	0	1	0	1	0	0	0	0	0	2	0
30–34	0	0	0	0	1	3	1	1	1	1	3	2
35–39	0	0	2	1	0	0	0	1	0	2	3	0
40–44	0	1	0	0	0	0	0	1	0	0	0	0
45–49	0	0	1	1	1	0	1	0	0	0	0	0
50–54	0	0	1	0	0	0	3	1	1	2	0	1
55–59	0	0	1	0	0	0	0	1	1	0	1	1
60–64	0	0	0	0	0	0	1	1	0	0	0	0
≥65	0	0	0	0	1	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	1	0	0	1	1	0	1	0	0	1	1
Midwest	0	0	0	1	0	0	0	0	2	0	0	0
South	0	0	1	1	1	2	4	1	1	1	3	1
West	0	0	4	0	2	0	5	6	3	5	5	3
Total	0	1	6	2	4	3	8	7	6	6	9	5
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	3	3	0	0	1	2
15–19	2	3	3	4	3	3	19	28	20	32	29	35
20–24	17	19	13	32	18	18	99	108	90	106	103	95
25–29	37	38	37	39	44	51	108	126	113	138	110	138
30–34	31	41	33	49	48	62	113	128	116	145	132	133
35–39	42	31	35	46	51	47	106	113	104	114	113	125
40–44	76	56	48	52	53	35	95	102	104	96	85	109
45–49	65	62	63	47	49	43	111	104	106	109	111	116
50–54	57	72	45	76	65	43	88	109	108	100	99	101
55–59	53	43	46	50	47	50	71	77	89	90	99	78
60–64	36	29	37	33	35	36	51	27	34	56	42	40
≥65	47	38	47	42	36	29	27	16	26	23	24	28
Region of residence^a												
Northeast	91	91	79	97	70	63	147	149	122	131	121	114
Midwest	62	54	47	49	57	56	149	148	156	162	155	169
South	231	208	222	258	245	238	446	488	485	519	517	557
West	79	79	60	66	76	61	149	156	144	197	157	159
Total	463	431	408	470	448	417	891	940	908	1,008	949	999

Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	0	0	1	0	0
15–19	3	1	1	0	1	0	21	12	9	9	5	11
20–24	9	5	9	9	3	3	34	37	21	27	25	14
25–29	15	9	11	10	5	8	32	38	26	23	22	22
30–34	11	7	8	6	8	5	34	38	31	23	19	23
35–39	11	17	7	17	6	2	34	29	27	23	18	17
40–44	15	9	6	12	8	4	27	32	15	15	11	8
45–49	18	22	9	8	7	5	36	15	23	19	20	14
50–54	13	10	12	9	5	6	24	16	20	14	15	5
55–59	11	9	8	8	5	0	16	9	14	14	12	6
60–64	7	2	2	4	5	2	11	11	5	5	3	7
≥65	6	6	8	2	4	3	7	3	4	9	4	7
Region of residence^a												
Northeast	43	29	20	24	16	12	74	53	49	34	35	23
Midwest	9	9	8	10	8	4	34	24	17	36	21	18
South	55	42	42	45	28	20	143	137	110	96	70	71
West	10	16	11	7	5	1	25	25	20	16	27	24
Total	117	96	81	85	57	37	276	239	195	182	153	136
Total												
Age at diagnosis (yr)												
13–14	0	2	1	0	1	0	12	9	7	10	8	7
15–19	46	39	40	48	35	41	270	271	225	215	215	216
20–24	197	226	221	259	185	166	699	750	717	654	665	601
25–29	329	322	352	382	319	320	869	880	831	889	810	816
30–34	378	364	344	391	340	376	861	877	836	903	844	787
35–39	379	381	387	395	364	344	799	868	844	847	785	768
40–44	421	438	398	381	329	277	732	757	689	680	624	675
45–49	472	420	409	376	302	295	759	676	641	680	667	638
50–54	403	420	388	382	325	308	655	593	641	612	564	559
55–59	314	299	317	282	275	266	473	496	452	484	490	483
60–64	201	165	193	198	197	164	245	233	258	295	294	278
≥65	209	195	199	199	179	170	188	171	195	198	240	223
Region of residence^a												
Northeast	724	720	645	652	514	459	1,257	1,303	1,178	1,179	1,087	996
Midwest	341	279	293	303	285	289	788	742	744	777	776	732
South	1,992	1,967	2,032	2,045	1,796	1,751	3,837	3,769	3,702	3,697	3,625	3,593
West	293	305	278	293	256	229	679	767	711	813	717	729
Total	3,350	3,271	3,248	3,293	2,850	2,727	6,562	6,582	6,336	6,465	6,206	6,051

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	1	2	1	0	0	1
20–24	1	0	1	0	0	1	3	1	2	0	2	1
25–29	2	0	0	1	1	0	1	6	7	5	5	2
30–34	3	3	1	1	2	1	2	1	6	3	2	2
35–39	1	1	1	1	3	1	2	3	5	6	4	2
40–44	0	1	0	1	0	0	2	2	4	6	5	4
45–49	3	3	3	1	1	0	1	1	3	4	5	1
50–54	0	0	2	1	0	2	5	5	4	2	4	3
55–59	0	1	1	0	1	2	1	3	3	2	1	3
60–64	0	0	0	1	0	0	0	0	0	1	2	0
≥65	0	0	0	2	0	1	2	0	1	1	0	0
Region of residence^a												
Northeast	3	2	2	0	0	0	0	0	1	4	0	0
Midwest	5	1	1	1	0	2	5	3	6	1	4	2
South	1	1	2	2	4	2	5	7	14	8	6	8
West	2	7	4	6	4	4	10	13	13	16	21	9
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	11	10	10	9	8	9	20	23	35	29	30	18
Asian												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	0	0	1	0	0
15–19	0	1	0	0	0	0	2	1	3	0	1	0
20–24	1	1	0	3	2	5	8	9	13	9	6	7
25–29	6	6	6	3	4	1	18	19	17	19	19	13
30–34	6	13	4	10	4	8	22	17	20	33	8	17
35–39	4	6	18	13	9	7	22	24	19	24	25	10
40–44	11	5	10	5	3	10	16	21	15	15	10	12
45–49	9	4	9	7	6	6	12	10	10	10	12	11
50–54	5	8	6	4	2	6	7	8	8	10	13	8
55–59	4	3	4	4	2	2	7	8	4	7	7	9
60–64	2	1	1	4	4	6	2	5	6	4	7	5
≥65	1	5	4	6	4	5	3	1	5	5	5	6
Region of residence^a												
Northeast	11	15	10	10	9	13	20	24	21	33	18	28
Midwest	6	6	7	9	4	3	19	14	16	13	20	5
South	16	15	24	24	12	24	37	32	42	43	31	28
West	17	15	20	16	15	17	44	52	39	47	44	36
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	50	51	61	59	40	56	120	121	119	135	112	96

Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	2	1	0	0	0	5	5	7	6	5	2
15–19	34	29	31	39	24	31	183	184	151	143	142	136
20–24	134	160	164	163	132	111	460	466	469	409	416	395
25–29	193	204	245	255	205	210	564	560	537	570	519	505
30–34	225	210	211	235	205	224	559	531	530	544	550	485
35–39	226	222	222	231	218	204	506	547	549	557	498	472
40–44	239	270	255	229	187	163	478	476	428	428	414	436
45–49	299	246	256	235	183	171	481	435	396	436	399	384
50–54	267	262	258	236	202	195	413	366	390	383	346	331
55–59	199	200	211	185	186	167	319	327	283	303	298	311
60–64	135	112	128	128	123	101	143	154	175	190	199	176
≥65	132	123	104	123	109	102	120	127	135	122	171	136
Region of residence^a												
Northeast	412	418	383	358	292	251	689	766	711	677	657	593
Midwest	216	174	191	193	188	192	521	480	496	506	517	487
South	1,371	1,353	1,420	1,413	1,232	1,159	2,793	2,683	2,575	2,603	2,540	2,414
West	80	90	93	93	61	72	222	244	265	303	241	275
U.S. dependent areas	4	5	0	2	0	3	7	6	4	0	2	0
Total	2,083	2,040	2,087	2,058	1,773	1,678	4,232	4,179	4,051	4,090	3,956	3,768
Hispanic/Latino^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	3	1	0	2	2	3
15–19	9	5	4	5	8	7	47	51	41	33	40	37
20–24	41	47	39	53	37	31	104	138	128	107	119	97
25–29	85	77	58	80	63	62	155	139	142	140	145	142
30–34	111	97	94	96	81	79	142	174	139	162	138	131
35–39	105	111	110	96	88	87	146	170	150	137	135	146
40–44	89	108	86	97	89	71	128	144	137	135	107	115
45–49	100	93	84	95	63	74	139	128	120	116	132	126
50–54	80	83	77	68	60	72	137	102	124	109	97	122
55–59	57	56	52	46	43	49	75	84	69	82	81	85
60–64	32	35	29	40	39	26	43	40	37	45	44	54
≥65	37	34	46	41	37	41	34	30	35	41	41	52
Region of residence^a												
Northeast	163	163	151	163	126	119	326	310	274	301	256	238
Midwest	43	35	39	41	27	32	61	73	51	59	60	52
South	320	348	321	303	274	306	409	421	475	427	459	514
West	106	99	86	106	94	75	226	273	226	228	224	225
U.S. dependent areas	113	100	83	103	85	66	131	123	97	93	81	79
Total	744	746	679	716	607	597	1,153	1,201	1,123	1,108	1,079	1,109

Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	1	1	0	0	1
20–24	0	0	0	0	1	0	3	2	2	1	0	0
25–29	0	0	1	0	1	0	0	0	0	0	2	0
30–34	0	0	0	0	1	3	1	1	1	1	3	2
35–39	0	0	2	1	0	0	0	1	0	2	3	0
40–44	0	1	0	0	0	0	0	1	0	0	0	0
45–49	0	0	1	1	1	0	1	0	0	0	0	0
50–54	0	0	1	0	0	0	3	1	1	2	0	1
55–59	0	0	1	0	0	1	0	1	1	0	1	1
60–64	0	0	0	0	0	0	1	1	0	0	0	0
≥65	0	0	0	0	1	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	1	0	0	1	1	0	1	0	0	1	1
Midwest	0	0	0	1	0	0	0	0	2	0	0	0
South	0	0	1	1	1	2	4	1	1	1	3	1
West	0	0	4	0	2	0	5	6	3	5	5	3
U.S. dependent areas	0	0	0	0	1	1	0	1	0	0	0	0
Total	0	1	6	3	5	4	8	8	6	6	9	5
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	3	3	0	0	1	2
15–19	2	3	3	4	3	3	19	28	20	32	30	35
20–24	17	19	13	32	18	18	99	108	90	106	103	95
25–29	37	38	37	39	44	51	108	126	113	138	110	138
30–34	31	41	33	49	48	62	113	128	116	145	132	133
35–39	42	31	35	46	51	47	106	113	104	114	113	125
40–44	76	56	48	52	53	35	95	102	104	96	85	109
45–49	65	62	63	47	49	43	111	104	106	109	111	116
50–54	57	72	45	76	65	43	88	109	108	100	100	101
55–59	53	43	46	50	47	50	71	77	89	90	99	78
60–64	36	29	37	33	35	36	52	27	34	56	42	40
≥65	47	38	47	42	36	29	27	17	26	23	24	28
Region of residence^a												
Northeast	91	91	79	97	70	63	147	149	122	131	121	114
Midwest	62	54	47	49	57	56	149	148	156	162	155	169
South	231	208	222	258	245	238	446	488	485	519	517	557
West	79	79	60	66	76	61	149	156	144	197	157	159
U.S. dependent areas	0	0	0	0	0	0	1	1	0	0	2	0
Total	463	431	408	470	448	417	892	941	908	1,008	951	999

Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	1	0	0	1	0	0
15–19	3	1	1	0	1	0	21	12	9	9	5	11
20–24	9	5	9	9	3	3	34	37	22	27	25	14
25–29	15	9	11	10	5	8	32	38	26	23	22	22
30–34	11	7	8	6	8	5	34	38	31	23	19	23
35–39	11	17	7	17	6	3	34	29	27	23	18	17
40–44	15	9	6	12	8	4	27	32	15	15	11	8
45–49	18	22	9	8	7	5	36	15	23	19	20	14
50–54	13	10	12	9	5	6	24	16	20	14	15	5
55–59	11	9	8	8	5	0	16	9	14	14	12	6
60–64	7	2	2	4	5	2	11	11	5	5	3	7
≥65	6	6	8	2	4	3	7	3	4	9	4	7
Region of residence^a												
Northeast	43	29	20	24	16	12	74	53	49	34	35	23
Midwest	9	9	8	10	8	4	34	24	17	36	21	18
South	55	42	42	45	28	20	143	137	110	96	70	71
West	10	16	11	7	5	1	25	25	20	16	27	24
U.S. dependent areas	0	0	0	0	0	1	0	0	1	0	0	0
Total	117	96	81	85	57	38	276	239	196	182	153	136
Total												
Age at diagnosis (yr)												
13–14	0	2	1	0	1	0	13	9	7	10	8	7
15–19	48	39	40	48	36	41	273	278	227	218	218	220
20–24	203	232	227	260	193	169	711	761	726	659	670	609
25–29	337	333	358	387	323	331	879	888	842	894	822	822
30–34	387	371	351	397	349	382	873	891	842	911	851	792
35–39	389	388	396	405	374	349	816	886	853	862	796	772
40–44	431	450	404	396	340	282	745	777	704	694	631	684
45–49	493	429	425	395	309	298	780	693	656	693	679	651
50–54	421	434	402	394	332	324	676	605	655	619	575	571
55–59	323	313	323	292	283	271	490	509	463	498	500	491
60–64	212	178	197	210	206	170	251	237	258	300	297	282
≥65	222	206	209	215	189	181	193	178	205	201	244	229
Region of residence^a												
Northeast	724	720	645	652	514	459	1,257	1,303	1,178	1,179	1,087	996
Midwest	341	279	293	303	285	289	788	742	744	777	776	732
South	1,992	1,967	2,032	2,045	1,796	1,751	3,837	3,769	3,702	3,697	3,625	3,593
West	293	305	278	293	256	229	679	767	711	813	717	729
U.S. dependent areas	118	105	84	106	86	71	139	131	102	93	84	79
Total	3,468	3,376	3,331	3,399	2,937	2,799	6,700	6,713	6,437	6,558	6,290	6,130

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Hispanics/Latinos can be of any race.

Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	0	0	0	0	0	1	0	0	0
20–24	3	2	5	3	1	1	1	0	2	3	2	0
25–29	5	4	5	10	7	14	0	0	1	1	2	0
30–34	9	8	6	11	3	4	3	0	0	1	0	0
35–39	2	4	5	9	7	5	0	0	1	0	0	0
40–44	10	8	3	7	5	2	0	0	0	1	2	0
45–49	4	5	4	5	2	1	0	2	2	0	1	2
50–54	7	6	3	3	3	6	1	2	1	0	1	0
55–59	0	2	2	3	0	1	2	0	0	0	0	0
60–64	0	0	0	0	1	0	0	0	0	0	1	0
≥65	1	0	1	1	0	1	0	0	0	0	0	0
Region of residence^a												
Northeast	1	1	1	2	0	1	1	0	0	0	0	0
Midwest	3	2	3	8	4	4	1	1	0	1	0	0
South	8	8	15	15	7	6	0	1	2	1	6	1
West	29	28	16	28	18	24	5	3	6	4	3	2
Total	41	39	35	52	29	34	8	5	8	7	9	3
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	2	2	2	1	0	0	0	0	0	0
20–24	20	13	13	16	25	20	0	0	0	0	0	0
25–29	35	26	36	49	37	45	1	2	0	0	0	2
30–34	40	30	32	39	40	41	0	0	1	1	1	0
35–39	33	40	26	23	29	35	1	2	0	2	1	0
40–44	51	36	42	35	29	33	3	6	2	0	2	1
45–49	30	36	26	27	33	21	0	1	0	0	1	1
50–54	20	12	28	16	23	14	0	0	1	1	2	0
55–59	8	4	13	9	15	15	0	0	0	0	0	0
60–64	3	3	1	2	5	7	0	0	0	0	0	0
≥65	4	5	3	7	4	5	0	0	0	1	0	0
Region of residence^a												
Northeast	34	38	51	42	48	55	2	0	0	1	1	2
Midwest	23	26	29	24	21	19	2	3	3	1	0	0
South	50	45	32	54	60	60	0	2	0	2	0	0
West	135	97	112	106	111	105	2	7	1	2	8	3
Total	242	205	223	225	240	239	7	12	5	5	9	5

Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	2	0	0	0	1	0	0	0	0	0	0	0
15–19	156	81	83	82	88	70	0	2	2	3	1	1
20–24	911	588	568	535	493	440	23	12	9	13	10	9
25–29	982	833	858	944	878	906	34	22	28	23	27	27
30–34	677	576	612	602	667	734	33	27	23	37	29	28
35–39	475	407	419	436	424	427	30	15	23	28	24	26
40–44	457	368	340	317	328	300	42	30	20	23	21	23
45–49	475	361	353	300	294	279	47	32	28	30	20	23
50–54	356	279	303	304	275	295	42	29	33	30	30	27
55–59	198	187	163	181	189	169	38	25	22	20	23	20
60–64	100	92	77	89	91	106	16	11	15	21	12	12
≥65	61	60	72	63	71	69	4	7	9	11	9	8
Region of residence^a												
Northeast	655	472	489	473	457	449	45	28	28	33	30	31
Midwest	784	625	609	654	597	612	50	34	38	41	31	30
South	3,052	2,431	2,471	2,415	2,450	2,434	178	121	126	138	119	117
West	358	303	280	310	295	299	37	30	19	26	24	25
Total	4,849	3,831	3,848	3,852	3,798	3,794	310	213	210	238	205	203
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	1	0	0	1	1	1	0	0	0	0	0	0
15–19	50	18	15	24	38	31	3	0	1	1	1	2
20–24	284	236	224	225	182	208	19	13	10	14	10	14
25–29	518	427	413	458	440	443	33	29	38	20	35	20
30–34	512	456	449	475	503	424	44	36	36	30	22	24
35–39	491	416	399	441	363	413	43	23	32	30	30	36
40–44	426	331	316	305	294	293	32	26	27	29	16	24
45–49	378	313	292	280	280	256	27	20	27	21	22	20
50–54	241	184	213	226	223	227	23	16	19	23	17	21
55–59	109	101	107	107	118	132	7	12	11	7	16	10
60–64	45	57	50	52	56	60	6	8	5	7	9	9
≥65	42	40	36	51	47	52	2	4	2	4	4	7
Region of residence^a												
Northeast	570	461	461	427	406	451	45	31	31	29	29	28
Midwest	235	200	205	201	168	192	17	16	19	12	13	7
South	1,213	1,034	1,019	1,125	1,078	1,038	96	68	79	73	54	71
West	1,079	883	831	891	894	859	82	70	79	71	85	80
Total	3,096	2,577	2,514	2,645	2,547	2,540	240	185	208	186	181	186

Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	2	1	2	2	0	0	1	0	0	0
25–29	5	0	3	2	2	2	0	0	0	1	0	0
30–34	2	3	0	1	3	2	0	1	1	0	0	1
35–39	2	3	2	3	1	4	0	0	0	0	0	0
40–44	2	1	1	0	3	3	0	0	0	0	0	0
45–49	1	2	3	0	3	2	0	0	0	0	0	0
50–54	2	1	4	0	1	0	0	0	0	0	0	0
55–59	0	0	0	0	0	2	0	0	0	0	0	0
60–64	0	1	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	1	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	1	0	0	1	0	0	1	1	0	0
Midwest	0	1	0	0	0	2	0	0	0	0	0	0
South	0	2	3	0	4	5	0	0	0	0	0	0
West	14	8	11	7	11	10	0	1	1	0	0	1
Total	14	11	14	7	15	18	0	1	2	1	0	1
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	17	4	11	10	11	11	0	1	2	1	0	1
20–24	176	109	103	86	116	113	17	20	15	14	5	5
25–29	324	261	270	247	231	224	39	29	28	31	41	25
30–34	394	329	319	315	290	273	57	39	49	47	47	35
35–39	426	320	311	273	296	294	52	37	56	50	53	47
40–44	585	404	348	320	266	252	64	55	46	45	33	32
45–49	663	559	464	420	353	326	72	57	44	51	45	35
50–54	606	504	524	500	447	354	62	62	55	56	37	43
55–59	383	311	313	336	331	290	35	26	32	27	39	26
60–64	227	183	174	196	169	176	17	16	17	17	18	14
≥65	161	165	168	160	182	176	10	6	5	6	11	13
Region of residence^a												
Northeast	538	439	436	400	362	320	36	43	28	40	33	24
Midwest	730	603	596	569	487	494	68	55	57	51	53	61
South	1,704	1,343	1,237	1,195	1,201	1,113	171	126	141	124	124	95
West	989	765	738	698	641	561	150	123	123	130	118	95
Total	3,961	3,149	3,007	2,862	2,691	2,488	426	348	349	345	329	274

Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	26	5	3	5	6	3	1	0	1	2	0	1
20–24	128	60	49	42	25	29	4	5	5	4	1	0
25–29	101	104	94	71	69	47	8	11	9	8	4	4
30–34	98	67	65	69	69	72	8	14	9	9	6	10
35–39	94	64	62	55	56	46	11	9	4	9	13	4
40–44	65	66	50	35	40	36	11	6	10	6	4	9
45–49	86	67	52	53	42	38	16	11	9	6	8	4
50–54	50	55	44	52	37	35	9	9	10	11	6	5
55–59	36	33	27	32	35	23	6	10	6	5	9	3
60–64	22	12	14	15	16	12	3	3	4	4	5	3
≥65	12	15	11	11	16	20	3	1	1	1	3	1
Region of residence^a												
Northeast	136	105	110	105	91	69	13	12	10	9	7	8
Midwest	99	77	71	48	60	42	10	9	8	12	9	3
South	338	256	209	191	183	186	36	32	29	30	26	18
West	142	111	81	96	76	63	20	23	23	14	17	15
Total	715	548	470	439	411	360	79	77	70	65	59	44
Total												
Age at diagnosis (yr)												
13–14	3	0	0	1	2	1	0	0	0	0	0	0
15–19	249	108	115	122	145	116	5	3	7	7	2	5
20–24	1,521	1,008	964	908	843	812	64	50	42	47	28	28
25–29	1,969	1,654	1,679	1,781	1,664	1,681	116	93	104	84	109	78
30–34	1,731	1,469	1,483	1,512	1,575	1,551	145	117	119	124	105	98
35–39	1,522	1,254	1,224	1,240	1,175	1,224	137	87	116	119	121	113
40–44	1,596	1,214	1,099	1,019	965	919	153	123	106	103	78	89
45–49	1,637	1,343	1,194	1,085	1,007	923	162	123	110	109	97	85
50–54	1,281	1,040	1,119	1,101	1,008	931	137	119	119	122	92	96
55–59	734	638	626	668	688	631	89	73	71	59	87	59
60–64	396	347	317	355	338	361	41	38	41	49	45	38
≥65	281	285	292	293	320	323	20	16	17	23	27	28
Region of residence^a												
Northeast	1,933	1,515	1,548	1,448	1,364	1,346	143	115	98	112	100	93
Midwest	1,873	1,533	1,512	1,505	1,336	1,365	148	119	126	117	107	101
South	6,366	5,118	4,985	4,995	4,984	4,841	482	351	377	369	330	302
West	2,746	2,194	2,068	2,135	2,046	1,920	297	256	252	248	255	220
Total	12,918	10,360	10,112	10,083	9,730	9,473	1,069	840	853	846	792	717

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	0	0	0	0	0	1	0	0	0
20–24	3	2	5	3	1	1	1	0	2	3	2	0
25–29	5	4	5	10	7	14	0	0	1	1	2	0
30–34	9	8	6	11	3	4	3	0	0	1	0	0
35–39	2	4	5	9	7	5	0	0	1	0	0	0
40–44	10	8	3	7	5	2	0	0	0	1	2	0
45–49	4	5	4	5	2	1	0	2	2	0	1	2
50–54	7	6	3	3	3	6	1	2	1	0	1	0
55–59	0	2	2	3	0	1	2	0	0	0	0	0
60–64	0	0	0	0	1	0	0	0	0	0	1	0
≥65	1	0	1	1	0	1	0	0	0	0	0	0
Region of residence^a												
Northeast	1	1	1	2	0	1	1	0	0	0	0	0
Midwest	3	2	3	8	4	4	1	1	0	1	0	0
South	8	8	15	15	7	6	0	1	2	1	6	1
West	29	28	16	28	18	24	5	3	6	4	3	2
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	41	39	35	52	29	34	8	5	8	7	9	3
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	1	0	2	2	2	1	0	0	0	0	0	0
20–24	20	13	13	16	25	20	0	0	0	0	0	0
25–29	35	27	36	49	37	45	1	2	0	0	0	2
30–34	40	30	32	39	42	41	0	0	1	1	1	0
35–39	33	40	26	23	30	35	1	2	0	2	1	0
40–44	51	36	42	35	29	33	3	6	2	0	2	1
45–49	30	36	26	27	33	21	0	1	0	0	1	1
50–54	20	13	28	16	23	14	0	0	1	1	2	0
55–59	8	4	13	9	15	15	0	0	0	0	0	0
60–64	3	3	1	2	5	7	0	0	0	0	0	0
≥65	4	5	3	7	4	5	0	0	0	1	0	0
Region of residence^a												
Northeast	34	38	51	42	48	55	2	0	0	1	1	2
Midwest	23	26	29	24	21	19	2	3	3	1	0	0
South	50	45	32	54	60	60	0	2	0	2	0	0
West	135	97	112	106	111	105	2	7	1	2	8	3
U.S. dependent areas	0	2	0	0	3	0	0	0	0	0	0	0
Total	242	207	223	225	243	239	7	12	5	5	9	5

Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	2	0	0	0	1	0	0	0	0	0	0	0
15–19	156	81	83	82	88	70	0	2	2	3	1	1
20–24	911	588	569	535	493	441	23	12	9	13	10	9
25–29	982	833	858	944	878	906	34	22	28	23	27	27
30–34	677	576	612	602	667	735	33	27	23	37	29	28
35–39	475	407	420	436	424	427	30	15	23	28	24	26
40–44	457	368	340	317	328	300	42	30	20	23	21	23
45–49	475	362	354	300	294	279	47	32	28	30	20	23
50–54	356	279	303	304	275	295	42	29	33	30	30	27
55–59	198	187	163	181	189	169	38	25	22	20	23	20
60–64	100	92	77	89	91	106	16	11	15	21	12	12
≥65	61	60	72	63	71	69	4	7	9	11	9	8
Region of residence^a												
Northeast	655	472	489	473	457	449	45	28	28	33	30	31
Midwest	784	625	609	654	597	612	50	34	38	41	31	30
South	3,052	2,431	2,471	2,415	2,450	2,434	178	121	126	138	119	117
West	358	303	280	310	295	299	37	30	19	26	24	25
U.S. dependent areas	0	1	3	0	0	2	0	0	0	0	0	0
Total	4,849	3,832	3,851	3,852	3,798	3,797	310	213	211	238	205	203
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	1	0	0	1	1	1	0	0	0	0	0	0
15–19	51	20	15	27	38	31	3	0	1	1	1	2
20–24	297	249	233	234	183	211	22	13	10	14	10	15
25–29	537	436	427	466	448	453	34	29	39	20	35	22
30–34	535	470	462	487	513	434	46	36	37	32	24	25
35–39	505	427	409	460	371	420	46	25	32	33	31	37
40–44	445	343	328	313	302	302	35	31	29	35	16	24
45–49	391	327	300	292	287	266	28	22	27	23	22	21
50–54	258	189	223	237	238	233	26	18	26	25	18	23
55–59	112	104	113	110	126	139	7	12	14	11	16	12
60–64	51	63	51	53	58	68	6	8	6	8	9	9
≥65	46	44	38	52	50	53	2	4	3	4	4	8
Region of residence^a												
Northeast	570	461	461	427	406	451	45	31	31	29	29	28
Midwest	235	200	205	201	168	192	17	16	19	12	13	7
South	1,213	1,034	1,019	1,125	1,078	1,038	96	68	79	73	54	71
West	1,079	883	831	891	894	859	82	70	79	71	85	80
U.S. dependent areas	132	94	85	88	70	72	16	11	16	20	4	11
Total	3,228	2,671	2,600	2,733	2,616	2,612	256	196	224	206	185	197

Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	2	2	2	2	0	0	1	0	0	0
25–29	5	1	4	2	2	2	0	0	0	1	0	0
30–34	2	3	0	2	3	2	0	1	1	0	0	1
35–39	2	3	2	3	1	5	0	0	0	0	0	0
40–44	2	2	1	0	3	3	0	0	0	0	0	0
45–49	1	2	3	0	3	2	0	0	0	0	0	0
50–54	2	1	4	0	2	0	0	0	0	0	0	0
55–59	0	0	0	0	1	2	0	0	0	0	0	0
60–64	0	1	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	1	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	1	0	0	1	0	0	1	1	0	0
Midwest	0	1	0	0	0	2	0	0	0	0	0	0
South	0	2	3	0	4	5	0	0	0	0	0	0
West	14	8	11	7	11	10	0	1	1	0	0	1
U.S. dependent areas	0	2	2	2	2	1	0	0	0	0	0	0
Total	14	13	16	9	17	18	0	1	2	1	0	1
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	17	4	11	10	11	11	0	1	2	1	0	1
20–24	176	109	103	86	116	113	17	20	15	14	5	5
25–29	324	261	270	247	231	224	39	29	28	31	41	25
30–34	394	329	319	316	290	273	57	39	49	47	47	35
35–39	426	320	311	273	296	294	52	37	56	50	53	47
40–44	585	404	348	320	266	252	64	55	46	45	33	32
45–49	664	559	464	420	353	326	72	57	44	51	45	35
50–54	606	504	526	500	447	355	62	62	55	56	37	43
55–59	383	312	313	336	331	290	35	26	32	27	39	26
60–64	227	183	174	196	169	176	17	16	17	17	18	14
≥65	161	165	168	160	182	176	10	6	5	6	11	13
Region of residence^a												
Northeast	538	439	436	400	362	320	36	43	28	40	33	24
Midwest	730	603	596	569	487	494	68	55	57	51	53	61
South	1,704	1,343	1,237	1,195	1,201	1,113	171	126	141	124	124	95
West	989	765	738	698	641	561	150	123	123	130	118	95
U.S. dependent areas	0	1	1	1	0	1	0	0	0	0	0	0
Total	3,962	3,150	3,008	2,863	2,691	2,489	426	348	349	345	329	274

Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact *and* injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (*cont*)

	Male-to-male sexual contact						Male-to-male sexual contact <i>and</i> injection drug use					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	26	5	3	5	6	3	1	0	1	2	0	1
20–24	128	60	49	42	25	29	4	5	5	4	1	0
25–29	101	104	94	71	69	47	8	11	9	8	4	4
30–34	98	67	65	69	69	72	8	14	9	9	6	10
35–39	94	64	62	55	56	46	11	9	4	9	13	4
40–44	65	66	50	35	40	36	11	6	10	6	4	9
45–49	86	67	52	53	42	38	16	11	9	6	8	4
50–54	50	55	44	52	37	35	9	9	10	11	6	5
55–59	36	33	27	32	35	23	6	10	6	5	9	3
60–64	22	12	14	15	16	12	3	3	4	4	5	3
≥65	12	15	11	11	16	20	3	1	1	1	3	1
Region of residence^a												
Northeast	136	105	110	105	91	69	13	12	10	9	7	8
Midwest	99	77	71	48	60	42	10	9	8	12	9	3
South	338	256	209	191	183	186	36	32	29	30	26	18
West	142	111	81	96	76	63	20	23	23	14	17	15
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	715	548	470	439	411	360	79	77	70	65	59	44
Total												
Age at diagnosis (yr)												
13–14	3	0	0	1	2	1	0	0	0	0	0	0
15–19	250	110	115	125	145	116	5	3	7	7	2	5
20–24	1,534	1,021	974	918	844	816	67	50	42	47	28	29
25–29	1,988	1,665	1,694	1,789	1,672	1,690	117	93	105	84	109	80
30–34	1,754	1,483	1,496	1,526	1,587	1,562	147	117	120	126	107	99
35–39	1,536	1,265	1,235	1,259	1,184	1,231	140	89	116	122	122	114
40–44	1,615	1,227	1,112	1,027	973	929	156	128	108	109	78	89
45–49	1,650	1,358	1,203	1,097	1,014	934	163	125	110	111	97	86
50–54	1,298	1,046	1,131	1,112	1,024	939	140	121	126	124	93	98
55–59	737	642	632	672	697	638	89	73	74	63	87	61
60–64	402	353	318	356	340	368	41	38	42	50	45	38
≥65	285	289	294	294	323	325	20	16	18	23	27	29
Region of residence^a												
Northeast	1,933	1,515	1,548	1,448	1,364	1,346	143	115	98	112	100	93
Midwest	1,873	1,533	1,512	1,505	1,336	1,365	148	119	126	117	107	101
South	6,366	5,118	4,985	4,995	4,984	4,841	482	351	377	369	330	302
West	2,746	2,194	2,068	2,135	2,046	1,920	297	256	252	248	255	220
U.S. dependent areas	132	100	91	92	75	76	16	11	16	20	4	11
Total	13,051	10,460	10,203	10,174	9,805	9,549	1,086	851	869	866	796	728

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States

	Male						Female					
	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	1	0	0
25–29	0	2	0	0	2	3	1	0	1	1	1	0
30–34	1	1	2	0	3	1	1	2	1	1	0	0
35–39	0	0	0	0	0	0	1	2	2	0	1	1
40–44	0	4	1	1	1	1	0	2	1	1	0	2
45–49	2	1	0	2	0	0	2	0	1	1	1	0
50–54	1	2	2	0	2	2	1	1	2	0	2	1
55–59	0	1	1	1	0	0	0	0	2	2	1	0
60–64	0	0	0	0	0	0	1	1	0	0	0	0
≥65	1	0	0	0	1	0	0	0	0	0	1	0
Region of residence^a												
Northeast	0	0	1	0	1	0	0	0	0	0	0	0
Midwest	0	1	0	0	2	1	0	0	2	1	0	2
South	2	4	1	0	0	1	2	3	4	1	2	0
West	3	7	6	4	7	5	4	5	4	4	6	2
Total	6	12	7	5	10	7	6	8	10	7	8	5
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	1	0	0	0	0	0	0
25–29	0	0	0	1	1	1	0	0	0	0	1	1
30–34	1	1	4	2	1	1	0	0	0	1	0	0
35–39	1	2	1	2	1	0	0	0	0	1	1	0
40–44	1	1	2	1	1	0	1	0	0	0	0	1
45–49	2	0	1	2	1	2	1	1	0	0	0	0
50–54	0	1	1	1	2	2	1	0	0	0	1	1
55–59	1	0	0	2	1	0	0	0	0	0	0	0
60–64	1	0	1	1	0	0	0	0	1	0	0	0
≥65	0	1	1	1	1	0	0	0	1	1	0	0
Region of residence^a												
Northeast	3	2	5	5	3	4	0	0	1	2	1	1
Midwest	1	0	1	2	1	0	1	0	0	1	0	0
South	3	4	1	1	2	1	1	1	0	0	1	0
West	2	1	6	5	2	2	3	2	1	2	1	3
Total	9	7	13	13	8	7	4	3	3	4	3	4

Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	1	1	1	1	0	2	2	1	1	2	2
20–24	6	4	4	2	5	4	7	7	8	3	7	4
25–29	20	10	17	10	11	18	23	16	17	14	16	12
30–34	33	23	21	16	19	21	35	26	22	27	23	18
35–39	40	42	34	41	32	29	55	31	34	34	41	29
40–44	49	42	35	35	27	24	59	61	43	41	35	33
45–49	106	75	57	48	53	42	80	74	53	43	42	43
50–54	140	90	89	61	54	53	85	78	60	59	58	44
55–59	104	87	78	69	86	74	82	61	44	51	43	49
60–64	73	60	57	54	63	51	35	20	33	36	40	40
≥65	52	47	37	39	56	63	19	19	17	22	15	24
Region of residence^a												
Northeast	192	138	119	103	117	123	107	110	97	77	75	73
Midwest	66	36	51	49	55	39	70	62	31	49	43	51
South	329	279	241	198	208	196	276	201	180	183	179	158
West	38	27	20	24	26	21	28	22	23	22	25	15
Total	625	480	431	375	406	380	482	394	331	330	322	298
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	1	0	2	0	0	0	0	0
20–24	9	2	6	6	4	3	4	5	7	4	3	3
25–29	12	15	13	14	13	16	10	13	8	4	7	8
30–34	33	22	25	26	28	27	21	15	11	12	8	10
35–39	35	47	33	33	30	22	20	15	17	22	15	14
40–44	45	40	35	26	25	26	26	19	20	14	16	11
45–49	68	45	36	29	34	36	33	23	24	19	16	18
50–54	49	44	39	30	38	34	23	25	18	18	17	23
55–59	34	37	23	34	31	22	14	16	11	11	7	14
60–64	22	13	16	22	24	20	12	6	8	6	11	10
≥65	11	12	15	22	17	15	8	3	8	8	5	8
Region of residence^a												
Northeast	157	118	97	98	92	81	95	65	66	51	49	56
Midwest	15	11	19	12	14	10	5	6	6	8	6	5
South	85	82	67	77	66	72	49	42	43	34	30	30
West	62	68	58	54	70	56	24	27	17	28	19	30
Total	319	279	241	241	241	219	173	139	131	120	104	120

Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	0	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	0	0	0	1	0	0	0	0	0	0	0	0
40–44	0	0	0	0	0	0	0	0	0	0	0	0
45–49	1	0	0	0	0	0	0	0	0	0	0	0
50–54	0	0	0	0	0	0	0	0	0	0	0	0
55–59	0	0	0	0	0	0	0	0	0	0	0	0
60–64	0	0	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	0	1	0	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	0	0	0
West	1	0	0	0	0	0	0	0	0	0	0	0
Total	1	0	0	1	0	0	0	0	0	0	0	0
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	0	0	2	0	0	0
20–24	2	6	4	5	5	5	2	11	6	4	10	7
25–29	8	12	18	19	10	25	16	23	24	24	19	24
30–34	26	21	21	18	26	30	30	14	30	36	31	31
35–39	23	31	16	19	29	33	30	31	39	40	45	50
40–44	35	45	35	34	29	26	42	39	38	33	30	26
45–49	55	50	46	39	35	25	54	37	39	34	34	41
50–54	57	43	50	42	41	43	53	39	38	29	43	32
55–59	44	36	23	33	28	27	25	24	26	20	30	22
60–64	19	18	19	17	20	14	17	13	12	12	10	14
≥65	13	17	10	11	12	15	7	4	8	4	7	9
Region of residence^a												
Northeast	56	45	49	49	45	41	54	47	41	45	41	34
Midwest	28	32	30	31	31	46	38	24	43	38	49	42
South	120	112	97	95	95	83	133	108	117	115	127	134
West	78	91	67	61	65	74	52	57	60	38	43	46
Total	282	280	242	236	236	243	277	236	260	236	259	255

Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	1
20–24	1	1	0	0	1	1	1	2	1	0	1	1
25–29	0	3	4	2	3	1	6	4	2	3	3	1
30–34	2	5	1	1	1	1	7	4	14	7	4	4
35–39	3	5	1	2	2	6	10	7	5	4	6	4
40–44	14	3	3	1	7	4	16	7	9	3	8	4
45–49	8	8	9	4	4	2	11	12	10	7	7	7
50–54	14	9	6	10	5	6	8	11	13	10	9	8
55–59	4	16	7	5	9	9	9	5	9	6	6	7
60–64	7	7	5	6	2	5	5	5	4	2	4	6
≥65	5	3	5	8	5	3	3	4	1	1	1	4
Region of residence^a												
Northeast	18	23	14	19	13	8	28	24	13	15	19	17
Midwest	3	7	3	3	3	6	3	5	11	9	5	7
South	26	19	17	15	18	9	38	21	30	13	17	17
West	9	11	7	3	3	13	7	10	13	6	8	6
Total	57	60	41	40	37	37	76	60	66	43	48	47
Total												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	2	1	1	2	0	4	3	3	1	2	3
20–24	18	13	15	13	15	14	15	25	22	13	21	14
25–29	41	43	53	47	39	64	56	55	51	46	46	46
30–34	97	73	75	62	77	80	94	60	78	84	66	64
35–39	103	127	84	99	93	90	118	86	96	101	109	99
40–44	144	135	110	98	90	81	145	128	112	92	89	77
45–49	241	179	150	124	128	107	180	147	126	105	100	109
50–54	261	189	187	143	140	139	170	155	130	117	129	110
55–59	188	178	133	144	154	131	130	107	91	90	86	92
60–64	121	98	98	100	109	90	70	45	58	56	65	70
≥65	83	80	68	80	91	96	38	30	34	36	30	45
Region of residence^a												
Northeast	427	327	284	276	272	258	284	246	216	189	185	180
Midwest	113	88	103	96	106	102	118	97	93	106	102	107
South	567	500	424	386	388	363	498	375	373	346	356	340
West	194	204	164	152	172	171	118	122	119	99	101	102
Total	1,300	1,119	975	910	938	894	1,018	840	801	741	744	730

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	1	0	0
25–29	0	2	0	0	2	3	1	0	1	1	1	0
30–34	1	1	2	0	3	1	1	2	1	1	0	0
35–39	0	0	0	0	0	0	1	2	2	0	1	1
40–44	0	4	1	1	1	1	0	2	1	1	0	2
45–49	2	1	0	2	0	0	2	0	1	1	1	0
50–54	1	2	2	0	2	2	1	1	2	0	2	1
55–59	0	1	1	1	0	0	0	0	2	2	1	0
60–64	0	0	0	0	0	0	1	1	0	0	0	0
≥65	1	0	0	0	1	0	0	0	0	0	1	0
Region of residence^a												
Northeast	0	0	1	0	1	0	0	0	0	0	0	0
Midwest	0	1	0	0	2	1	0	0	2	1	0	2
South	2	4	1	0	0	1	2	3	4	1	2	0
West	3	7	6	4	7	5	4	5	4	4	6	2
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	6	12	7	5	10	7	6	8	10	7	8	5
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	1	0	0	0	0	0	0
25–29	0	0	0	1	1	1	0	0	0	0	1	1
30–34	1	1	4	2	1	1	0	0	0	1	0	0
35–39	1	2	1	3	1	0	0	0	0	1	1	0
40–44	1	1	2	1	1	0	1	0	0	0	0	1
45–49	2	0	1	2	1	2	1	1	0	0	0	0
50–54	0	1	1	1	2	2	1	0	0	0	1	1
55–59	1	0	0	2	1	0	0	0	0	0	0	0
60–64	1	0	1	1	0	0	0	0	1	0	0	0
≥65	0	1	1	1	1	0	0	0	1	1	0	0
Region of residence^a												
Northeast	3	2	5	5	3	4	0	0	1	2	1	1
Midwest	1	0	1	2	1	0	1	0	0	1	0	0
South	3	4	1	1	2	1	1	1	0	0	1	0
West	2	1	6	5	2	2	3	2	1	2	1	3
U.S. dependent areas	0	0	0	1	0	0	0	0	0	0	0	0
Total	9	7	13	14	8	7	4	3	3	4	3	4

Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (*cont*)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	1	1	1	1	0	2	2	1	1	2	2
20–24	6	4	4	2	5	4	7	7	8	3	7	4
25–29	20	10	17	10	11	18	23	16	17	14	16	12
30–34	33	23	21	16	19	21	35	26	22	27	23	18
35–39	40	42	34	41	32	29	55	31	34	34	41	29
40–44	49	42	36	35	27	24	59	61	43	42	35	33
45–49	106	75	57	48	53	42	80	74	54	43	43	43
50–54	140	90	89	61	54	53	85	79	60	59	58	44
55–59	104	87	78	69	86	74	82	61	44	51	43	49
60–64	73	61	57	54	63	51	35	20	33	36	40	40
≥65	52	47	37	39	56	63	19	19	17	22	15	24
Region of residence^a												
Northeast	192	138	119	103	117	123	107	110	97	77	75	73
Midwest	66	36	51	49	55	39	70	62	31	49	43	51
South	329	279	241	198	208	196	276	201	180	183	179	158
West	38	27	20	24	26	21	28	22	23	22	25	15
U.S. dependent areas	0	1	1	0	0	0	0	0	0	1	0	0
Total	625	482	432	375	406	380	482	395	332	331	323	298
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	1	0	2	0	0	0	0	0
20–24	11	2	6	7	4	3	4	5	7	4	3	3
25–29	15	16	14	14	13	16	13	14	8	5	7	8
30–34	41	26	29	30	29	29	21	22	12	14	9	10
35–39	47	62	39	38	36	24	24	18	20	25	16	18
40–44	51	47	40	32	27	30	27	23	20	14	17	13
45–49	81	59	45	38	38	43	46	27	25	22	17	18
50–54	62	58	48	39	45	42	28	29	19	19	17	23
55–59	46	50	30	41	35	26	17	20	11	13	8	14
60–64	26	16	19	25	27	22	13	6	9	7	11	10
≥65	13	13	16	26	18	16	8	3	9	8	5	8
Region of residence^a												
Northeast	157	118	97	98	92	81	95	65	66	51	49	56
Midwest	15	11	19	12	14	10	5	6	6	8	6	5
South	85	82	67	77	66	72	49	42	43	34	30	30
West	62	68	58	54	70	56	24	27	17	28	19	30
U.S. dependent areas	75	71	45	49	28	31	29	27	8	13	5	6
Total	394	350	286	289	269	249	202	166	139	133	109	126

Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (*cont*)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	0	0
30–34	0	0	0	0	0	0	0	0	0	0	0	0
35–39	0	0	0	1	0	0	0	0	0	0	0	0
40–44	0	0	0	0	0	0	0	0	0	0	0	0
45–49	1	0	0	0	0	0	0	0	0	0	0	0
50–54	0	0	0	0	0	0	0	0	0	0	0	0
55–59	0	0	0	1	0	0	0	0	0	0	0	0
60–64	0	0	0	0	0	0	0	0	0	0	0	0
≥65	0	0	0	0	0	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	0	1	0	0	0	0	0	0	0	0
Midwest	0	0	0	0	0	0	0	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	0	0	0
West	1	0	0	0	0	0	0	0	0	0	0	0
U.S. dependent areas	0	0	0	1	0	0	0	0	0	0	0	0
Total	1	0	0	2	0	0	0	0	0	0	0	0
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	1	0	0	0	0	0	0	2	0	0	0
20–24	2	6	4	5	5	5	2	11	6	4	10	7
25–29	8	12	18	19	10	25	16	23	24	24	19	24
30–34	26	21	21	18	26	30	30	14	30	36	31	31
35–39	23	31	16	19	29	33	30	31	39	40	45	50
40–44	35	45	35	34	29	26	42	39	38	33	30	26
45–49	55	50	46	39	35	25	54	37	39	34	34	41
50–54	57	43	50	42	41	43	53	39	38	29	43	32
55–59	44	36	23	33	28	27	25	24	26	20	30	22
60–64	19	18	19	17	20	14	17	13	12	12	10	14
≥65	13	17	10	11	12	15	7	4	8	4	7	9
Region of residence^a												
Northeast	56	45	49	49	45	41	54	47	41	45	41	34
Midwest	28	32	30	31	31	46	38	24	43	38	49	42
South	120	112	97	95	95	83	133	108	117	115	127	134
West	78	91	67	61	65	74	52	57	60	38	43	46
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	282	280	243	236	236	243	277	237	260	236	259	255

Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	1
20–24	1	1	0	0	1	1	1	2	1	0	1	1
25–29	0	3	4	2	3	1	6	4	2	3	3	1
30–34	2	5	1	1	1	1	7	4	14	7	4	4
35–39	3	5	1	2	2	6	10	7	5	4	6	4
40–44	14	3	3	1	7	4	16	7	9	3	8	4
45–49	8	8	9	4	4	2	11	12	10	7	7	7
50–54	14	9	6	10	5	6	8	11	13	10	9	8
55–59	4	16	7	5	9	9	9	5	9	6	6	7
60–64	7	7	5	6	2	5	5	5	4	2	4	6
≥65	5	3	5	8	5	3	3	4	1	1	1	4
Region of residence^a												
Northeast	18	23	14	19	13	8	28	24	13	15	19	17
Midwest	3	7	3	3	3	6	3	5	11	9	5	7
South	26	19	17	15	18	9	38	21	30	13	17	17
West	9	11	7	3	3	13	7	10	13	6	8	6
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	57	60	41	40	37	37	76	60	66	43	48	47
Total												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	2	2	1	1	2	0	4	3	3	1	2	3
20–24	20	13	15	14	15	14	15	25	22	13	21	14
25–29	44	44	54	47	39	64	58	56	51	47	46	46
30–34	105	77	79	66	78	82	94	67	79	86	67	64
35–39	115	142	91	105	99	92	122	89	99	104	110	103
40–44	150	142	115	104	92	85	146	132	112	93	90	79
45–49	254	193	159	133	131	114	193	151	127	108	102	109
50–54	274	203	197	152	148	148	175	159	131	118	129	110
55–59	200	191	140	152	158	136	133	111	91	92	87	92
60–64	125	101	101	103	112	92	71	45	59	57	65	70
≥	85	81	69	84	92	98	38	30	35	36	30	45
Region of residence^a												
Northeast	427	327	284	276	272	258	284	246	216	189	185	180
Midwest	113	88	103	96	106	102	118	97	93	106	102	107
South	567	500	424	386	388	363	498	375	373	346	356	340
West	194	204	164	152	172	171	118	122	119	99	101	102
U.S. dependent areas	75	72	47	51	28	31	29	28	8	14	6	6
Total	1,375	1,191	1,022	961	966	925	1,047	868	810	755	750	736

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States

	Male						Female					
	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	1	0	0	0
25–29	1	0	1	0	0	0	2	1	5	1	0	2
30–34	2	1	2	1	0	0	3	1	2	3	1	0
35–39	3	0	0	2	1	0	0	2	5	5	1	0
40–44	0	1	0	0	0	1	1	2	2	5	1	5
45–49	3	0	1	1	2	1	1	0	3	1	3	1
50–54	0	0	1	0	1	0	3	3	4	1	4	1
55–59	0	1	0	0	0	2	2	1	3	2	0	2
60–64	1	0	0	0	0	0	0	2	1	0	2	0
≥65	0	0	0	1	0	1	3	0	0	0	1	0
Region of residence^a												
Northeast	1	1	0	0	0	0	0	1	0	1	0	0
Midwest	6	0	0	1	1	2	4	1	4	6	0	1
South	0	0	1	2	1	1	3	2	15	4	3	3
West	3	3	4	4	2	2	6	8	5	7	9	7
Total	11	4	5	7	5	5	13	12	24	17	13	10
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	1	0	0	0	0	1
20–24	0	0	0	0	0	1	0	5	2	2	3	2
25–29	4	1	2	0	2	0	4	6	3	4	8	4
30–34	3	4	2	0	2	7	6	5	7	9	7	8
35–39	5	3	3	8	5	4	12	12	8	18	7	5
40–44	6	5	6	2	1	7	9	5	8	7	5	9
45–49	4	4	1	4	6	4	4	7	8	4	5	7
50–54	5	6	3	4	1	3	1	4	1	3	7	7
55–59	3	1	1	3	3	2	2	6	5	5	4	5
60–64	2	0	1	0	2	3	2	2	3	3	2	2
≥65	0	1	2	4	1	3	3	1	3	1	4	3
Region of residence^a												
Northeast	8	3	5	7	6	9	10	7	8	15	9	16
Midwest	2	4	5	5	4	5	7	7	10	9	6	1
South	9	9	4	10	9	13	11	14	14	12	15	14
West	13	10	7	4	5	7	15	25	15	19	22	21
Total	31	26	21	26	23	33	42	52	47	55	51	51

Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	2	0	0	0	0	0	1	2	0	0	0
15–19	7	2	1	11	2	2	37	20	20	16	16	14
20–24	42	35	31	40	38	22	155	108	106	108	96	77
25–29	101	75	70	91	81	90	292	236	243	219	191	168
30–34	159	120	117	119	115	119	394	334	331	267	275	282
35–39	177	160	124	154	142	120	418	371	353	357	333	315
40–44	238	189	194	183	131	117	442	368	328	317	319	288
45–49	257	223	203	186	173	141	455	350	328	282	307	291
50–54	243	222	188	200	169	170	342	293	262	248	246	255
55–59	173	163	173	157	157	140	250	207	188	189	208	214
60–64	123	91	94	108	111	79	127	130	120	128	136	145
≥65	109	103	88	104	98	91	89	104	115	83	110	99
Region of residence^a												
Northeast	293	270	244	233	212	171	502	442	391	326	369	352
Midwest	158	113	115	146	103	108	285	283	233	266	273	241
South	1,126	960	870	915	864	767	2,097	1,684	1,644	1,505	1,502	1,433
West	53	42	52	60	37	44	115	110	126	117	92	119
Total	1,629	1,385	1,281	1,354	1,217	1,090	2,999	2,519	2,393	2,214	2,237	2,146
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	1	0	1	1	0
15–19	0	0	0	0	3	0	9	7	2	5	3	4
20–24	14	8	9	17	11	8	36	15	22	27	20	21
25–29	40	39	27	42	19	22	58	46	51	51	54	43
30–34	77	43	61	49	51	34	87	81	62	74	72	60
35–39	75	63	50	56	49	53	105	95	82	77	77	74
40–44	62	63	62	51	50	31	98	86	79	71	69	52
45–49	70	60	56	67	44	54	91	76	72	58	68	59
50–54	64	49	59	45	40	39	85	53	66	73	57	65
55–59	38	38	35	30	20	23	33	47	34	55	46	46
60–64	23	20	21	23	25	12	31	24	28	22	30	33
≥65	30	26	23	17	19	19	27	18	17	37	20	33
Region of residence^a												
Northeast	142	118	104	105	83	73	238	186	149	196	156	137
Midwest	28	21	31	28	19	20	34	31	28	33	40	25
South	246	207	213	209	176	162	279	230	233	215	221	224
West	78	63	54	55	52	39	108	102	105	106	99	103
Total	494	410	402	397	331	295	658	549	516	549	516	488

Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	1	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	1	0
30–34	0	0	0	0	0	0	0	1	1	1	4	0
35–39	0	0	1	1	0	0	0	0	1	2	1	0
40–44	0	2	0	0	0	0	0	0	0	0	0	0
45–49	0	0	1	1	1	0	2	0	0	0	0	0
50–54	0	0	1	0	0	0	2	0	0	1	0	0
55–59	0	0	0	0	0	0	0	1	0	0	1	0
60–64	0	0	0	0	0	1	0	1	0	0	0	0
≥65	1	0	0	0	1	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	0	0	1	0	0	0	0	0	1	0
Midwest	0	0	0	1	0	0	0	0	1	0	1	0
South	0	1	0	1	1	0	3	1	0	0	1	0
West	1	1	3	0	0	1	2	2	1	4	4	0
Total	1	2	3	2	2	1	5	3	2	4	7	0
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	2	2	0	2	4	1
20–24	5	3	1	3	5	2	21	16	14	17	15	14
25–29	15	16	18	15	14	18	39	39	34	35	39	35
30–34	18	18	15	24	14	27	60	55	50	43	60	53
35–39	26	20	18	19	24	23	66	66	62	71	65	67
40–44	44	36	26	36	37	25	81	72	61	53	57	66
45–49	44	45	42	36	30	32	89	66	69	66	60	66
50–54	45	53	39	51	41	34	74	67	81	62	64	61
55–59	39	31	33	31	39	39	56	58	60	61	55	54
60–64	27	26	28	23	19	24	42	15	26	30	33	27
≥65	35	23	27	35	35	27	15	24	26	26	22	31
Region of residence^a												
Northeast	64	68	55	58	45	48	88	75	59	65	69	59
Midwest	34	35	34	37	37	42	88	79	79	83	78	80
South	151	120	122	140	127	133	283	259	270	243	266	256
West	49	47	37	37	46	27	84	66	76	74	60	80
Total	298	270	247	272	256	250	543	479	484	464	473	475

Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	6	1	0	1	2	3
20–24	2	2	3	3	1	1	29	11	8	7	5	4
25–29	5	4	6	5	5	6	24	17	17	15	11	8
30–34	12	9	7	8	4	4	24	20	21	20	16	15
35–39	8	9	4	7	7	5	40	34	23	22	18	21
40–44	9	13	6	8	10	3	37	29	28	25	15	18
45–49	20	20	16	10	9	2	35	23	29	22	24	16
50–54	15	12	16	14	8	6	24	20	15	20	25	13
55–59	14	13	9	8	6	5	24	6	10	11	13	8
60–64	4	3	2	5	2	2	14	10	8	7	5	9
≥65	8	6	11	3	4	9	9	8	5	7	8	10
Region of residence^a												
Northeast	31	23	25	16	18	11	66	43	41	41	38	26
Midwest	6	11	8	7	2	4	19	22	16	18	19	14
South	57	49	41	37	30	26	157	101	93	81	64	63
West	4	8	6	9	7	2	22	13	15	16	20	22
Total	98	91	80	70	57	42	264	178	165	156	141	125
Total												
Age at diagnosis (yr)												
13–14	0	2	0	0	0	0	0	2	2	1	1	0
15–19	8	2	1	11	5	2	55	29	22	24	25	22
20–24	63	48	44	63	54	35	242	156	154	161	138	117
25–29	166	135	124	153	121	136	418	344	353	325	305	260
30–34	272	195	204	201	187	190	573	496	473	416	434	418
35–39	294	255	202	246	227	205	639	580	533	551	502	480
40–44	359	309	293	279	230	183	667	562	506	478	466	439
45–49	398	353	321	305	265	234	674	521	508	432	466	440
50–54	372	342	305	314	260	251	530	440	429	406	403	400
55–59	265	247	251	230	226	210	367	325	300	322	327	328
60–64	180	140	146	160	159	121	215	184	185	190	207	215
≥65	184	159	150	165	158	150	145	155	166	153	164	176
Region of residence^a												
Northeast	539	483	433	420	365	312	903	754	647	643	641	591
Midwest	234	184	194	224	166	181	437	422	371	414	418	361
South	1,589	1,347	1,251	1,314	1,209	1,102	2,833	2,291	2,269	2,059	2,072	1,993
West	200	174	162	169	150	121	352	326	343	343	307	350
Total	2,561	2,187	2,039	2,127	1,890	1,716	4,525	3,793	3,630	3,459	3,438	3,295

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas

	Male						Female					
	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.	2013 No.	2014 No.	2015 No.	2016 No.	2017 No.	2018 No.
American Indian/Alaska Native												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	1	0	0	0
25–29	1	0	1	0	0	0	2	1	5	1	0	2
30–34	2	1	2	1	0	0	3	1	2	3	1	0
35–39	3	0	0	2	1	0	0	2	5	5	1	0
40–44	0	1	0	0	0	1	1	2	2	5	1	5
45–49	3	0	1	1	2	1	1	0	3	1	3	1
50–54	0	0	1	0	1	0	3	3	4	1	4	1
55–59	0	1	0	0	0	2	2	1	3	2	0	2
60–64	1	0	0	0	0	0	0	2	1	0	2	0
≥65	0	0	0	1	0	1	3	0	0	0	1	0
Region of residence^a												
Northeast	1	1	0	0	0	0	0	1	0	1	0	0
Midwest	6	0	0	1	1	2	4	1	4	6	0	1
South	0	0	1	2	1	1	3	2	15	4	3	3
West	3	3	4	4	2	2	6	8	5	7	9	7
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	11	4	5	7	5	5	13	12	24	17	13	10
Asian^b												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	1	0	0	0	0	1
20–24	0	0	0	0	0	1	0	5	2	2	3	2
25–29	4	1	2	0	2	0	4	6	3	4	8	4
30–34	3	4	2	0	2	7	6	5	7	9	7	8
35–39	5	3	3	8	5	4	12	12	8	18	7	5
40–44	6	5	6	2	1	7	9	5	8	7	5	9
45–49	4	4	1	4	6	4	4	7	8	4	5	7
50–54	5	6	3	4	1	3	1	4	1	3	7	7
55–59	3	1	1	3	3	2	2	6	5	5	4	5
60–64	2	0	1	0	2	3	2	2	3	3	2	2
≥65	0	1	2	4	1	3	3	1	3	1	4	3
Region of residence^a												
Northeast	8	3	5	7	6	9	10	7	8	15	9	16
Midwest	2	4	5	5	4	5	7	7	10	9	6	1
South	9	9	4	10	9	13	11	14	14	12	15	14
West	13	10	7	4	5	7	15	25	15	19	22	21
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0	0	0
Total	31	26	21	26	23	33	42	52	47	55	51	51

Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Black/African American												
Age at diagnosis (yr)												
13–14	0	2	0	0	0	0	0	1	2	0	0	0
15–19	7	2	1	11	2	2	37	20	20	16	16	14
20–24	42	35	31	40	38	22	155	108	106	108	96	77
25–29	101	75	71	91	81	90	292	236	244	219	191	168
30–34	159	120	117	119	115	119	394	334	331	267	275	282
35–39	177	160	125	154	142	120	418	371	353	357	333	315
40–44	238	189	194	183	131	117	442	368	328	317	320	288
45–49	257	223	203	187	173	141	457	350	328	282	308	292
50–54	243	225	188	200	169	171	342	294	262	248	246	256
55–59	174	163	173	157	157	140	251	208	188	190	208	214
60–64	124	92	94	108	111	79	127	131	120	128	136	145
≥65	109	103	88	104	98	91	89	104	116	83	110	99
Region of residence^a												
Northeast	293	270	244	233	212	171	502	442	391	326	369	352
Midwest	158	113	115	146	103	108	285	283	233	266	273	241
South	1,126	960	870	915	864	767	2,097	1,684	1,644	1,505	1,502	1,433
West	53	42	52	60	37	44	115	110	126	117	92	119
U.S. dependent areas	2	3	2	2	0	1	3	3	3	1	3	2
Total	1,631	1,388	1,283	1,355	1,217	1,091	3,002	2,522	2,396	2,215	2,240	2,148
Hispanic/Latino^c												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	1	0	1	1	0
15–19	0	0	0	0	3	0	11	9	2	5	4	4
20–24	15	8	11	17	15	9	37	16	23	28	23	22
25–29	41	42	27	45	19	24	60	50	51	53	57	44
30–34	82	46	62	53	55	34	97	94	68	75	78	62
35–39	81	71	56	62	53	54	117	104	87	85	83	75
40–44	73	75	68	56	58	32	113	102	88	75	75	57
45–49	82	71	67	79	47	56	108	82	81	66	76	66
50–54	78	55	70	53	45	47	99	63	74	78	68	74
55–59	53	46	38	37	21	25	46	57	38	63	52	51
60–64	33	30	24	27	30	17	35	26	28	26	31	34
≥65	41	33	29	30	26	26	33	23	23	39	24	35
Region of residence^a												
Northeast	142	118	104	105	83	73	238	186	149	196	156	137
Midwest	28	21	31	28	19	20	34	31	28	33	40	25
South	246	207	213	209	176	162	279	230	233	215	221	224
West	78	63	54	55	52	39	108	102	105	106	99	103
U.S. dependent areas	86	67	48	62	41	30	96	78	48	43	55	34
Total	580	477	451	458	371	325	754	626	564	592	571	522

Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Native Hawaiian/Other Pacific Islander												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	1	1	0	0	0	0	0
25–29	0	0	0	0	0	0	0	0	0	0	1	0
30–34	0	0	0	0	0	0	0	1	1	1	5	0
35–39	0	0	1	1	0	0	0	0	1	2	1	0
40–44	0	2	0	0	0	0	0	0	0	1	0	0
45–49	0	0	1	1	1	0	2	0	0	0	0	0
50–54	0	0	1	0	0	0	2	0	0	1	0	0
55–59	0	0	0	0	0	1	0	1	0	0	1	0
60–64	0	0	0	0	0	1	0	1	0	0	0	0
≥65	1	0	0	0	1	0	0	0	0	0	0	0
Region of residence^a												
Northeast	0	0	0	0	1	0	0	0	0	0	1	0
Midwest	0	0	0	1	0	0	0	0	1	0	1	0
South	0	1	0	1	1	0	3	1	0	0	1	0
West	1	1	3	0	0	1	2	2	1	4	4	0
U.S. dependent areas	0	0	0	0	0	2	0	0	0	1	1	0
Total	1	2	4	2	2	3	5	3	2	5	8	0
White												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	2	2	0	2	4	1
20–24	5	3	1	3	5	2	21	16	14	17	15	14
25–29	15	16	18	15	14	18	39	39	34	35	39	35
30–34	18	18	15	24	14	27	60	55	50	43	60	53
35–39	26	20	18	19	24	23	66	67	62	71	65	67
40–44	44	36	26	36	37	25	81	72	61	53	57	66
45–49	44	45	42	36	30	32	89	66	69	66	61	66
50–54	45	53	39	51	41	34	74	67	81	62	64	61
55–59	39	31	33	31	39	39	56	58	60	61	55	54
60–64	27	26	28	23	19	24	42	15	26	30	33	27
≥65	35	23	27	35	35	27	15	24	26	26	22	31
Region of residence^a												
Northeast	64	68	55	58	45	48	88	75	59	65	69	59
Midwest	34	35	34	37	37	42	88	79	79	83	78	80
South	151	120	122	140	127	133	283	259	270	243	266	256
West	49	47	37	37	46	27	84	66	76	74	60	80
U.S. dependent areas	0	0	0	0	0	0	0	1	0	0	1	0
Total	298	270	247	272	256	250	543	480	484	464	474	475

Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2013–2018—United States and 6 dependent areas (cont)

	Male						Female					
	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
Multiple races												
Age at diagnosis (yr)												
13–14	0	0	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	6	1	0	1	2	3
20–24	2	2	3	3	1	1	29	11	8	8	5	4
25–29	5	4	6	5	5	6	24	17	17	15	11	8
30–34	12	9	7	8	4	4	24	20	21	20	16	15
35–39	8	9	4	7	7	5	40	34	23	22	18	21
40–44	9	13	6	8	10	3	37	29	28	25	15	18
45–49	20	20	16	10	9	2	35	23	29	22	24	16
50–54	15	12	16	14	8	6	24	20	15	20	25	13
55–59	14	13	9	8	6	5	24	6	10	11	13	8
60–64	4	3	2	5	2	2	14	10	8	7	5	9
≥65	8	6	11	3	4	9	9	8	5	7	8	10
Region of residence^a												
Northeast	31	23	25	16	18	11	66	43	41	41	38	26
Midwest	6	11	8	7	2	4	19	22	16	18	19	14
South	57	49	41	37	30	26	157	101	93	81	64	63
West	4	8	6	9	7	2	22	13	15	16	20	22
U.S. dependent areas	0	0	0	0	0	0	0	0	0	1	0	0
Total	98	91	80	70	57	42	264	178	165	157	141	125
Total												
Age at diagnosis (yr)												
13–14	0	2	0	0	0	0	0	2	2	1	1	0
15–19	8	2	1	11	5	2	57	31	22	24	26	22
20–24	64	48	46	63	58	37	243	157	155	163	141	118
25–29	167	138	125	156	121	138	420	348	354	327	308	261
30–34	277	198	205	205	191	190	583	509	479	417	441	420
35–39	300	263	208	251	231	206	651	589	538	559	508	481
40–44	370	321	300	284	238	184	682	578	515	483	473	444
45–49	410	364	332	319	268	236	693	527	517	440	477	448
50–54	386	351	317	322	264	260	544	451	437	411	414	410
55–59	281	255	254	237	227	212	381	336	304	331	333	333
60–64	191	150	149	164	164	126	219	187	185	194	208	216
≥65	195	166	156	178	165	157	151	160	173	155	168	178
Region of residence^a												
Northeast	539	483	433	420	365	312	903	754	647	643	641	591
Midwest	234	184	194	224	166	181	437	422	371	414	418	361
South	1,589	1,347	1,251	1,314	1,209	1,102	2,833	2,291	2,269	2,059	2,072	1,993
West	200	174	162	169	150	121	352	326	343	343	307	350
U.S. dependent areas	88	70	51	64	41	33	99	81	51	46	59	36
Total	2,650	2,257	2,090	2,191	1,930	1,749	4,624	3,874	3,681	3,504	3,497	3,331

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.

^a Data are based on residence at time of stage 3 (AIDS) classification.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

Table 13a. Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2013–2018—United States

Race/ethnicity	2013		2014		2015		2016		2017		2018	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
American Indian/Alaska Native	0	0.0	3	0.7	2	0.4	0	0.0	0	0.0	0	0.0
Asian	16	0.6	9	0.4	10	0.4	9	0.3	4	0.2	5	0.2
Black/African American	118	1.6	110	1.5	91	1.3	77	1.1	59	0.8	59	0.8
Hispanic/Latino ^b	10	0.1	19	0.1	13	0.1	18	0.1	18	0.1	9	0.1
Native Hawaiian/Other Pacific Islander	0	0.0	1	1.0	0	0.0	0	0.0	1	0.9	0	0.0
White	24	0.1	28	0.1	17	0.1	16	0.1	14	0.1	14	0.1
Multiple races	16	0.7	11	0.5	10	0.4	7	0.3	7	0.3	4	0.2
Total	184	0.3	181	0.3	143	0.3	127	0.2	103	0.2	91	0.2

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.

^b Hispanics/Latinos can be of any race.

Table 13b. Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2013–2018—United States and 6 dependent areas

Race/ethnicity	2013	2014	2015	2016	2017	2018
	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native	0	3	2	0	0	0
Asian	16	9	10	9	4	5
Black/African American	118	110	91	77	59	59
Hispanic/Latino ^a	10	19	13	18	18	9
Native Hawaiian/Other Pacific Islander	0	1	0	0	1	0
White	24	28	17	16	14	14
Multiple races	16	11	10	7	7	4
Total	184	181	143	127	103	91

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a Hispanics/Latinos can be of any race.

Table 14a. Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2013–2018 and cumulative—United States

Race/ethnicity	2013		2014		2015		2016		2017		2018		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
American Indian/Alaska Native	0	0.0	1	0.2	0	0.0	1	0.2	2	0.5	0	0.0	29
Asian ^c	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	50
Black/African American	5	0.1	47	0.7	29	0.4	26	0.4	24	0.3	29	0.4	5,625
Hispanic/Latino ^d	2	0.0	13	0.1	5	0.0	2	0.0	6	0.0	6	0.0	2,035
Native Hawaiian/Other Pacific Islander	0	0.0	0	0.0	0	0.0	0	0.0	1	0.9	0	0.0	6
White	0	0.0	6	0.0	3	0.0	5	0.0	0	0.0	2	0.0	1,510
Multiple races	2	0.1	3	0.1	1	0.0	5	0.2	1	0.0	5	0.2	325
Total^e	9	0.0	70	0.1	40	0.1	39	0.1	34	0.1	42	0.1	9,581

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

^a From the beginning of the epidemic through 2018.

^b Rates are per 100,000 population.

^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^d Hispanics/Latinos can be of any race.

^e Cumulative total includes persons whose race/ethnicity is unknown.

Table 14b. Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2013–2018 and cumulative—United States and 6 dependent areas

Race/ethnicity	2013	2014	2015	2016	2017	2018	Cumulative ^a
	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native	0	1	0	1	2	0	29
Asian ^b	0	0	2	0	0	0	51
Black/African American	5	47	29	27	24	29	5,637
Hispanic/Latino ^c	2	13	5	2	6	6	2,450
Native Hawaiian/Other Pacific Islander	0	0	0	0	1	0	7
White	0	6	3	5	0	2	1,510
Multiple races	2	3	1	5	1	5	326
Total^d	9	70	40	40	34	42	10,011

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

^a From the beginning of the epidemic through 2018.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Cumulative total includes persons whose race/ethnicity is unknown.

Table 15. Stage 3 (AIDS) among children aged <13 years, by year of diagnosis, 1992–2018—United States and 6 dependent areas

Year of diagnosis	United States	United States and dependent areas
	No.	No.
1992	897	946
1993	880	918
1994	808	834
1995	670	692
1996	516	530
1997	334	346
1998	248	255
1999	200	205
2000	132	134
2001	129	130
2002	108	115
2003	76	78
2004	59	61
2005	55	55
2006	40	43
2007	35	36
2008	38	39
2009	16	17
2010	23	23
2011	18	19
2012	11	11
2013	9	9
2014	70	70
2015	40	40
2016	39	40
2017	34	34
2018	42	42

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay. Data for the year 2018 should not be used when assessing trends.

Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

Table 16. Diagnoses of HIV infection among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2018—United States and 6 dependent areas

Transmission category ^a	Central America		Cuba		Mexico		Puerto Rico		South America		United States		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No. ^b	%
Male adult or adolescent														
Male-to-male sexual contact	359	81.5	221	86.7	870	87.0	385	71.9	705	90.6	2,389	85.2	7,543	85.4
Injection drug use	11	2.6	2	0.8	22	2.2	53	10.0	7	0.8	133	4.7	362	4.1
Male-to-male sexual contact and injection drug use	12	2.8	3	1.0	24	2.4	18	3.4	9	1.1	153	5.4	323	3.7
Heterosexual contact ^c	55	12.6	29	11.5	83	8.3	79	14.7	58	7.4	127	4.5	597	6.8
Other ^d	2	0.5	0	0.0	1	0.1	0	0.0	0	0.0	2	0.1	8	0.1
Subtotal	440	100	255	100	1,000	100	535	100	778	100	2,803	100	8,833	100
Female adult or adolescent														
Injection drug use	4	3.2	0	0.0	4	4.2	8	5.7	2	2.4	73	18.8	149	11.8
Heterosexual contact ^c	105	94.7	21	100	80	95.4	125	94.3	64	96.1	312	80.5	1,109	87.7
Other ^d	2	2.1	0	0.0	0	0.5	0	0.0	1	1.5	3	0.6	7	0.5
Subtotal	111	100	21	100	84	100	132	100	67	100	387	100	1,264	100
Total	551	100	276	100	1,084	100	667	100	845	100	3,190	100	10,097	100

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12, and percentages based on these numbers, should be interpreted with caution.

^a Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^b Total include persons whose place of birth is not among those listed and persons whose place of birth is unknown.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

Table 17. Stage 3 (AIDS) among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2018—United States and 6 dependent areas

Transmission category ^a	Central America		Cuba		Mexico		Puerto Rico		South America		United States		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No. ^b	%
Male adult or adolescent														
Male-to-male sexual contact	150	75.8	65	71.4	413	79.3	113	50.5	173	86.4	938	77.3	2,612	76.8
Injection drug use	8	4.0	6	6.8	22	4.3	52	23.4	3	1.4	88	7.2	249	7.3
Male-to-male sexual contact and injection drug use	6	3.2	7	7.7	21	4.0	16	7.3	3	1.5	109	9.0	197	5.8
Heterosexual contact ^c	34	17.0	13	14.1	64	12.3	39	17.4	22	10.8	69	5.7	325	9.5
Other ^d	0	0.0	0	0.0	1	0.1	3	1.4	0	0.0	9	0.8	18	0.5
Subtotal	198	100	91	100	521	100	223	100	200	100	1,213	100	3,401	100
Female adult or adolescent														
Injection drug use	5	7.6	0	2.5	5	7.5	13	14.7	1	5.7	75	28.2	126	19.0
Heterosexual contact ^c	60	90.6	8	96.3	58	91.7	71	84.0	20	94.3	180	67.5	522	78.5
Other ^d	1	1.8	0	1.3	1	0.8	1	1.3	0	0.0	12	4.3	17	2.6
Subtotal	66	100	8	100	63	100	85	100	21	100	267	100	666	100
Total	264	100	99	100	584	100	308	100	221	100	1,480	100	4,067	100

Note. Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12, and percentages based on these numbers, should be interpreted with caution.

^a Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^b Totals include persons whose place of birth is not among those listed and persons whose place of birth is unknown.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

Table 18a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2013–2017—United States

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at death (yr)										
<13	1	0.0	1	0.0	4	0.0	2	0.0	2	0.0
13–14	1	0.0	3	0.0	0	0.0	1	0.0	0	0.0
15–19	9	0.0	13	0.1	11	0.1	10	0.0	7	0.0
20–24	169	0.7	171	0.7	149	0.7	156	0.7	140	0.6
25–29	422	2.0	361	1.6	399	1.8	448	2.0	436	1.9
30–34	631	3.0	635	3.0	589	2.7	657	3.0	583	2.7
35–39	850	4.3	886	4.5	813	4.0	830	4.0	847	4.0
40–44	1,460	7.0	1,361	6.6	1,230	6.1	1,125	5.7	942	4.8
45–49	2,429	11.5	2,200	10.6	2,000	9.6	1,801	8.6	1,683	8.0
50–54	3,051	13.5	2,962	13.2	2,946	13.2	2,842	13.0	2,668	12.5
55–59	2,715	12.8	2,902	13.5	2,844	13.1	2,988	13.6	2,918	13.3
60–64	1,939	10.7	2,202	11.9	2,156	11.3	2,411	12.4	2,441	12.2
≥65	2,241	5.0	2,452	5.3	2,722	5.7	3,065	6.2	3,304	6.5
Race/ethnicity										
American Indian/Alaska Native	64	2.7	61	2.6	62	2.6	47	2.0	39	1.6
Asian ^b	71	0.4	60	0.4	81	0.5	102	0.6	84	0.5
Black/African American	7,391	18.9	7,349	18.6	7,130	17.9	7,220	17.9	7,049	17.4
Hispanic/Latino ^c	2,541	4.7	2,652	4.8	2,505	4.4	2,615	4.5	2,606	4.4
Native Hawaiian/Other Pacific Islander	10	1.9	9	1.7	7	1.3	14	2.5	8	1.4
White	4,871	2.5	5,023	2.5	5,049	2.6	5,312	2.7	5,123	2.6
Multiple races	967	15.6	991	15.6	1023	15.6	1024	15.2	1061	15.3
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	6,401	—	6,538	—	6,575	—	6,883	—	6,855	—
Injection drug use	2,373	—	2,411	—	2,288	—	2,281	—	2,117	—
Male-to-male sexual contact and injection drug use	1,335	—	1,346	—	1,402	—	1,387	—	1,326	—
Heterosexual contact ^e	1,632	—	1,577	—	1,587	—	1,674	—	1,665	—
Perinatal	35	—	32	—	28	—	40	—	41	—
Other ^f	74	—	60	—	77	—	63	—	62	—
Subtotal	11,851	9.2	11,965	9.2	11,958	9.1	12,328	9.3	12,067	9.1

Table 18a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2013–2017—United States (cont)

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	1,505	—	1,458	—	1,349	—	1,380	—	1,334	—
Heterosexual contact ^e	2,501	—	2,665	—	2,477	—	2,552	—	2,498	—
Perinatal	33	—	30	—	46	—	47	—	42	—
Other ^f	27	—	30	—	29	—	27	—	29	—
Subtotal	4,066	3.0	4,183	3.1	3,901	2.8	4,006	2.9	3,902	2.8
Child (<13 yrs at death)										
Perinatal	1	—	1	—	2	—	1	—	2	—
Other ^f	0	—	0	—	2	—	1	—	0	—
Subtotal	1	0.0	1	0.0	4	0.0	2	0.0	2	0.0
Region of residence^g										
Northeast	3,856	6.9	3,735	6.7	3,583	6.4	3,693	6.6	3,622	6.5
Midwest	1,785	2.6	1,845	2.7	1,808	2.7	1,836	2.7	1,866	2.7
South	7,745	6.5	7,981	6.7	7,870	6.5	8,065	6.6	7,854	6.4
West	2,532	3.4	2,588	3.5	2,602	3.4	2,742	3.6	2,629	3.4
Total^h	15,918	5.0	16,149	5.1	15,863	4.9	16,336	5.1	15,971	4.9

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

^h Includes persons whose race/ethnicity is unknown.

Table 18b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2013–2017—United States and 6 dependent areas

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at death (yr)										
<13	1	0.0	1	0.0	4	0.0	2	0.0	2	0.0
13–14	1	0.0	3	0.0	0	0.0	1	0.0	0	0.0
15–19	11	0.1	13	0.1	11	0.1	11	0.1	7	0.0
20–24	172	0.7	173	0.7	151	0.7	160	0.7	142	0.6
25–29	431	2.0	368	1.7	404	1.8	455	2.0	443	1.9
30–34	655	3.0	651	3.0	610	2.8	665	3.0	594	2.7
35–39	881	4.4	907	4.5	833	4.1	861	4.1	861	4.0
40–44	1,495	7.1	1,398	6.7	1,265	6.2	1,156	5.8	977	4.9
45–49	2,518	11.7	2,264	10.7	2,051	9.8	1,852	8.7	1,729	8.2
50–54	3,140	13.8	3,059	13.4	3,041	13.5	2,912	13.2	2,740	12.7
55–59	2,779	13.0	2,989	13.8	2,909	13.2	3,062	13.8	2,992	13.5
60–64	1,988	10.8	2,262	12.1	2,203	11.4	2,464	12.5	2,480	12.3
≥65	2,309	5.1	2,534	5.4	2,781	5.8	3,146	6.3	3,385	6.6
Race/ethnicity										
American Indian/Alaska Native	64	—	61	—	62	—	47	—	39	—
Asian ^b	71	—	62	—	82	—	102	—	84	—
Black/African American	7,397	—	7,358	—	7,136	—	7,229	—	7,054	—
Hispanic/Latino ^c	2,992	—	3,114	—	2,896	—	3,013	—	2,981	—
Native Hawaiian/Other Pacific Islander	12	—	9	—	8	—	16	—	8	—
White	4,873	—	5,023	—	5,049	—	5,313	—	5,124	—
Multiple races	969	—	991	—	1,024	—	1,025	—	1,061	—
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	6,483	—	6,623	—	6,650	—	6,957	—	6,918	—
Injection drug use	2,513	—	2,556	—	2,421	—	2,411	—	2,241	—
Male-to-male sexual contact and injection drug use	1,365	—	1,374	—	1,428	—	1,419	—	1,345	—
Heterosexual contact ^e	1,718	—	1,658	—	1,646	—	1,749	—	1,735	—
Perinatal	37	—	32	—	29	—	46	—	42	—
Other ^f	74	—	62	—	78	—	63	—	63	—
Subtotal	12,191	9.4	12,306	9.4	12,252	9.2	12,645	9.5	12,344	9.2

Table 18b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2013–2017—United States and 6 dependent areas (*cont*)

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	1,548	—	1,499	—	1,373	—	1,415	—	1,365	—
Heterosexual contact ^e	2,581	—	2,754	—	2,558	—	2,609	—	2,570	—
Perinatal	34	—	31	—	47	—	49	—	43	—
Other ^f	27	—	30	—	29	—	28	—	29	—
Subtotal	4,189	3.1	4,315	3.1	4,007	2.9	4,100	2.9	4,006	2.8
Child (<13 yrs at death)										
Perinatal	1	—	1	—	2	—	1	—	2	—
Other ^f	0	—	0	—	2	—	1	—	0	—
Subtotal	1	0.0	1	0.0	4	0.0	2	0.0	2	0.0
Region of residence^g										
Northeast	3,856	6.9	3,735	6.7	3,583	6.4	3,693	6.6	3,622	6.5
Midwest	1,785	2.6	1,845	2.7	1,808	2.7	1,836	2.7	1,866	2.7
South	7,745	6.5	7,981	6.7	7,870	6.5	8,065	6.6	7,854	6.4
West	2,532	3.4	2,588	3.5	2,602	3.4	2,742	3.6	2,629	3.4
U.S. dependent areas	463	11.6	473	12.0	400	10.3	411	10.8	381	10.2
Total^h	16,381	5.1	16,622	5.2	16,263	5.0	16,747	5.1	16,352	5.0

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

^h Includes persons whose race/ethnicity is unknown.

Table 19a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2013–2017 and cumulative—United States

	2013		2014		2015		2016		2017		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Age at death (yr)											
<13	1	0.0	0	0.0	2	0.0	0	0.0	0	0.0	4,951
13–14	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	293
15–19	6	0.0	8	0.0	6	0.0	4	0.0	3	0.0	1,305
20–24	123	0.5	118	0.5	109	0.5	91	0.4	83	0.4	10,212
25–29	313	1.5	268	1.2	298	1.3	293	1.3	285	1.2	47,924
30–34	513	2.4	491	2.3	455	2.1	479	2.2	416	1.9	103,122
35–39	699	3.6	710	3.6	640	3.2	632	3.0	658	3.1	129,907
40–44	1,212	5.8	1,116	5.4	996	4.9	897	4.6	721	3.7	124,900
45–49	2,030	9.6	1,817	8.7	1,657	8.0	1,489	7.1	1,360	6.5	100,822
50–54	2,538	11.3	2,486	11.0	2,470	11.1	2,332	10.7	2,167	10.2	74,498
55–59	2,247	10.6	2,353	11.0	2,344	10.8	2,446	11.1	2,380	10.8	50,581
60–64	1,573	8.7	1,794	9.7	1,732	9.1	1,905	9.8	1,974	9.9	31,658
≥65	1,745	3.9	1,911	4.1	2,088	4.4	2,371	4.8	2,533	5.0	33,712
Race/ethnicity											
American Indian/Alaska Native	52	2.2	44	1.9	51	2.2	37	1.6	33	1.4	2,019
Asian ^c	64	0.4	47	0.3	63	0.4	82	0.5	65	0.4	3,664
Black/African American	5,977	15.3	5,929	15.0	5,695	14.3	5,712	14.2	5,557	13.7	294,697
Hispanic/Latino ^d	2,180	4.0	2,244	4.1	2,119	3.8	2,164	3.8	2,183	3.7	110,311
Native Hawaiian/Other Pacific Islander	7	1.3	6	1.1	5	0.9	10	1.8	7	1.2	384
White	3,878	2.0	3,957	2.0	3,984	2.0	4,076	2.1	3,848	1.9	285,638
Multiple races	841	13.6	846	13.3	880	13.4	858	12.7	887	12.8	17,129
Transmission category^e											
Male adult or adolescent											
Male-to-male sexual contact	5,171	—	5,242	—	5,255	—	5,356	—	5,335	—	333,600
Injection drug use	1,968	—	1,982	—	1,889	—	1,861	—	1,732	—	136,501
Male-to-male sexual contact and injection drug use	1,131	—	1,155	—	1,187	—	1,150	—	1,097	—	56,031
Heterosexual contact ^f	1,313	—	1,277	—	1,260	—	1,340	—	1,299	—	41,407
Perinatal	31	—	28	—	26	—	34	—	36	—	532
Other ^g	56	—	51	—	65	—	49	—	48	—	8,847
Subtotal	9,670	7.5	9,735	7.5	9,682	7.4	9,791	7.4	9,547	7.2	576,918

Table 19a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2013–2017 and cumulative—United States (*cont*)

	2013		2014		2015		2016		2017		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Female adult or adolescent											
Injection drug use	1,259	—	1,199	—	1,104	—	1,115	—	1,066	—	61,264
Heterosexual contact ^f	2,015	—	2,087	—	1,940	—	1,966	—	1,903	—	66,386
Perinatal	33	—	29	—	45	—	45	—	40	—	671
Other ^g	23	—	23	—	24	—	22	—	23	—	3,695
Subtotal	3,329	2.5	3,338	2.5	3,113	2.3	3,148	2.3	3,033	2.2	132,016
Child (<13 yrs at death)											
Perinatal	1	—	0	—	0	—	0	—	0	—	4,495
Other ^g	0	—	0	—	2	—	0	—	0	—	456
Subtotal	1	0.0	0	0.0	2	0.0	0	0.0	0	0.0	4,951
Region of residence^h											
Northeast	3,196	5.7	3,018	5.4	2,892	5.2	2,915	5.2	2,837	5.1	216,845
Midwest	1,420	2.1	1,448	2.1	1,422	2.1	1,425	2.1	1,412	2.1	76,857
South	6,289	5.3	6,465	5.4	6,337	5.2	6,383	5.2	6,177	5.0	283,496
West	2,095	2.8	2,142	2.9	2,146	2.8	2,216	2.9	2,154	2.8	136,687
Totalⁱ	13,000	4.1	13,073	4.1	12,797	4.0	12,939	4.0	12,580	3.9	713,885

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2017.

^b Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^d Hispanics/Latinos can be of any race.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

ⁱ Includes persons whose race/ethnicity is unknown.

Table 19b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2013–2017 and cumulative—United States and 6 dependent areas

	2013		2014		2015		2016		2017		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Age at death (yr)											
<13	1	0.0	0	0.0	2	0.0	0	0.0	0	0.0	5,192
13–14	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	303
15–19	8	0.0	8	0.0	6	0.0	5	0.0	3	0.0	1,376
20–24	126	0.5	120	0.5	111	0.5	95	0.4	85	0.4	10,746
25–29	315	1.4	271	1.2	302	1.3	296	1.3	289	1.2	50,157
30–34	528	2.5	504	2.3	471	2.2	484	2.2	423	1.9	107,394
35–39	718	3.6	727	3.6	653	3.2	651	3.1	667	3.1	135,113
40–44	1,237	5.9	1,140	5.5	1,020	5.0	920	4.6	745	3.8	129,492
45–49	2,094	9.8	1,860	8.8	1,698	8.1	1,523	7.2	1,385	6.5	104,216
50–54	2,603	11.4	2,561	11.2	2,542	11.3	2,386	10.8	2,219	10.3	76,854
55–59	2,295	10.7	2,423	11.2	2,392	10.9	2,498	11.3	2,435	11.0	51,983
60–64	1,613	8.8	1,839	9.8	1,770	9.2	1,941	9.9	2,002	9.9	32,603
≥65	1,792	4.0	1,974	4.2	2,132	4.4	2,428	4.9	2,583	5.0	34,948
Race/ethnicity											
American Indian/Alaska Native	52	—	44	—	51	—	37	—	33	—	2,020
Asian ^c	64	—	48	—	63	—	82	—	65	—	3,713
Black/African American	5,980	—	5,933	—	5,699	—	5,721	—	5,560	—	294,992
Hispanic/Latino ^d	2,501	—	2,594	—	2,415	—	2,439	—	2,436	—	136,329
Native Hawaiian/Other Pacific Islander	9	—	6	—	6	—	12	—	7	—	402
White	3,880	—	3,957	—	3,984	—	4,077	—	3,848	—	285,735
Multiple races	843	—	846	—	881	—	859	—	887	—	17,143
Transmission category^e											
Male adult or adolescent											
Male-to-male sexual contact	5,235	—	5,303	—	5,315	—	5,408	—	5,376	—	337,867
Injection drug use	2,062	—	2,092	—	1,987	—	1,953	—	1,815	—	147,721
Male-to-male sexual contact and injection drug use	1,156	—	1,178	—	1,211	—	1,179	—	1,111	—	58,148
Heterosexual contact ^f	1,374	—	1,330	—	1,302	—	1,388	—	1,344	—	44,104
Perinatal	33	—	28	—	27	—	38	—	37	—	564
Other ^g	56	—	53	—	65	—	49	—	48	—	8,978
Subtotal	9,917	7.6	9,984	7.6	9,907	7.5	10,016	7.5	9,732	7.2	597,383

Table 19b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2013–2017 and cumulative—United States and 6 dependent areas (*cont*)

	2013		2014		2015		2016		2017		Cumulative ^a
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.
Female adult or adolescent											
Injection drug use	1,289	—	1,235	—	1,120	—	1,140	—	1,085	—	63,546
Heterosexual contact ^f	2,067	—	2,156	—	2,000	—	2,002	—	1,954	—	69,751
Perinatal	34	—	30	—	46	—	47	—	41	—	707
Other ^g	23	—	23	—	24	—	22	—	23	—	3,798
Subtotal	3,412	2.5	3,444	2.5	3,190	2.3	3,211	2.3	3,104	2.2	137,802
Child (<13 yrs at death)											
Perinatal	1	—	0	—	0	—	0	—	0	—	4,720
Other ^g	0	—	0	—	2	—	0	—	0	—	472
Subtotal	1	0.0	0	0.0	2	0.0	0	0.0	0	0.0	5,192
Region of residence^h											
Northeast	3,196	5.7	3,018	5.4	2,892	5.2	2,915	5.2	2,837	5.1	216,845
Midwest	1,420	2.1	1,448	2.1	1,422	2.1	1,425	2.1	1,412	2.1	76,857
South	6,289	5.3	6,465	5.4	6,337	5.2	6,383	5.2	6,177	5.0	283,496
West	2,095	2.8	2,142	2.9	2,146	2.8	2,216	2.9	2,154	2.8	136,687
U.S. dependent areas	330	8.3	355	9.0	302	7.8	288	7.6	256	6.9	26,492
Totalⁱ	13,330	4.2	13,428	4.2	13,099	4.0	13,227	4.0	12,836	3.9	740,377

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2017.

^b Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^d Hispanics/Latinos can be of any race.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

ⁱ Includes persons whose race/ethnicity is unknown.

Table 20a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2017—United States

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Age at death (yr)																
<13	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0	2	0.0
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	4	0.1	2	0.0	0	0.0	0	0.0	1	0.1	7	0.0
20–24	1	0.5	3	0.2	70	2.2	29	0.6	1	2.3	24	0.2	12	1.9	140	0.6
25–29	0	0.0	1	0.1	255	7.5	74	1.6	0	0.0	68	0.5	38	7.2	436	1.9
30–34	1	0.6	2	0.1	288	10.1	123	2.7	2	4.0	125	1.0	42	10.3	583	2.7
35–39	3	2.0	5	0.3	400	14.7	158	3.6	0	0.0	230	1.9	51	14.4	847	4.0
40–44	4	2.9	5	0.4	443	17.9	172	4.3	1	2.6	250	2.2	67	23.3	942	4.8
45–49	7	4.8	18	1.3	720	27.7	299	8.1	0	0.0	520	4.0	119	44.8	1,683	8.0
50–54	6	3.9	20	1.7	1,046	39.7	450	14.1	2	5.8	958	6.9	186	78.3	2,668	12.5
55–59	8	5.1	8	0.8	1,280	49.3	457	17.3	0	0.0	965	6.3	199	87.1	2,918	13.3
60–64	4	3.0	11	1.2	1,156	52.2	348	17.1	1	3.8	770	5.4	151	79.7	2,441	12.2
≥65	5	1.8	11	0.5	1,386	30.3	494	11.8	1	1.9	1,212	3.1	195	50.9	3,304	6.5
Transmission category^e																
Male adult or adolescent																
Male-to-male sexual contact	15	—	52	—	2,183	—	1,086	—	4	—	3,083	—	431	—	6,855	—
Injection drug use	5	—	6	—	1,059	—	484	—	0	—	411	—	153	—	2,117	—
Male-to-male sexual contact and injection drug use	6	—	0	—	408	—	237	—	0	—	558	—	118	—	1,327	—
Heterosexual contact ^f	4	—	10	—	1,118	—	220	—	0	—	231	—	82	—	1,665	—
Perinatal	0	—	0	—	22	—	7	—	0	—	6	—	6	—	41	—
Other ^g	0	—	1	—	17	—	8	—	0	—	32	—	5	—	62	—
Subtotal	29	3.0	70	1.0	4,806	30.5	2,042	9.0	4	1.7	4,321	5.1	794	36.1	12,067	9.1

Table 20a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2017—United States (*cont*)

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Female adult or adolescent																
Injection drug use	2	—	2	—	641	—	232	—	0	—	355	—	102	—	1,334	—
Heterosexual contact ^f	7	—	11	—	1,566	—	321	—	3	—	433	—	158	—	2,498	—
Perinatal	1	—	1	—	23	—	9	—	1	—	1	—	5	—	42	—
Other ^g	0	—	1	—	12	—	3	—	0	—	12	—	1	—	29	—
Subtotal	10	1.0	14	0.2	2,242	12.7	564	2.5	4	1.7	801	0.9	267	11.4	3,902	2.8
Child (<13 yrs at death)																
Perinatal	0	—	0	—	1	—	0	—	0	—	1	—	0	—	2	—
Other ^g	0	—	0	—	0	—	0	—	0	—	0	—	0	—	0	—
Subtotal	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0	2	0.0
Region of residence^h																
Northeast	2	1.6	17	0.5	1,409	22.2	1,008	12.4	0	0.0	837	2.3	348	36.8	3,622	6.5
Midwest	4	1.0	4	0.2	839	11.8	126	2.3	0	0.0	785	1.5	108	8.2	1,866	2.7
South	14	1.8	19	0.4	4,361	18.5	815	3.7	1	1.1	2,222	3.2	422	18.3	7,854	6.4
West	19	1.8	44	0.6	440	12.5	657	2.8	7	1.6	1,279	3.3	183	7.7	2,629	3.4
Total	39	1.6	84	0.5	7,049	17.4	2,606	4.4	8	1.4	5,123	2.6	1,061	15.3	15,971	4.9

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 20b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian ^a	Black/African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Age at death (yr)								
<13	0	0	1	0	0	1	0	2
13–14	0	0	0	0	0	0	0	0
15–19	0	0	4	2	0	0	1	7
20–24	1	3	70	31	1	24	12	142
25–29	0	1	255	81	0	68	38	443
30–34	1	2	288	134	2	125	42	594
35–39	3	5	400	172	0	230	51	861
40–44	4	5	444	206	1	250	67	977
45–49	7	18	720	345	0	520	119	1,729
50–54	6	20	1,046	522	2	958	186	2,740
55–59	8	8	1,282	529	0	965	199	2,992
60–64	4	11	1,157	386	1	770	151	2,480
≥65	5	11	1,387	573	1	1,213	195	3,385
Transmission category^d								
Male adult or adolescent								
Male-to-male sexual contact	15	52	2,184	1,147	4	3,084	431	6,918
Injection drug use	5	6	1,059	607	0	411	153	2,241
Male-to-male sexual contact and injection drug use	6	0	408	256	0	558	118	1,346
Heterosexual contact ^e	4	10	1,120	288	0	231	82	1,735
Perinatal	0	0	22	8	0	6	6	42
Other ^f	0	1	17	8	0	32	5	63
Subtotal	29	70	4,810	2,314	4	4,322	794	12,344

Table 20b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas (*cont*)

	American Indian/ Alaska Native	Asian ^a	Black/African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	2	2	641	263	0	355	102	1,365
Heterosexual contact ^e	7	11	1,567	391	3	433	158	2,570
Perinatal	1	1	23	10	1	1	5	43
Other ^f	0	1	12	3	0	12	1	29
Subtotal	10	14	2,243	667	4	801	267	4,006
Child (<13 yrs at end of year)								
Perinatal	0	0	1	0	0	1	0	2
Other ^f								
Subtotal	0	0	1	0	0	1	0	2
Region of residence^g								
Northeast	2	17	1,409	1,008	0	837	348	3,622
Midwest	4	4	839	126	0	785	108	1,866
South	14	19	4,361	815	1	2,222	422	7,854
West	19	44	440	657	7	1,279	183	2,629
U.S. dependent areas	0	0	5	375	0	1	0	381
Total	39	84	7,054	2,981	8	5,124	1,061	16,352

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 21a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total	
	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c
Age at death (yr)																
<13	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	2	0.1	1	0.0	0	0.0	0	0.0	0	0.0	3	0.0
20–24	1	0.5	1	0.1	44	1.4	20	0.4	1	2.3	8	0.1	8	1.3	83	0.4
25–29	0	0.0	1	0.1	176	5.2	49	1.0	0	0.0	32	0.2	27	5.1	285	1.2
30–34	0	0.0	2	0.1	222	7.8	91	2.0	2	4.0	67	0.5	32	7.9	416	1.9
35–39	1	0.7	3	0.2	323	11.9	131	3.0	0	0.0	157	1.3	43	12.2	658	3.1
40–44	3	2.1	4	0.3	351	14.2	140	3.5	0	0.0	170	1.5	53	18.4	721	3.7
45–49	7	4.8	16	1.2	589	22.7	251	6.8	0	0.0	397	3.1	100	37.6	1,360	6.5
50–54	6	3.9	17	1.5	857	32.5	387	12.2	2	5.8	732	5.3	166	69.9	2,167	10.2
55–59	7	4.5	5	0.5	1,024	39.4	399	15.1	0	0.0	772	5.1	173	75.7	2,380	10.8
60–64	3	2.2	9	0.9	928	41.9	295	14.5	1	3.8	604	4.2	134	70.8	1,974	9.9
≥65	5	1.8	7	0.3	1,041	22.7	419	10.0	1	1.9	909	2.3	151	39.4	2,533	5.0
Transmission category^d																
Male adult or adolescent																
Male-to-male sexual contact	13	—	40	—	1,704	—	898	—	4	—	2,322	—	354	—	5,335	—
Injection drug use	4	—	4	—	865	—	411	—	0	—	316	—	133	—	1,732	—
Male-to-male sexual contact and injection drug use	6	—	0	—	355	—	194	—	0	—	443	—	99	—	1,097	—
Heterosexual contact ^e	2	—	10	—	859	—	194	—	0	—	164	—	70	—	1,299	—
Perinatal	0	—	0	—	20	—	7	—	0	—	4	—	5	—	36	—
Other ^f	0	—	1	—	13	—	5	—	0	—	25	—	4	—	48	—
Subtotal	25	2.6	55	0.7	3,814	24.2	1,709	7.5	4	1.7	3,274	3.9	666	30.3	9,547	7.2

Table 21a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States (*cont*)

	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total	
	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c	No.	Rate ^c
Female adult or adolescent																
Injection drug use	2	—	2	—	520	—	202	—	0	—	257	—	83	—	1,066	—
Heterosexual contact ^e	5	—	7	—	1,192	—	260	—	2	—	305	—	131	—	1,903	—
Perinatal	1	—	1	—	22	—	9	—	1	—	1	—	5	—	40	—
Other ^f	0	—	1	—	9	—	2	—	0	—	11	—	1	—	23	—
Subtotal	8	0.8	10	0.1	1,743	9.9	474	2.1	3	1.3	574	0.7	221	9.4	3,033	2.2
Child (<13 yrs at death)																
Perinatal	0	—	0	—	0	—	0	—	0	—	0	—	0	—	0	—
Other ^f	0	—	0	—	0	—	0	—	0	—	0	—	0	—	0	—
Subtotal	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Region of residence^g																
Northeast	1	0.8	11	0.3	1,100	17.4	825	10.2	0	0.0	605	1.6	295	31.2	2,837	5.1
Midwest	3	0.7	3	0.1	641	9.0	108	2.0	0	0.0	568	1.1	89	6.7	1,412	2.1
South	13	1.6	15	0.3	3,447	14.6	694	3.1	1	1.1	1,655	2.4	352	15.3	6,177	5.0
West	16	1.5	36	0.5	369	10.5	556	2.4	6	1.4	1,020	2.6	151	6.4	2,154	2.8
Total	33	1.4	65	0.4	5,557	13.7	2,183	3.7	7	1.2	3,848	1.9	887	12.8	12,580	3.9

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 21b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Age at death (yr)								
<13	0	0	0	0	0	0	0	0
13–14	0	0	0	0	0	0	0	0
15–19	0	0	2	1	0	0	0	3
20–24	1	1	44	22	1	8	8	85
25–29	0	1	176	53	0	32	27	289
30–34	0	2	222	98	2	67	32	423
35–39	1	3	323	140	0	157	43	667
40–44	3	4	351	164	0	170	53	745
45–49	7	16	589	276	0	397	100	1,385
50–54	6	17	857	439	2	732	166	2,219
55–59	7	5	1,025	453	0	772	173	2,435
60–64	3	9	929	322	1	604	134	2,002
≥65	5	7	1,042	468	1	909	151	2,583
Transmission category^c								
Male adult or adolescent								
Male-to-male sexual contact	13	40	1,705	939	4	2,322	354	5,376
Injection drug use	4	4	865	493	0	316	133	1,815
Male-to-male sexual contact and injection drug use	6	0	355	208	0	443	99	1,111
Heterosexual contact ^d	2	10	860	238	0	164	70	1,344
Perinatal	0	0	20	8	0	4	5	37
Other ^e	0	1	13	5	0	25	4	48
Subtotal	25	55	3,817	1,891	4	3,274	666	9,732

Table 21b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas (*cont*)

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	2	2	520	221	0	257	83	1,085
Heterosexual contact ^d	5	7	1,192	311	2	305	131	1,954
Perinatal	1	1	22	10	1	1	5	41
Other ^e	0	1	9	2	0	11	1	23
Subtotal	8	10	1,743	545	3	574	221	3,104
Child (<13 yrs at end of year)								
Perinatal	0	0	0	0	0	0	0	0
Other ^e	0	0	0	0	0	0	0	0
Subtotal	0	0	0	0	0	0	0	0
Region of residence^f								
Northeast	1	11	1,100	825	0	605	295	2,837
Midwest	3	3	641	108	0	568	89	1,412
South	13	15	3,447	694	1	1,655	352	6,177
West	16	36	369	556	6	1,020	151	2,154
U.S. dependent areas	0	0	3	253	0	0	0	256
Total	33	65	5,560	2,436	7	3,848	887	12,836

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.

Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^e Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^f Data are based on residence at death. When information on residence at death was not available, state at death (where a person's death occurred) was used.

Table 22a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2013–2017—United States

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at end of year (yr)										
<13	2,599	4.9	2,479	4.7	2,345	4.4	2,222	4.2	2,064	3.9
13–14	764	9.1	736	8.8	724	8.8	679	8.3	672	8.1
15–19	5,660	26.7	5,255	25.0	4,942	23.4	4,612	21.8	4,502	21.3
20–24	31,859	139.6	31,609	138.2	30,750	135.6	29,741	133.0	28,320	128.3
25–29	56,902	263.8	61,119	278.4	65,173	290.8	68,328	298.1	70,374	301.6
30–34	72,083	338.9	73,942	343.8	75,939	351.0	79,287	363.3	82,924	378.0
35–39	83,016	423.3	84,295	424.0	87,098	428.7	89,780	431.8	92,041	434.4
40–44	114,628	549.8	108,595	528.7	101,674	504.7	97,784	496.5	96,470	492.4
45–49	154,829	729.9	147,997	710.4	143,064	688.6	136,860	654.1	130,846	625.6
50–54	156,351	693.3	163,496	726.0	166,905	749.7	167,372	767.3	163,914	767.8
55–59	110,687	522.7	119,011	554.4	128,133	589.3	136,318	621.0	145,059	660.6
60–64	64,377	355.5	72,081	389.0	79,437	417.7	87,908	451.7	96,521	484.0
≥65	51,619	115.6	59,445	128.8	68,866	144.5	78,824	160.1	90,075	177.3
Race/ethnicity										
American Indian/Alaska Native	2,437	104.6	2,554	108.6	2,678	113.0	2,855	119.6	3,032	126.2
Asian ^b	10,508	65.0	11,391	68.3	12,319	71.5	13,274	74.7	14,244	78.1
Black/African American	373,454	954.5	383,704	971.5	394,245	988.7	404,678	1,005.6	414,747	1,022.0
Hispanic/Latino ^c	192,091	355.4	199,345	361.3	206,914	367.1	214,819	373.1	222,662	379.3
Native Hawaiian/Other Pacific Islander	668	125.3	703	129.3	768	138.5	795	140.5	839	145.6
White	280,035	141.7	285,557	144.4	290,865	147.1	295,718	149.5	300,619	152.1
Multiple races	45,385	733.8	46,014	722.2	46,475	708.3	46,793	693.2	46,857	675.9
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	474,770	—	494,900	—	515,113	—	534,878	—	554,159	—
Injection drug use	73,615	—	72,519	—	71,598	—	70,634	—	69,956	—
Male-to-male sexual contact and injection drug use	55,110	—	55,179	—	55,210	—	55,255	—	55,318	—
Heterosexual contact ^e	71,571	—	73,300	—	75,010	—	76,729	—	78,025	—
Perinatal	4,326	—	4,454	—	4,559	—	4,646	—	4,733	—
Other ^f	2,952	—	2,943	—	2,938	—	2,923	—	2,937	—
Subtotal	682,344	530.6	703,296	541.8	724,427	553.1	745,064	563.9	765,129	574.4

Table 22a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2013–2017—United States (cont)

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	50,578	—	50,109	—	49,822	—	49,494	—	49,288	—
Heterosexual contact ^e	163,349	—	167,488	—	171,626	—	175,950	—	180,137	—
Perinatal	4,763	—	4,918	—	5,025	—	5,133	—	5,274	—
Other ^f	1,741	—	1,769	—	1,805	—	1,852	—	1,890	—
Subtotal	220,431	163.6	224,285	165.0	228,278	166.6	232,429	168.2	236,589	169.9
Child (<13 yrs at end of year)										
Perinatal	2,151	—	2,015	—	1,902	—	1,805	—	1,677	—
Other ^f	448	—	464	—	443	—	417	—	387	—
Subtotal	2,599	4.9	2,479	4.7	2,345	4.4	2,222	4.2	2,064	3.9
Region of residence^g										
Northeast	221,324	395.9	225,573	402.7	227,689	406.2	231,824	413.5	233,941	417.2
Midwest	107,465	159.1	110,466	163.0	113,152	166.7	116,821	171.8	119,944	176.0
South	402,128	339.7	414,257	346.2	428,039	353.6	438,560	358.3	451,784	365.5
West	174,457	235.1	179,764	239.8	186,170	245.6	192,510	251.3	198,113	256.2
Total^h	905,374	286.5	930,060	292.1	955,050	297.8	979,715	303.3	1,003,782	308.7

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^h Includes persons whose race/ethnicity is unknown.

Table 22b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2013–2017—United States and 6 dependent areas

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at end of year (yr)										
<13	2,617	4.9	2,496	4.7	2,357	4.4	2,235	4.2	2,073	3.9
13–14	784	9.2	743	8.7	729	8.7	682	8.2	677	8.1
15–19	5,751	26.8	5,345	25.1	5,007	23.4	4,658	21.8	4,545	21.3
20–24	32,291	139.7	32,043	138.3	31,148	135.7	30,096	133.0	28,620	128.2
25–29	57,587	263.9	61,845	278.5	65,939	290.9	69,091	298.2	71,094	301.4
30–34	73,230	340.2	74,994	344.8	76,903	351.6	80,253	364.0	83,834	378.4
35–39	84,530	425.5	85,759	426.1	88,566	430.8	91,184	433.6	93,337	435.8
40–44	116,700	552.8	110,557	531.7	103,463	507.4	99,466	499.0	98,068	494.8
45–49	157,761	734.6	150,723	714.7	145,678	692.7	139,279	657.8	133,055	628.9
50–54	159,354	698.4	166,587	731.2	169,990	754.7	170,402	772.1	166,849	772.4
55–59	112,914	527.0	121,346	558.9	130,596	593.9	138,897	625.7	147,739	665.3
60–64	65,671	358.1	73,514	391.9	81,002	420.9	89,636	455.3	98,367	487.7
≥65	52,965	117.0	60,928	130.1	70,559	146.0	80,698	161.7	92,161	179.0
Race/ethnicity										
American Indian/Alaska Native	2,439	—	2,556	—	2,680	—	2,857	—	3,034	—
Asian ^b	10,555	—	11,438	—	12,371	—	13,327	—	14,301	—
Black/African American	373,765	—	384,022	—	394,556	—	404,981	—	415,043	—
Hispanic/Latino ^c	208,404	—	215,676	—	223,311	—	231,195	—	238,809	—
Native Hawaiian/Other Pacific Islander	690	—	727	—	795	—	826	—	875	—
White	280,104	—	285,637	—	290,943	—	295,796	—	300,697	—
Multiple races	45,399	—	46,029	—	46,492	—	46,809	—	46,875	—
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	478,898	—	499,246	—	519,619	—	539,547	—	558,873	—
Injection drug use	77,574	—	76,368	—	75,371	—	74,295	—	73,503	—
Male-to-male sexual contact and injection drug use	55,974	—	56,010	—	56,042	—	56,061	—	56,095	—
Heterosexual contact ^e	73,955	—	75,704	—	77,445	—	79,173	—	80,464	—
Perinatal	4,454	—	4,578	—	4,683	—	4,766	—	4,850	—
Other ^f	2,993	—	2,982	—	2,976	—	2,961	—	2,975	—
Subtotal	693,848	532.9	714,888	544.1	736,136	555.4	756,803	566.2	776,761	576.6

Table 22b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2013–2017—United States and 6 dependent areas (cont)

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	51,726	—	51,224	—	50,912	—	50,551	—	50,295	—
Heterosexual contact ^e	167,321	—	171,451	—	175,561	—	179,866	—	183,992	—
Perinatal	4,884	—	5,034	—	5,146	—	5,250	—	5,388	—
Other ^f	1,760	—	1,787	—	1,825	—	1,872	—	1,910	—
Subtotal	225,690	165.3	229,496	166.7	233,444	168.2	237,539	169.8	241,585	171.4
Child (<13 yrs at end of year)										
Perinatal	2,169	—	2,032	—	1,914	—	1,818	—	1,686	—
Other ^f	448	—	464	—	443	—	417	—	387	—
Subtotal	2,617	4.9	2,496	4.7	2,357	4.4	2,235	4.2	2,073	3.9
Region of residence^g										
Northeast	221,324	395.9	225,573	402.7	227,689	406.2	231,824	413.5	233,941	417.2
Midwest	107,465	159.1	110,466	163.0	113,152	166.7	116,821	171.8	119,944	176.0
South	402,128	339.7	414,257	346.2	428,039	353.6	438,560	358.3	451,784	365.5
West	174,457	235.1	179,764	239.8	186,170	245.6	192,510	251.3	198,113	256.2
U.S. dependent areas	16,781	420.1	16,820	427.3	16,887	435.9	16,862	442.9	16,637	446.7
Total^h	922,155	288.1	946,880	293.8	971,937	299.4	996,577	304.9	1,020,419	310.3

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^h Includes persons whose race/ethnicity is unknown.

Table 23a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2013–2017—United States

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at end of year (yr)										
<13	282	0.5	301	0.6	276	0.5	285	0.5	282	0.5
13–14	153	1.8	134	1.6	131	1.6	106	1.3	80	1.0
15–19	1,692	8.0	1,292	6.1	966	4.6	827	3.9	743	3.5
20–24	8,235	36.1	7,499	32.8	6,718	29.6	5,953	26.6	5,235	23.7
25–29	17,312	80.2	17,812	81.1	17,990	80.3	18,072	78.9	17,768	76.1
30–34	28,023	131.7	27,449	127.6	27,159	125.5	27,094	124.1	27,156	123.8
35–39	39,392	200.9	38,590	194.1	38,341	188.7	38,257	184.0	37,872	178.7
40–44	62,652	300.5	58,081	282.7	53,013	263.1	49,539	251.5	47,475	242.3
45–49	93,745	441.9	88,071	422.8	83,332	401.1	77,982	372.7	73,065	349.3
50–54	99,946	443.2	103,647	460.3	104,731	470.4	103,670	475.3	100,117	469.0
55–59	72,891	344.2	77,661	361.8	82,986	381.7	87,828	400.1	92,594	421.7
60–64	42,814	236.4	47,824	258.1	52,463	275.8	57,726	296.6	63,139	316.6
≥65	34,589	77.5	39,712	86.0	45,850	96.2	52,222	106.1	59,378	116.9
Race/ethnicity										
American Indian/Alaska Native	1,300	55.8	1,336	56.8	1,374	58.0	1,433	60.0	1,475	61.4
Asian ^b	5,390	33.3	5,647	33.8	5,904	34.3	6,155	34.7	6,440	35.3
Black/African American	203,685	520.6	206,740	523.4	209,705	525.9	212,540	528.1	215,316	530.6
Hispanic/Latino ^c	112,909	208.9	114,866	208.2	116,813	207.2	118,919	206.6	120,823	205.8
Native Hawaiian/Other Pacific Islander	358	67.1	369	67.9	385	69.4	390	68.9	406	70.4
White	151,023	76.4	151,871	76.8	152,505	77.1	152,878	77.3	153,316	77.6
Multiple races	27,021	436.9	27,204	427.0	27,230	415.0	27,206	403.0	27,088	390.7
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	248,905	—	254,013	—	258,911	—	263,686	—	268,141	—
Injection drug use	49,718	—	48,863	—	47,944	—	47,014	—	46,247	—
Male-to-male sexual contact and injection drug use	35,357	—	35,039	—	34,696	—	34,392	—	34,096	—
Heterosexual contact ^e	44,007	—	44,915	—	45,685	—	46,490	—	47,098	—
Perinatal	2,396	—	2,439	—	2,502	—	2,542	—	2,573	—
Other ^f	2,029	—	2,013	—	1,981	—	1,951	—	1,929	—
Subtotal	382,412	297.4	387,282	298.4	391,720	299.1	396,076	299.8	400,084	300.4

Table 23a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2013–2017—United States (cont)

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	31,121	—	30,770	—	30,470	—	30,108	—	29,804	—
Heterosexual contact ^e	84,215	—	85,956	—	87,677	—	89,219	—	90,811	—
Perinatal	2,617	—	2,679	—	2,729	—	2,787	—	2,835	—
Other ^f	1,079	—	1,086	—	1,084	—	1,086	—	1,087	—
Subtotal	119,032	88.3	120,490	88.6	121,960	89.0	123,200	89.2	124,538	89.4
Child (<13 yrs at end of year)										
Perinatal	260	—	269	—	242	—	247	—	242	—
Other ^f	22	—	32	—	34	—	38	—	40	—
Subtotal	282	0.5	301	0.6	276	0.5	285	0.5	282	0.5
Region of residence^g										
Northeast	130,552	233.5	131,364	234.5	130,974	233.7	131,874	235.2	131,110	233.8
Midwest	55,845	82.7	56,800	83.8	57,385	84.6	58,543	86.1	59,349	87.1
South	215,780	182.3	219,297	183.3	223,522	184.7	225,614	184.3	229,807	185.9
West	99,549	134.2	100,612	134.2	102,075	134.7	103,530	135.1	104,638	135.3
Total^h	501,726	158.7	508,073	159.6	513,956	160.2	519,561	160.8	524,904	161.4

^a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^h Includes persons whose race/ethnicity is unknown.

Table 23b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2013–2017—United States and 6 dependent areas

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Age at end of year (yr)										
<13	285	0.5	304	0.6	278	0.5	288	0.5	284	0.5
13–14	158	1.9	135	1.6	132	1.6	107	1.3	81	1.0
15–19	1,728	8.0	1,322	6.2	986	4.6	841	3.9	753	3.5
20–24	8,339	36.1	7,594	32.8	6,806	29.7	6,033	26.7	5,306	23.8
25–29	17,492	80.2	18,002	81.1	18,177	80.2	18,242	78.7	17,912	75.9
30–34	28,363	131.8	27,763	127.7	27,435	125.4	27,375	124.2	27,398	123.7
35–39	39,988	201.3	39,147	194.5	38,862	189.0	38,746	184.3	38,329	178.9
40–44	63,692	301.7	59,049	284.0	53,887	264.2	50,310	252.4	48,176	243.1
45–49	95,467	444.5	89,619	424.9	84,769	403.1	79,265	374.4	74,209	350.7
50–54	101,866	446.5	105,616	463.6	106,661	473.5	105,559	478.3	101,910	471.8
55–59	74,376	347.1	79,199	364.8	84,615	384.8	89,510	403.2	94,318	424.8
60–64	43,702	238.3	48,816	260.2	53,521	278.1	58,875	299.0	64,355	319.0
≥65	35,513	78.4	40,720	87.0	47,001	97.2	53,501	107.2	60,809	118.1
Race/ethnicity										
American Indian/Alaska Native	1,301	—	1,337	—	1,375	—	1,434	—	1,476	—
Asian ^b	5,407	—	5,665	—	5,922	—	6,174	—	6,462	—
Black/African American	203,855	—	206,911	—	209,878	—	212,709	—	215,481	—
Hispanic/Latino ^c	121,910	—	123,830	—	125,734	—	127,756	—	129,501	—
Native Hawaiian/Other Pacific Islander	369	—	381	—	399	—	406	—	427	—
White	151,059	—	151,911	—	152,544	—	152,917	—	153,354	—
Multiple races	27,028	—	27,211	—	27,238	—	27,216	—	27,099	—
Transmission category^d										
Male adult or adolescent										
Male-to-male sexual contact	250,987	—	256,139	—	261,053	—	265,848	—	270,314	—
Injection drug use	52,079	—	51,173	—	50,220	—	49,240	—	48,402	—
Male-to-male sexual contact and injection drug use	35,902	—	35,572	—	35,229	—	34,915	—	34,602	—
Heterosexual contact ^e	45,364	—	46,285	—	47,072	—	47,876	—	48,469	—
Perinatal	2,471	—	2,513	—	2,575	—	2,613	—	2,642	—
Other ^f	2,050	—	2,033	—	2,001	—	1,972	—	1,949	—
Subtotal	388,854	298.7	393,716	299.7	398,150	300.4	402,464	301.1	406,379	301.7

Table 23b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2013–2017—United States and 6 dependent areas (*cont*)

	2013		2014		2015		2016		2017	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Female adult or adolescent										
Injection drug use	31,801	—	31,438	—	31,127	—	30,747	—	30,413	—
Heterosexual contact ^e	86,254	—	87,982	—	89,674	—	91,195	—	92,758	—
Perinatal	2,688	—	2,751	—	2,805	—	2,860	—	2,907	—
Other ^f	1,088	—	1,095	—	1,095	—	1,098	—	1,099	—
Subtotal	121,830	89.2	123,266	89.5	124,702	89.9	125,900	90.0	127,177	90.2
Child (<13 yrs at end of year)										
Perinatal	263	—	272	—	244	—	250	—	244	—
Other ^f	22	—	32	—	34	—	38	—	40	—
Subtotal	285	0.5	304	0.6	278	0.5	288	0.5	284	0.5
Region of residence^g										
Northeast	130,552	233.5	131,364	234.5	130,974	233.7	131,874	235.2	131,110	233.8
Midwest	55,845	82.7	56,800	83.8	57,385	84.6	58,543	86.1	59,349	87.1
South	215,780	182.3	219,297	183.3	223,522	184.7	225,614	184.3	229,807	185.9
West	99,549	134.2	100,612	134.2	102,075	134.7	103,530	135.1	104,638	135.3
U.S. dependent areas	9,243	231.4	9,213	234.1	9,174	236.8	9,091	238.8	8,936	239.9
Total^h	510,969	159.7	517,286	160.5	523,130	161.2	528,652	161.7	533,840	162.3

^a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

^b Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^h Includes persons whose race/ethnicity is unknown.

Table 24a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2017—United States

	American Indian/ Alaska Native		Asian ^a		Black/ African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Age at end of year (yr)																
<13	6	1.4	109	4.2	1,276	17.6	270	2.0	3	2.8	249	0.9	151	6.3	2,064	3.9
13–14	1	1.4	30	7.1	422	38.0	101	5.0	1	6.1	88	2.0	29	9.3	672	8.1
15–19	10	5.5	70	6.5	2,805	94.8	904	18.5	2	4.9	490	4.4	219	30.5	4,502	21.3
20–24	88	46.8	448	35.1	15,907	496.2	6,472	134.6	21	47.6	4,064	34.1	1,311	205.9	28,320	128.3
25–29	303	154.1	1,149	72.8	36,868	1,087.7	16,102	337.4	70	134.7	12,248	95.5	3,628	688.9	70,374	301.6
30–34	299	178.5	1,486	93.4	38,594	1,355.5	21,044	466.7	99	197.9	17,215	139.2	4,181	1,029.9	82,924	378.0
35–39	343	223.8	1,728	115.1	39,004	1,433.3	24,701	561.8	109	238.3	21,574	179.5	4,569	1,294.4	92,041	434.4
40–44	330	235.2	2,065	144.9	39,401	1,590.2	26,087	646.9	107	278.5	23,807	212.8	4,647	1,617.5	96,470	492.4
45–49	441	302.7	2,270	168.8	50,614	1,946.5	31,778	865.6	112	309.0	39,298	305.8	6,246	2,351.0	130,846	625.6
50–54	454	295.1	1,835	157.4	61,320	2,325.3	35,199	1,106.2	119	343.7	57,117	409.8	7,704	3,244.4	163,914	767.8
55–59	372	237.9	1,269	119.9	55,328	2,130.3	27,328	1,037.2	84	256.8	53,948	353.7	6,568	2,873.9	145,059	660.6
60–64	217	162.3	860	90.2	38,717	1,748.6	16,940	832.0	61	231.5	35,445	246.3	4,143	2,187.7	96,521	484.0
≥65	168	61.6	925	41.4	34,491	753.5	15,736	376.7	51	96.2	35,076	89.7	3,461	903.9	90,075	177.3
Transmission category^e																
Male adult or adolescent																
Male-to-male sexual contact	1,547	—	9,739	—	171,877	—	130,843	—	593	—	213,479	—	25,704	—	554,159	—
Injection drug use	225	—	422	—	33,500	—	19,570	—	22	—	13,407	—	2,733	—	69,956	—
Male-to-male sexual contact and injection drug use	282	—	389	—	15,612	—	12,341	—	41	—	22,526	—	4,071	—	55,318	—
Heterosexual contact ^f	159	—	975	—	49,074	—	15,228	—	39	—	9,707	—	2,812	—	78,025	—
Perinatal	6	—	34	—	2,686	—	1,166	—	2	—	542	—	288	—	4,733	—
Other ^g	13	—	74	—	856	—	440	—	2	—	1,406	—	141	—	2,937	—
Subtotal	2,233	233.3	11,633	158.3	273,605	1,739.1	179,588	790.3	698	295.6	261,066	310.8	35,749	1,623.8	765,129	574.4

Table 24a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2017—United States (cont)

	American Indian/ Alaska Native		Asian ^a		Black/ African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Female adult or adolescent																
Injection drug use	256	—	182	—	24,093	—	9,409	—	22	—	12,356	—	2,896	—	49,288	—
Heterosexual contact ^f	517	—	2,212	—	111,744	—	31,892	—	115	—	25,853	—	7,670	—	180,137	—
Perinatal	8	—	33	—	3,105	—	1,217	—	—	—	600	—	303	—	5,274	—
Other ^g	11	—	75	—	924	—	286	—	1	—	496	—	88	—	1,890	—
Subtotal	793	79.2	2,502	30.2	139,866	794.4	42,804	191.2	138	58.9	39,304	45.0	10,957	467.7	236,589	169.9
Child (<13 yrs at end of year)																
Perinatal	6	—	72	—	1,046	—	237	—	3	—	179	—	134	—	1,677	—
Other ^g	0	—	37	—	230	—	33	—	0	—	70	—	17	—	387	—
Subtotal	6	1.4	109	4.2	1,276	17.6	270	2.0	3	2.8	249	0.9	151	6.3	2,064	3.9
Region of residence^h																
Northeast	145	114.8	3,074	82.4	90,350	1,426.1	70,826	873.8	63	292.6	54,519	148.1	14,590	1,541.8	233,941	417.2
Midwest	353	85.9	1,427	62.7	51,832	728.1	14,066	262.0	40	119.8	46,767	90.6	5,339	403.3	119,944	176.0
South	754	94.5	2,880	66.7	241,525	1,023.6	73,491	332.6	144	159.5	113,807	161.7	19,013	826.5	451,784	365.5
West	1,780	166.7	6,863	86.6	31,040	879.4	64,279	277.9	592	137.3	85,526	220.0	7,915	335.1	198,113	256.2
Total	3,032	126.2	14,244	78.1	414,747	1,022.0	222,662	379.3	839	145.6	300,619	152.1	46,857	675.9	1,003,782	308.7

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 24b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2017—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Age at end of year (yr)								
<13	6	109	1,277	277	4	249	151	2,073
13–14	1	30	424	103	1	88	30	677
15–19	10	70	2,805	946	2	491	219	4,545
20–24	88	448	15,909	6,766	22	4,065	1,313	28,620
25–29	303	1,150	36,877	16,804	77	12,249	3,628	71,094
30–34	299	1,490	38,602	21,935	104	17,217	4,181	83,834
35–39	343	1,737	39,027	25,952	115	21,578	4,572	93,337
40–44	330	2,069	39,431	27,644	109	23,812	4,647	98,068
45–49	441	2,279	50,662	33,910	115	39,309	6,250	133,055
50–54	455	1,844	61,373	38,047	123	57,131	7,710	166,849
55–59	373	1,282	55,361	29,939	89	53,965	6,568	147,739
60–64	217	862	38,750	18,738	61	35,456	4,144	98,367
≥65	168	931	34,545	17,748	53	35,087	3,462	92,161
Transmission category^d								
Male adult or adolescent								
Male-to-male sexual contact	1,548	9,775	171,944	135,362	614	213,532	25,718	558,873
Injection drug use	225	427	33,534	23,071	24	13,411	2,733	73,503
Male-to-male sexual contact and injection drug use	282	391	15,620	13,105	42	22,529	4,073	56,096
Heterosexual contact ^e	160	979	49,134	17,597	43	9,709	2,812	80,464
Perinatal	6	34	2,688	1,281	2	542	288	4,850
Other ^f	13	74	856	478	2	1,406	141	2,975
Subtotal	2,235	11,679	273,775	190,895	726	261,128	35,764	776,761

Table 24b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2017—United States and 6 dependent areas (*cont*)

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	256	184	24,107	10,395	22	12,359	2,896	50,295
Heterosexual contact ^e	517	2,221	111,848	35,613	122	25,865	7,672	183,992
Perinatal	8	33	3,109	1,326	—	600	304	5,388
Other ^f	11	75	927	303	1	496	88	1,910
Subtotal	793	2,513	139,991	47,637	145	39,320	10,960	241,585
Child (<13 yrs at end of year)								
Perinatal	6	72	1,047	244	4	179	134	1,686
Other ^f	—	37	230	33	—	70	17	387
Subtotal	6	109	1,277	277	4	249	151	2,073
Region of residence^g								
Northeast	145	3,074	90,350	70,826	63	54,519	14,590	233,941
Midwest	353	1,427	51,832	14,066	40	46,767	5,339	119,944
South	754	2,880	241,525	73,491	144	113,807	19,013	451,784
West	1,780	6,863	31,040	64,279	592	85,526	7,915	198,113
U.S. dependent areas	2	57	296	16,147	36	78	18	16,637
Total	3,034	14,301	415,043	238,809	875	300,697	46,875	1,020,419

Note. Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 25a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2017—United States

	American Indian/ Alaska Native		Asian ^a		Black/ African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Age at end of year (yr)																
<13	3	0.7	7	0.3	182	2.5	43	0.3	1	0.9	23	0.1	23	1.0	282	0.5
13–14	0	0.0	2	0.5	53	4.8	13	0.6	1	6.1	7	0.2	4	1.3	80	1.0
15–19	3	1.7	11	1.0	490	16.6	151	3.1	1	2.5	49	0.4	38	5.3	743	3.5
20–24	16	8.5	59	4.6	3,248	101.3	1,094	22.7	3	6.8	513	4.3	301	47.3	5,235	23.7
25–29	63	32.0	215	13.6	10,237	302.0	3,991	83.6	19	36.5	2,180	17.0	1,063	201.9	17,768	76.1
30–34	93	55.5	406	25.5	13,643	479.2	7,142	158.4	29	58.0	4,260	34.4	1,583	389.9	27,156	123.8
35–39	145	94.6	574	38.2	17,177	631.2	10,637	241.9	49	107.1	7,211	60.0	2,079	589.0	37,872	178.7
40–44	159	113.3	867	60.8	20,201	815.3	13,484	334.4	54	140.5	10,075	90.0	2,634	916.8	47,475	242.3
45–49	244	167.5	1,199	89.1	29,132	1,120.4	18,778	511.5	59	162.8	19,692	153.2	3,956	1,489.0	73,065	349.3
50–54	259	168.4	1,071	91.9	37,990	1,440.6	23,090	725.7	79	228.1	32,348	232.1	5,275	2,221.5	100,117	469.0
55–59	245	156.7	813	76.8	35,145	1,353.2	18,933	718.6	48	146.7	32,713	214.5	4,689	2,051.7	92,594	421.7
60–64	135	101.0	585	61.3	25,310	1,143.1	12,037	591.2	30	113.8	22,077	153.4	2,955	1,560.4	63,139	316.6
≥65	110	40.4	631	28.2	22,508	491.7	11,430	273.6	33	62.2	22,168	56.7	2,488	649.8	59,378	116.9
Transmission category^e																
Male adult or adolescent																
Male-to-male sexual contact	676	—	4,205	—	78,982	—	64,203	—	278	—	106,246	—	13,526	—	268,141	—
Injection drug use	129	—	236	—	22,048	—	13,612	—	10	—	8,196	—	2,015	—	46,247	—
Male-to-male sexual contact and injection drug use	170	—	223	—	10,204	—	7,861	—	26	—	12,878	—	2,734	—	34,096	—
Heterosexual contact ^f	94	—	571	—	28,896	—	10,041	—	21	—	5,603	—	1,867	—	47,098	—
Perinatal	2	—	13	—	1,461	—	656	—	2	—	271	—	168	—	2,573	—
Other ^g	12	—	51	—	451	—	307	—	1	—	1,007	—	100	—	1,929	—
Subtotal	1,082	113.0	5,300	72.1	142,042	902.9	96,679	425.5	338	143.1	134,200	159.7	20,410	927.1	400,084	300.4

Table 25a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2017—United States (cont)

	American Indian/ Alaska Native		Asian ^a		Black/ African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Female adult or adolescent																
Injection drug use	125	—	90	—	14,957	—	6,115	—	12	—	6,498	—	2,005	—	29,804	—
Heterosexual contact ^f	254	—	990	—	55,957	—	17,105	—	55	—	12,019	—	4,428	—	90,812	—
Perinatal	4	—	8	—	1,682	—	689	—	0	—	276	—	175	—	2,835	—
Other ^g	8	—	45	—	496	—	192	—	1	—	300	—	46	—	1,087	—
Subtotal	390	39.0	1,133	13.7	73,092	415.1	24,101	107.7	67	28.6	19,093	21.8	6,655	284.0	124,538	89.4
Child (<13 yrs at end of year)																
Perinatal	3	—	5	—	158	—	34	—	1	—	20	—	21	—	242	—
Other ^g	0	—	2	—	24	—	9	—	0	—	3	—	2	—	40	—
Subtotal	3	0.7	7	0.3	182	2.5	43	0.3	1	0.9	23	0.1	23	1.0	282	0.5
Region of residence^h																
Northeast	72	57.0	1,407	37.7	50,698	800.2	41,211	508.4	24	111.5	28,715	78.0	8,959	946.7	131,110	233.8
Midwest	169	41.1	586	25.8	25,357	356.2	7,394	137.7	15	44.9	22,846	44.3	2,981	225.2	59,349	87.1
South	329	41.2	1,174	27.2	123,244	522.3	37,454	169.5	50	55.4	56,755	80.6	10,797	469.3	229,807	185.9
West	905	84.8	3,273	41.3	16,017	453.8	34,764	150.3	317	73.5	45,000	115.8	4,351	184.2	104,638	135.3
Total	1,475	61.4	6,440	35.3	215,316	530.6	120,823	205.8	406	70.4	153,316	77.6	27,088	390.7	524,904	161.4

Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^h Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 25b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2017—United States and 6 dependent areas

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Age at end of year								
<13	3	7	183	43	2	23	23	284
13–14	0	2	53	14	1	7	4	81
15–19	3	11	490	161	1	49	38	753
20–24	16	59	3,249	1,163	3	513	302	5,306
25–29	63	215	10,241	4,129	21	2,180	1,063	17,912
30–34	93	409	13,645	7,378	30	4,260	1,583	27,398
35–39	145	577	17,189	11,074	54	7,211	2,079	38,329
40–44	159	867	20,215	14,169	54	10,077	2,634	48,176
45–49	244	1,203	29,158	19,883	61	19,696	3,959	74,209
50–54	259	1,077	38,027	24,823	83	32,356	5,280	101,910
55–59	246	816	35,163	20,621	52	32,723	4,689	94,318
60–64	135	585	25,328	13,228	30	22,083	2,956	64,355
≥65	110	634	22,540	12,815	35	22,176	2,489	60,809
Transmission category^d								
Male adult or adolescent								
Male-to-male sexual contact	676	4,221	79,021	66,271	290	106,275	13,535	270,314
Injection drug use	129	238	22,064	15,746	12	8,197	2,015	48,403
Male-to-male sexual contact and injection drug use	170	224	10,209	8,360	26	12,879	2,734	34,602
Heterosexual contact ^e	95	572	28,935	11,369	23	5,604	1,867	48,469
Perinatal	2	13	1,462	724	2	271	168	2,642
Other ^f	12	51	451	327	1	1,007	100	1,949
Subtotal	1,083	5,319	142,142	102,797	353	134,233	20,419	406,379

Table 25b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2017—United States and 6 dependent areas (*cont*)

	American Indian/ Alaska Native	Asian ^a	Black/ African American	Hispanic/Latino ^b	Native Hawaiian/ Other Pacific Islander	White	Multiple races	Total ^c
	No.	No.	No.	No.	No.	No.	No.	No.
Female adult or adolescent								
Injection drug use	125	90	14,966	6,712	12	6,501	2,005	30,413
Heterosexual contact ^e	254	993	56,008	18,989	60	12,021	4,430	92,758
Perinatal	4	8	1,685	758	—	276	175	2,907
Other ^f	8	45	498	202	1	300	46	1,099
Subtotal	390	1,136	73,156	26,661	72	19,098	6,657	127,177
Child (<13 yrs at end of year)								
Perinatal	3	5	159	34	2	20	21	244
Other ^f	0	2	24	9	0	3	2	40
Subtotal	3	7	183	43	2	23	23	284
Region of residence^g								
Northeast	72	1,407	50,698	41,211	24	28,715	8,959	131,110
Midwest	169	586	25,357	7,394	15	22,846	2,981	59,349
South	329	1,174	123,244	37,454	50	56,755	10,797	229,807
West	905	3,273	16,017	34,764	317	45,000	4,351	104,638
U.S. dependent areas	1	22	165	8,678	21	38	11	8,936
Total	1,476	6,462	215,481	129,501	427	153,354	27,099	533,840

Note. Numbers less than 12 should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 26. Diagnoses of HIV infection, by area of residence, 2017 and 2018—United States and 6 dependent areas

Area of residence	2017						2018					
	Adults and adolescents		Children		Total		Adults and adolescents		Children		Total	
	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a	No.	Rate ^a
Alabama	651	15.9	4	0.5	655	13.4	572	13.9	3	0.4	575	11.8
Alaska	34	5.6	0	0.0	34	4.6	20	3.3	0	0.0	20	2.7
Arizona	725	12.3	3	0.3	728	10.3	806	13.4	6	0.5	812	11.3
Arkansas	287	11.5	1	0.2	288	9.6	281	11.2	2	0.4	283	9.4
California	4,766	14.5	6	0.1	4,772	12.1	4,398	13.3	4	0.1	4,402	11.1
Colorado	442	9.4	0	0.0	442	7.9	409	8.5	2	0.2	411	7.2
Connecticut	275	9.0	2	0.4	277	7.8	250	8.2	0	0.0	250	7.0
Delaware	126	15.5	1	0.7	127	13.3	91	11.1	1	0.7	92	9.5
District of Columbia	305	51.1	2	2.0	307	44.1	208	34.6	0	0.0	208	29.6
Florida	4,563	25.4	20	0.7	4,583	21.8	4,683	25.6	15	0.5	4,698	22.1
Georgia	2,564	29.7	7	0.4	2,571	24.7	2,552	29.2	6	0.3	2,558	24.3
Hawaii	78	6.5	2	0.9	80	5.6	66	5.5	0	0.0	66	4.6
Idaho	46	3.3	0	0.0	46	2.7	37	2.6	0	0.0	37	2.1
Illinois	1,352	12.6	10	0.5	1,362	10.7	1,352	12.6	5	0.2	1,357	10.7
Indiana	516	9.3	2	0.2	518	7.8	510	9.1	2	0.2	512	7.7
Iowa	124	4.7	0	0.0	124	3.9	116	4.4	0	0.0	116	3.7
Kansas	119	5.0	0	0.0	119	4.1	154	6.4	0	0.0	154	5.3
Kentucky	365	9.8	2	0.3	367	8.2	360	9.6	0	0.0	360	8.1
Louisiana	1,011	26.1	0	0.0	1,011	21.6	986	25.5	1	0.1	987	21.2
Maine	30	2.6	0	0.0	30	2.2	28	2.4	0	0.0	28	2.1
Maryland	1,021	20.2	3	0.3	1,024	17.0	979	19.3	2	0.2	981	16.2
Massachusetts	596	10.1	1	0.1	597	8.7	654	11.0	3	0.3	657	9.5
Michigan	778	9.2	1	0.1	779	7.8	718	8.5	0	0.0	718	7.2
Minnesota	273	5.9	1	0.1	274	4.9	283	6.1	0	0.0	283	5.0
Mississippi	427	17.2	0	0.0	427	14.3	479	19.3	0	0.0	479	16.0
Missouri	504	9.8	2	0.2	506	8.3	446	8.7	3	0.3	449	7.3
Montana	31	3.5	0	0.0	31	2.9	23	2.6	0	0.0	23	2.2
Nebraska	88	5.6	0	0.0	88	4.6	79	5.0	0	0.0	79	4.1
Nevada	491	19.8	1	0.2	492	16.6	508	20.0	1	0.2	509	16.8
New Hampshire	34	2.9	0	0.0	34	2.5	36	3.1	0	0.0	36	2.7
New Jersey	1,125	15.0	1	0.1	1,126	12.7	1,044	13.9	3	0.2	1,047	11.8
New Mexico	136	7.8	0	0.0	136	6.5	121	6.9	0	0.0	121	5.8
New York	2,730	16.4	2	0.1	2,732	13.9	2,470	14.9	2	0.1	2,472	12.6
North Carolina	1,297	15.0	4	0.2	1,301	12.7	1,200	13.7	3	0.2	1,203	11.6
North Dakota	37	5.9	0	0.0	37	4.9	36	5.8	0	0.0	36	4.7
Ohio	986	10.0	2	0.1	988	8.5	984	10.0	6	0.3	990	8.5
Oklahoma	299	9.2	0	0.0	299	7.6	234	7.2	0	0.0	234	5.9
Oregon	203	5.8	0	0.0	203	4.9	230	6.5	0	0.0	230	5.5
Pennsylvania	1,088	10.0	1	0.1	1,089	8.5	1,002	9.2	2	0.1	1,004	7.8
Rhode Island	83	9.1	0	0.0	83	7.9	76	8.3	0	0.0	76	7.2
South Carolina	711	16.8	4	0.5	715	14.2	719	16.8	0	0.0	719	14.1
South Dakota	40	5.6	0	0.0	40	4.6	28	3.9	1	0.6	29	3.3
Tennessee	731	13.0	3	0.3	734	10.9	759	13.3	4	0.4	763	11.3
Texas	4,358	18.9	7	0.1	4,365	15.4	4,483	19.2	6	0.1	4,489	15.6
Utah	117	4.8	0	0.0	117	3.8	121	4.9	0	0.0	121	3.8
Vermont	20	3.7	0	0.0	20	3.2	18	3.3	0	0.0	18	2.9
Virginia	865	12.1	6	0.4	871	10.3	867	12.1	4	0.3	871	10.2
Washington	433	7.0	2	0.2	435	5.9	503	8.0	4	0.3	507	6.7
West Virginia	76	4.9	0	0.0	76	4.2	85	5.5	0	0.0	85	4.7
Wisconsin	259	5.3	0	0.0	259	4.5	210	4.3	0	0.0	210	3.6
Wyoming	10	2.1	0	0.0	10	1.7	12	2.5	0	0.0	12	2.1
Subtotal	38,226	14.0	103	0.2	38,329	11.8	37,286	13.6	91	0.2	37,377	11.4
U.S. dependent areas												
American Samoa	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Guam	6	4.7	0	0.0	6	3.6	7	5.5	0	0.0	7	4.2
Northern Mariana Islands	1	2.5	0	0.0	1	1.9	1	2.5	0	0.0	1	1.9
Puerto Rico	446	15.5	0	0.0	446	13.4	438	15.7	0	0.0	438	13.7
Republic of Palau	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
U.S. Virgin Islands	7	7.9	0	0.0	7	6.5	9	10.2	0	0.0	9	8.4
Subtotal	460	14.4	0	0.0	460	12.3	455	14.6	0	0.0	455	12.7
Total	38,686	14.0	103	0.2	38,789	11.8	37,741	13.6	91	0.2	37,832	11.4

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address). Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Rates are per 100,000 population.

Table 27. Stage 3 (AIDS), by area of residence, 2017, 2018, and cumulative—United States and 6 dependent areas

Area of residence	2017						2018						Cumulative ^a		
	Adults and adolescents		Children		Total		Adults and adolescents		Children		Total				
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	Adults and adolescents	Children	Total
Alabama	295	7.2	0	0.0	295	6.1	284	6.9	1	0.1	285	5.8	12,817	80	12,897
Alaska	13	2.2	0	0.0	13	1.8	12	2.0	0	0.0	12	1.6	867	6	873
Arizona	305	5.2	2	0.2	307	4.4	301	5.0	3	0.3	304	4.2	14,682	54	14,736
Arkansas	135	5.4	0	0.0	135	4.5	122	4.9	0	0.0	122	4.0	5,455	38	5,493
California	1,913	5.8	0	0.0	1,913	4.9	1,750	5.3	2	0.0	1,752	4.4	177,497	711	178,208
Colorado	174	3.7	0	0.0	174	3.1	189	3.9	1	0.1	190	3.3	11,435	35	11,470
Connecticut	128	4.2	0	0.0	128	3.6	138	4.5	0	0.0	138	3.9	16,858	184	17,042
Delaware	57	7.0	0	0.0	57	6.0	56	6.8	1	0.7	57	5.9	4,571	30	4,601
District of Columbia	135	22.6	0	0.0	135	19.4	248	41.2	0	0.0	248	35.3	21,079	190	21,269
Florida	2,170	12.1	8	0.3	2,178	10.4	2,080	11.4	7	0.2	2,087	9.8	138,234	1,578	139,812
Georgia	1,316	15.3	6	0.3	1,322	12.7	1,214	13.9	3	0.2	1,217	11.6	52,117	273	52,390
Hawaii	30	2.5	2	0.9	32	2.2	24	2.0	0	0.0	24	1.7	3,552	21	3,573
Idaho	19	1.4	0	0.0	19	1.1	21	1.5	0	0.0	21	1.2	903	4	907
Illinois	624	5.8	4	0.2	628	4.9	600	5.6	1	0.0	601	4.7	44,323	290	44,613
Indiana	253	4.6	1	0.1	254	3.8	251	4.5	1	0.1	252	3.8	11,715	64	11,779
Iowa	57	2.2	0	0.0	57	1.8	41	1.6	0	0.0	41	1.3	2,533	15	2,548
Kansas	61	2.5	0	0.0	61	2.1	76	3.2	0	0.0	76	2.6	3,707	16	3,723
Kentucky	161	4.3	0	0.0	161	3.6	134	3.6	0	0.0	134	3.0	6,870	39	6,909
Louisiana	498	12.9	3	0.4	501	10.7	423	10.9	0	0.0	423	9.1	25,616	148	25,764
Maine	24	2.1	1	0.6	25	1.9	23	2.0	0	0.0	23	1.7	1,454	10	1,464
Maryland	578	11.4	0	0.0	578	9.6	505	9.9	1	0.1	506	8.4	40,394	338	40,732
Massachusetts	266	4.5	1	0.1	267	3.9	273	4.6	3	0.3	276	4.0	24,968	237	25,205
Michigan	333	3.9	0	0.0	333	3.3	321	3.8	0	0.0	321	3.2	20,325	121	20,446
Minnesota	145	3.1	0	0.0	145	2.6	118	2.5	0	0.0	118	2.1	7,030	33	7,063
Mississippi	244	9.8	0	0.0	244	8.2	262	10.6	0	0.0	262	8.8	10,241	58	10,299
Missouri	178	3.5	1	0.1	179	2.9	218	4.2	0	0.0	218	3.6	14,511	67	14,578
Montana	11	1.2	0	0.0	11	1.0	8	0.9	0	0.0	8	0.8	560	3	563
Nebraska	32	2.0	0	0.0	32	1.7	38	2.4	0	0.0	38	2.0	2,131	12	2,143
Nevada	192	7.7	0	0.0	192	6.5	205	8.1	1	0.2	206	6.8	8,349	29	8,378
New Hampshire	12	1.0	0	0.0	12	0.9	19	1.6	0	0.0	19	1.4	1,368	10	1,378
New Jersey	497	6.6	1	0.1	498	5.6	513	6.8	1	0.1	514	5.8	58,840	809	59,649
New Mexico	54	3.1	0	0.0	54	2.6	58	3.3	0	0.0	58	2.8	3,565	10	3,575
New York	1,432	8.6	1	0.0	1,433	7.3	1,367	8.2	5	0.2	1,372	7.0	200,943	2,405	203,348
North Carolina	587	6.8	0	0.0	587	5.7	508	5.8	1	0.1	509	4.9	25,280	145	25,425
North Dakota	14	2.2	0	0.0	14	1.9	10	1.6	0	0.0	10	1.3	260	2	262

Table 27. Stage 3 (AIDS), by area of residence, 2017, 2018, and cumulative—United States and 6 dependent areas (cont)

Area of residence	2017						2018						Cumulative ^a		
	Adults and adolescents		Children		Total		Adults and adolescents		Children		Total		Adults and adolescents	Children	Total
	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b	No.	Rate ^b			
Ohio	448	4.6	0	0.0	448	3.8	469	4.8	3	0.2	472	4.0	21,810	156	21,966
Oklahoma	145	4.5	0	0.0	145	3.7	127	3.9	1	0.1	128	3.2	6,785	28	6,813
Oregon	97	2.8	0	0.0	97	2.3	98	2.8	0	0.0	98	2.3	7,789	18	7,807
Pennsylvania	565	5.2	1	0.1	566	4.4	455	4.2	0	0.0	455	3.6	43,073	373	43,446
Rhode Island	37	4.1	0	0.0	37	3.5	34	3.7	0	0.0	34	3.2	3,211	28	3,239
South Carolina	415	9.8	1	0.1	416	8.3	370	8.6	0	0.0	370	7.3	19,459	119	19,578
South Dakota	13	1.8	0	0.0	13	1.5	12	1.7	0	0.0	12	1.4	442	7	449
Tennessee	315	5.6	1	0.1	316	4.7	356	6.3	2	0.2	358	5.3	18,065	71	18,136
Texas	1,922	8.4	0	0.0	1,922	6.8	1,886	8.1	2	0.0	1,888	6.6	99,162	412	99,574
Utah	40	1.6	0	0.0	40	1.3	42	1.7	0	0.0	42	1.3	2,968	21	2,989
Vermont	13	2.4	0	0.0	13	2.1	10	1.8	0	0.0	10	1.6	576	6	582
Virginia	388	5.4	0	0.0	388	4.6	400	5.6	2	0.1	402	4.7	22,996	192	23,188
Washington	195	3.1	0	0.0	195	2.6	196	3.1	0	0.0	196	2.6	15,057	33	15,090
West Virginia	41	2.6	0	0.0	41	2.3	38	2.5	0	0.0	38	2.1	2,058	11	2,069
Wisconsin	105	2.2	0	0.0	105	1.8	85	1.7	0	0.0	85	1.5	6,151	39	6,190
Wyoming	6	1.3	0	0.0	6	1.0	2	0.4	0	0.0	2	0.3	343	2	345
Subtotal	17,688	6.5	34	0.1	17,722	5.5	16,990	6.2	42	0.1	17,032	5.2	1,244,995	9,581	1,254,576
U.S. dependent areas															
American Samoa	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0	1
Guam	5	3.9	0	0.0	5	3.0	3	2.4	0	0.0	3	1.8	114	2	116
Northern Mariana Islands	1	2.5	0	0.0	1	1.9	1	2.5	0	0.0	1	1.9	12	0	12
Puerto Rico	204	7.1	0	0.0	204	6.1	187	6.7	0	0.0	187	5.9	34,954	407	35,361
Republic of Palau	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	7	0	7
U.S. Virgin Islands	5	5.7	0	0.0	5	4.7	5	5.7	0	0.0	5	4.7	808	21	829
Subtotal	215	6.7	0	0.0	215	5.8	196	6.3	0	0.0	196	5.5	35,896	430	36,326
Total	17,903	6.5	34	0.1	17,937	5.5	17,186	6.2	42	0.1	17,228	5.2	1,280,891	10,011	1,290,902

Note. Data are based on address of residence at the time of stage 3 (AIDS) classification.

Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a From the beginning of the epidemic through 2018.

^b Rates are per 100,000 population.

Table 28. Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2017—United States and 6 dependent areas

Area of residence	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Alabama	7	29.1	34	57.6	8,278	777.9	453	310.3	2	99.0	3,570	129.7	734	1,561.8	13,124	320.5
Alaska	188	227.8	23	57.8	99	486.0	73	188.8	3	40.8	294	76.9	40	124.6	720	119.4
Arizona	633	285.7	205	100.8	2,067	839.1	4,927	291.7	23	209.5	7,681	225.3	481	510.5	16,062	273.4
Arkansas	6	31.6	19	48.0	2,464	661.4	395	243.4	5	75.3	2,436	131.0	305	854.6	5,634	225.7
California	292	207.7	5,111	102.9	21,197	1,121.5	48,029	400.7	225	185.5	48,155	369.5	5,135	683.4	128,153	389.7
Colorado	70	229.2	123	79.8	1,821	983.0	2,813	304.4	11	180.4	7,172	215.7	293	341.5	12,352	262.2
Connecticut	9	146.0	92	65.7	3,437	1,136.1	3,554	800.5	7	673.7	2,977	140.0	251	612.0	10,328	337.4
Delaware	3	115.1	7	22.2	1,893	1,103.2	285	440.0	1	374.5	964	182.9	131	962.9	3,285	404.8
District of Columbia	13	1,035.0	74	275.5	10,053	3,799.3	1,173	1,958.5	7	2,341.1	2,247	965.9	744	6,617.5	14,316	2,398.9
Florida	67	142.2	550	108.2	49,943	1,881.7	26,313	594.9	44	391.8	30,460	301.5	2,655	1,179.9	110,034	612.3
Georgia	23	112.4	245	68.2	35,974	1,348.8	3,750	518.5	17	333.9	9,723	205.3	2,785	2,385.8	52,528	608.8
Hawaii	5	189.5	386	82.1	139	596.8	304	289.2	220	199.2	1,198	428.8	272	131.1	2,524	210.6
Idaho	14	90.6	7	32.5	99	1,044.3	179	114.6	3	124.1	800	68.1	43	187.2	1,145	81.7
Illinois	33	198.6	464	76.0	16,196	1,089.4	6,881	409.3	21	716.7	9,511	139.8	1,968	1,522.1	35,076	326.9
Indiana	7	52.9	197	153.4	4,135	825.1	1,044	312.2	0	0.0	5,418	120.7	417	569.9	11,218	202.5
Iowa	5	67.4	57	85.4	571	657.8	261	194.6	0	0.0	1,639	71.6	138	457.4	2,671	102.1
Kansas	11	56.4	43	58.3	749	553.6	514	206.0	1	49.1	1,522	81.3	154	330.0	2,997	125.0
Kentucky	6	73.8	57	102.1	2,306	781.8	511	437.9	1	47.3	3,943	123.1	282	597.4	7,108	190.6
Louisiana	27	107.5	68	99.1	13,940	1,150.4	1,009	561.8	4	262.6	5,000	213.6	373	900.6	20,424	527.9
Maine	6	83.3	7	50.0	252	1,707.4	111	653.6	0	0.0	1,150	105.5	49	331.1	1,576	136.1
Maryland	19	150.6	213	64.2	23,030	1,539.1	2,279	508.4	2	80.2	4,128	154.2	2,765	3,012.3	32,436	641.0
Massachusetts	26	248.6	427	106.8	5,991	1,476.7	5,477	869.6	6	256.7	8,077	184.9	368	451.9	20,374	345.4
Michigan	28	58.8	133	48.9	8,704	773.5	954	253.7	3	132.9	5,285	81.6	557	393.6	15,667	185.6
Minnesota	104	229.4	155	70.6	3,009	1,151.4	860	400.0	4	192.3	3,832	100.5	335	446.3	8,304	179.3
Mississippi	10	85.3	18	68.5	6,884	760.7	311	442.2	1	113.0	1,759	121.8	381	1,864.3	9,399	379.1
Missouri	7	31.3	86	81.9	5,405	942.1	731	392.2	5	85.4	5,653	136.4	419	523.7	12,308	240.5
Montana	29	60.4	3	37.9	23	521.7	44	147.6	2	312.0	491	63.1	33	185.0	625	70.5
Nebraska	26	215.2	47	119.4	597	843.6	334	227.5	1	108.6	1,069	83.5	61	286.5	2,136	135.9
Nevada	52	240.8	304	140.8	2,390	1,106.9	2,516	386.2	31	201.5	3,989	308.1	325	495.2	9,609	387.4
New Hampshire	0	0.0	9	27.2	151	1,018.1	163	425.9	0	0.0	812	76.1	53	377.4	1,189	101.6
New Jersey	10	93.0	344	47.9	15,453	1,608.1	10,093	716.1	8	320.0	6,595	153.1	2,340	2,651.5	34,891	465.3
New Mexico	280	188.6	12	42.9	196	605.0	1,654	203.9	1	83.8	1,189	169.6	95	428.1	3,428	196.5
New York	51	104.8	1,850	127.4	47,164	1,963.5	44,622	1,499.1	22	298.9	22,735	238.6	9,734	4,301.5	126,495	760.2
North Carolina	170	176.8	176	70.5	19,100	1,045.7	2,539	372.1	12	227.0	7,644	135.2	1,305	1080.7	30,953	358.5
North Dakota	17	60.0	4	39.5	152	886.5	22	113.8	0	0.0	198	36.8	14	156.3	407	65.4

Table 28. Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2017—United States and 6 dependent areas (cont)

Area of residence	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Ohio	12	61.6	121	53.3	9,564	811.3	1,518	467.8	3	86.5	9,584	121.1	994	669.7	21,899	223.2
Oklahoma	327	124.9	79	106.7	1,415	598.9	661	224.2	7	158.8	3,253	146.7	342	229.6	6,084	187.9
Oregon	52	134.0	152	92.2	475	741.1	995	249.1	17	125.6	4,970	181.1	218	233.1	6,879	195.5
Pennsylvania	37	236.9	287	75.9	17,054	1,505.1	5,971	856.0	19	594.5	10,483	122.7	1,665	1,283.4	35,520	325.8
Rhode Island	6	162.6	34	108.7	579	1,121.8	711	569.3	1	183.5	1,138	166.2	78	533.9	2,547	279.5
South Carolina	14	88.0	42	59.3	11,485	1,035.7	879	426.2	3	118.5	3,976	143.2	450	890.2	16,858	398.5
South Dakota	76	144.8	4	35.7	129	950.4	41	178.9	1	284.9	296	49.1	21	192.4	568	79.6
Tennessee	8	48.6	73	72.7	9,224	1,005.4	875	344.8	6	212.5	5,818	136.3	605	852.6	16,612	295.0
Texas	39	49.2	889	77.2	31,915	1,156.8	29,758	349.8	21	108.5	21,429	209.5	4,040	1,535.6	88,099	382.9
Utah	23	98.9	60	91.5	256	962.3	637	202.5	5	22.1	1,700	87.7	73	186.8	2,757	113.5
Vermont	0	0.0	14	138.3	68	1,083.3	55	565.3	0	0.0	525	103.5	31	398.9	693	127.6
Virginia	13	66.2	301	63.5	12,636	935.8	2,107	351.1	9	174.0	6,105	134.7	948	672.8	22,149	311.0
Washington	126	161.5	438	77.7	2,097	899.1	2,000	293.9	50	120.4	7,607	171.8	878	438.3	13,205	212.1
West Virginia	2	58.7	8	60.9	377	701.9	86	387.9	0	0.0	1,234	85.5	99	530.1	1,810	116.4
Wisconsin	26	63.1	81	60.4	2,316	808.6	865	306.0	1	62.3	2,705	66.3	221	380.3	6,216	127.3
Wyoming	11	118.4	2	41.5	19	357.1	55	128.9	0	0.0	231	56.3	8	122.4	326	68.0
Subtotal	3,026	154.5	14,135	90.5	413,471	1,240.2	222,392	493.0	836	177.8	300,370	175.2	46,706	1027.7	1,001,718	367.7
U.S. dependent areas^e																
American Samoa	0	—	0	—	0	—	0	—	1	—	0	—	2	—	3	7.9
Guam	0	—	46	—	3	—	7	—	22	—	9	—	8	—	95	74.9
Northern Mariana Islands	1	—	4	—	0	—	0	—	5	—	3	—	1	—	14	34.8
Puerto Rico	1	—	3	—	10	—	15,930	—	1	—	23	—	1	—	15,969	553.5
Republic of Palau	0	—	2	—	0	—	1	—	6	—	0	—	0	—	9	50.1
U.S. Virgin Islands	0	—	2	—	282	—	202	—	0	—	43	—	6	—	538	610.8
Subtotal	2	—	57	—	295	—	16,140	—	35	—	78	—	18	—	16,628	520.2
Total	3,028	—	14,192	—	413,766	—	238,532	—	871	—	300,448	—	46,724	—	1,018,346	369.4

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Numbers less than 12, and rates based on these numbers, should be interpreted with caution

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population.

^e Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

Table 29. Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2017—United States and 6 dependent areas

Area of residence	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Alabama	1	4.2	12	20.3	3,669	344.8	238	163.0	1	49.5	1,485	54.0	364	774.5	5,770	140.9
Alaska	101	122.4	13	32.7	44	216.0	43	111.2	2	27.2	162	42.4	22	68.5	387	64.2
Arizona	318	143.5	78	38.4	886	359.7	2,338	138.4	9	82.0	3,771	110.6	259	274.9	7,660	130.4
Arkansas	3	15.8	5	12.6	1,066	286.1	201	123.9	3	45.2	1,116	60.0	174	487.6	2,568	102.9
California	147	104.6	2,451	49.3	11,457	606.2	26,524	221.3	108	89.1	26,350	202.2	2,769	368.5	69,811	212.3
Colorado	33	108.1	50	32.5	821	443.2	1,384	149.8	4	65.6	2,932	88.2	155	180.6	5,379	114.2
Connecticut	6	97.3	48	34.3	2,087	689.9	2,236	503.6	6	577.5	1,794	84.4	170	414.5	6,347	207.4
Delaware	2	76.7	3	9.5	1,186	691.2	168	259.4	1	374.5	562	106.6	79	580.7	2,001	246.6
District of Columbia	6	477.7	32	119.1	5,570	2,105.0	571	953.4	2	668.9	946	406.7	437	3,886.9	7,565	1,267.6
Florida	28	59.4	239	47.0	28,180	1,061.7	13,018	294.3	14	124.7	16,090	159.3	1,628	723.5	59,198	329.4
Georgia	8	39.1	99	27.6	18,271	685.1	1,967	272.0	5	98.2	4,799	101.3	1,581	1,354.4	26,730	309.8
Hawaii	0	0.0	223	47.5	76	326.3	171	162.7	136	123.2	675	241.6	165	79.5	1,446	120.7
Idaho	5	32.3	2	9.3	40	421.9	99	63.4	1	41.4	392	33.4	27	117.5	566	40.4
Illinois	8	48.1	206	33.8	8,150	548.2	3,660	217.7	7	238.9	4,513	66.3	1,119	865.5	17,663	164.6
Indiana	4	30.3	86	67.0	1,947	388.5	559	167.1	0	0.0	2,736	61.0	238	325.3	5,570	100.5
Iowa	3	40.4	22	33.0	301	346.8	148	110.4	0	0.0	934	40.8	78	258.5	1,486	56.8
Kansas	3	15.4	17	23.1	354	261.6	277	111.0	0	0.0	807	43.1	79	169.3	1,537	64.1
Kentucky	3	36.9	19	34.0	1,103	374.0	285	244.2	0	0.0	1,948	60.8	158	334.7	3,516	94.3
Louisiana	12	47.8	24	35.0	7,142	589.4	528	294.0	3	197.0	2,544	108.7	216	521.5	10,470	270.6
Maine	3	41.6	5	35.7	94	636.9	58	341.5	0	0.0	608	55.8	25	168.9	793	68.5
Maryland	4	31.7	91	27.4	12,117	809.8	1,253	279.5	1	40.1	2,004	74.9	1,698	1,849.9	17,168	339.3
Massachusetts	15	143.4	209	52.3	3,476	856.8	3,096	491.6	2	85.6	4,267	97.7	203	249.3	11,269	191.0
Michigan	11	23.1	46	16.9	4,452	395.6	468	124.5	2	88.6	2,705	41.8	317	224.0	8,001	94.8
Minnesota	58	127.9	75	34.2	1,395	533.8	456	212.1	0	0.0	1,669	43.8	179	238.5	3,832	82.7
Mississippi	2	17.1	9	34.2	3,337	368.8	165	234.6	0	0.0	844	58.4	230	1,125.4	4,587	185.0
Missouri	6	26.8	39	37.2	2,752	479.7	389	208.7	4	68.3	2,869	69.2	257	321.2	6,316	123.4
Montana	19	39.6	1	12.6	10	226.8	23	77.2	1	156.0	270	34.7	20	112.1	344	38.8
Nebraska	10	82.8	20	50.8	298	421.1	176	119.9	1	108.6	518	40.5	35	164.4	1,058	67.3
Nevada	24	111.1	132	61.1	1,129	522.9	1,236	189.7	12	78.0	1,895	146.4	189	288.0	4,617	186.1
New Hampshire	0	0.0	4	12.1	77	519.1	91	237.8	0	0.0	398	37.3	35	249.2	605	51.7
New Jersey	5	46.5	151	21.0	7,915	823.7	5,229	371.0	1	40.0	3,254	75.5	1,425	1,614.7	17,982	239.8
New Mexico	131	88.2	6	21.5	85	262.4	886	109.2	1	83.8	712	101.6	62	279.4	1,883	107.9
New York	28	57.5	838	57.7	27,335	1,138.0	26,750	898.7	5	67.9	11,839	124.3	6,028	2,663.8	72,844	437.8
North Carolina	72	74.9	57	22.8	8,569	469.2	1,180	173.0	4	75.7	3,260	57.7	670	554.9	13,812	160.0
North Dakota	11	38.8	2	19.7	72	419.9	12	62.1	0	0.0	85	15.8	9	100.4	191	30.7

Table 29. Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2017—United States and 6 dependent areas (cont)

Area of residence	American Indian/ Alaska Native		Asian ^a		Black/African American		Hispanic/Latino ^b		Native Hawaiian/ Other Pacific Islander		White		Multiple races		Total ^c	
	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d	No.	Rate ^d
Ohio	5	25.7	37	16.3	4,462	378.5	753	232.1	0	0.0	4,555	57.6	537	361.8	10,350	105.5
Oklahoma	156	59.6	32	43.2	653	276.4	323	109.6	4	90.8	1,600	72.1	182	122.2	2,950	91.1
Oregon	32	82.5	69	41.8	266	415.0	564	141.2	10	73.9	2,838	103.4	112	119.8	3,891	110.6
Pennsylvania	12	76.8	128	33.9	9,319	822.5	3,298	472.8	9	281.6	5,654	66.2	1,013	780.8	19,433	178.2
Rhode Island	3	81.3	17	54.4	332	643.2	413	330.7	1	183.5	620	90.6	39	267.0	1,425	156.4
South Carolina	6	37.7	22	31.1	6,247	563.4	482	233.7	2	79.0	1,978	71.3	271	536.1	9,008	212.9
South Dakota	39	74.3	2	17.9	58	427.3	20	87.3	1	284.9	121	20.1	10	91.6	251	35.2
Tennessee	4	24.3	34	33.9	4,413	481.0	479	188.8	2	70.8	2,946	69.0	354	498.9	8,232	146.2
Texas	16	20.2	357	31.0	15,630	566.5	15,483	182.0	5	25.8	11,069	108.2	2,154	818.7	44,715	194.3
Utah	9	38.7	27	41.2	121	454.8	340	108.1	3	13.2	858	44.3	33	84.4	1,391	57.2
Vermont	0	0.0	6	59.3	36	573.5	33	339.2	0	0.0	279	55.0	17	218.7	371	68.3
Virginia	6	30.5	135	28.5	5,799	429.5	1,046	174.3	3	58.0	2,865	63.2	531	376.8	10,385	145.8
Washington	76	97.4	220	39.0	1,064	456.2	1,110	163.1	29	69.8	4,018	90.7	525	262.1	7,047	113.2
West Virginia	0	0.0	2	15.2	190	353.7	51	230.0	0	0.0	688	47.7	64	342.7	995	64.0
Wisconsin	11	26.7	31	23.1	1,075	375.3	467	165.2	0	0.0	1,329	32.6	116	199.6	3,029	62.1
Wyoming	7	75.3	0	0.0	6	112.8	35	82.0	0	0.0	122	29.7	7	107.1	177	36.9
Subtotal	1,472	75.2	6,433	41.2	215,134	645.3	120,780	267.7	405	86.1	153,293	89.4	27,065	595.5	524,622	192.5
U.S. dependent areas^e																
American Samoa	0	—	0	—	0	—	0	—	1	—	0	—	1	—	2	5.2
Guam	0	—	17	—	1	—	1	—	11	—	3	—	5	—	38	30.0
Northern Mariana Islands	0	—	3	—	0	—	0	—	4	—	1	—	1	—	9	22.3
Puerto Rico	1	—	0	—	8	—	8,567	—	0	—	9	—	0	—	8,585	297.6
Republic of Palau	0	—	1	—	0	—	0	—	4	—	0	—	0	—	5	27.8
U.S. Virgin Islands	0	—	1	—	155	—	110	—	0	—	25	—	4	—	295	334.9
Subtotal	1	—	22	—	164	—	8,678	—	20	—	38	—	11	—	8,934	279.5
Total	1,473	—	6,455	—	215,298	—	129,458	—	425	—	153,331	—	27,076	—	533,556	193.6

Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address).

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^a Includes Asian/Pacific Islander legacy cases (see Technical Notes).

^b Hispanics/Latinos can be of any race.

^c Includes persons whose race/ethnicity is unknown.

^d Rates are per 100,000 population.

^e Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.

Table 30. Diagnoses of HIV infection, 2018, and persons living with diagnosed HIV infection (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico

MSA of residence	Diagnosis, 2018 ^a			Prevalence of diagnosed HIV infection, year-end 2017 ^b	
	No.	Rate ^c	Rank ^d	No.	Rate ^c
Akron, OH	52	7.4	73	989	140.4
Albany–Schenectady–Troy, NY	52	5.9	86	2,140	242.6
Albuquerque, NM	55	6.0	82	1,729	189.4
Allentown–Bethlehem–Easton, PA–NJ	48	5.7	88	803	95.8
Atlanta–Sandy Springs–Roswell, GA	1,695	28.5	2	34,451	586.5
Augusta–Richmond County, GA–SC	142	23.5	8	2,252	375.3
Austin–Round Rock, TX	295	13.6	32	6,019	284.6
Bakersfield, CA	153	17.1	16	1,586	178.4
Baltimore–Columbia–Towson, MD	451	16.1	20	15,854	566.5
Baton Rouge, LA	229	27.5	4	5,128	617.0
Birmingham–Hoover, AL	133	11.5	42	4,178	363.4
Boise City, ID	19	2.6	104	249	35.1
Boston–Cambridge–Newton, MA–NH ^e	481	9.9	58	14,080	290.6
Boston Division	256	12.6	—	8,103	401.6
Cambridge Division	220	9.1	—	5,692	238.1
Bridgeport–Stamford–Norwalk, CT	51	5.4	93	2,628	278.6
Buffalo–Cheektowaga–Niagara Falls, NY	53	4.7	99	2,526	223.6
Cape Coral–Fort Myers, FL	76	10.1	56	2,146	290.2
Charleston–North Charleston, SC	133	16.9	17	2,536	327.2
Charlotte–Concord–Gastonia, NC–SC	371	14.4	26	8,225	325.8
Chattanooga, TN–GA	58	10.3	55	1,182	212.6
Chicago–Naperville–Elgin, IL–IN–WI	1,207	12.7	37	29,061	305.2
Chicago Division	1,062	14.6	—	26,494	362.4
Elgin Division	36	5.6	—	421	66.1
Gary Division	61	8.7	—	1,190	169.8
Lake County Division	48	5.5	—	956	109.7
Cincinnati, OH–KY–IN	283	12.9	36	4,231	194.1
Cleveland–Elyria, OH	174	8.5	68	5,357	260.2
Colorado Springs, CO	50	6.8	78	887	122.3
Columbia, SC	144	17.3	15	4,064	492.5
Columbus, OH	240	11.4	44	5,653	271.5
Dallas–Fort Worth–Arlington, TX	1,318	17.5	14	27,179	366.9
Dallas Division	1,022	20.4	—	21,192	431.0
Fort Worth Division	296	11.7	—	5,987	240.3
Dayton, OH	79	9.8	59	1,621	201.7
Deltona–Daytona Beach–Ormond Beach, FL	91	13.8	30	1,877	289.6
Denver–Aurora–Lakewood, CO	270	9.2	63	9,307	321.7
Des Moines–West Des Moines, IA	37	5.6	90	847	131.3
Detroit–Warren–Dearborn, MI	472	10.9	47	9,604	222.2
Detroit Division	299	17.0	—	6,441	366.7
Warren Division	173	6.7	—	3,163	123.3
Durham–Chapel Hill, NC	78	13.6	33	2,144	378.5
El Paso, TX	140	16.6	18	2,135	252.6
Fayetteville–Springdale–Rogers, AR–MO	26	4.7	98	618	114.8
Fresno, CA	108	10.9	49	1,914	194.0
Grand Rapids–Wyoming, MI	50	4.7	100	1,189	112.1
Greensboro–High Point, NC	121	15.8	22	2,735	358.2
Greenville–Anderson–Mauldin, SC	99	10.9	46	1,982	221.3
Harrisburg–Carlisle, PA	40	7.0	77	579	101.4
Hartford–West Hartford–East Hartford, CT	99	8.2	70	3,383	280.3
Honolulu (Urban), HI	53	5.4	92	1,570	159.2

Table 30. Diagnoses of HIV infection, 2018, and persons living with diagnosed HIV infection (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, 2018 ^a			Prevalence of diagnosed HIV infection, year-end 2017 ^b	
	No.	Rate ^c	Rank ^d	No.	Rate ^c
Houston–The Woodlands–Sugar Land, TX	1,438	20.6	10	29,517	427.4
Indianapolis–Carmel–Anderson, IN	253	12.3	39	5,605	276.6
Jackson, MS	137	23.6	7	3,282	564.4
Jacksonville, FL	325	21.2	9	6,914	459.5
Kansas City, MO–KS	204	9.5	61	4,691	220.5
Knoxville, TN	65	7.4	74	1,270	145.0
Lakeland–Winter Haven, FL	109	15.4	23	2,335	340.5
Lancaster, PA	16	2.9	103	268	49.5
Las Vegas–Henderson–Paradise, NV	455	20.4	11	8,087	370.4
Lexington–Fayette, KY	59	11.4	43	1,097	214.0
Little Rock–North Little Rock–Conway, AR	133	17.9	12	2,252	305.2
Los Angeles–Long Beach–Anaheim, CA	1,824	13.7	31	55,265	415.6
Anaheim Division	285	8.9	—	6,788	213.5
Los Angeles Division	1,539	15.2	—	48,477	479.1
Louisville/Jefferson County, KY–IN	186	14.3	27	3,657	282.9
Madison, WI	30	4.5	101	719	109.8
McAllen–Edinburg–Mission, TX	90	10.4	53	1,327	154.6
Memphis, TN–MS–AR	375	27.8	3	7,058	523.8
Miami–Fort Lauderdale–West Palm Beach, FL	2,130	34.4	1	53,846	875.6
Fort Lauderdale Division	624	32.0	—	19,383	1,002.0
Miami Division	1,216	44.0	—	26,486	964.9
West Palm Beach Division	290	19.5	—	7,977	542.5
Milwaukee–Waukesha–West Allis, WI	123	7.8	72	3,014	191.3
Minneapolis–St. Paul–Bloomington, MN–WI	226	6.2	81	7,072	196.8
Modesto, CA	59	10.7	51	742	136.1
Nashville–Davidson–Murfreesboro–Franklin, TN	202	10.5	52	5,105	268.6
New Haven–Milford, CT	77	9.0	65	3,295	384.1
New Orleans–Metairie, LA	313	24.6	6	7,807	614.5
New York–Newark–Jersey City, NY–NJ–PA ^e	3,006	15.0	24	137,723	688.7
Nassau County Division	188	6.6	—	6,044	212.7
New York Division	2,395	16.8	—	117,122	820.9
Newark Division	406	16.2	—	13,505	540.8
North Port–Sarasota–Bradenton, FL	70	8.5	67	1,972	244.9
Ogden–Clearfield, UT	15	2.2	105	361	54.3
Oklahoma City, OK	111	7.9	71	2,773	200.5
Omaha–Council Bluffs, NE–IA	50	5.3	94	448	48.1
Orlando–Kissimmee–Sanford, FL	703	27.3	5	11,794	469.3
Oxnard–Thousand Oaks–Ventura, CA	50	5.9	87	1,040	122.2
Palm Bay–Melbourne–Titusville, FL	65	10.9	48	1,559	265.0
Philadelphia–Camden–Wilmington, PA–NJ–DE–MD	725	11.9	41	23,878	392.8
Camden Division	101	8.1	—	2,892	232.8
Montgomery County Division	77	3.9	—	915	46.4
Philadelphia Division	475	22.1	—	17,707	826.0
Wilmington Division	72	9.9	—	2,364	327.5
Phoenix–Mesa–Scottsdale, AZ	610	12.6	38	11,915	250.2
Pittsburgh, PA	116	5.0	96	1,326	56.9
Portland–South Portland, ME	9	1.7	107	852	160.1
Portland–Vancouver–Hillsboro, OR–WA	178	7.2	76	5,375	218.8
Providence–Warwick, RI–MA	117	7.2	75	3,701	228.9
Provo–Orem, UT	13	2.1	106	194	31.4

Table 30. Diagnoses of HIV infection, 2018, and persons living with diagnosed HIV infection (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, 2018 ^a			Prevalence of diagnosed HIV infection, year-end 2017 ^b	
	No.	Rate ^c	Rank ^d	No.	Rate ^c
Raleigh, NC	131	9.6	60	3,761	281.9
Richmond, VA	207	15.8	21	3,165	244.8
Riverside–San Bernardino–Ontario, CA	498	10.8	50	12,633	276.4
Rochester, NY	59	5.5	91	2,913	271.8
Sacramento–Roseville–Arden–Arcade, CA	119	5.1	95	4,968	214.1
St. Louis, MO–IL	255	9.1	64	6,997	249.4
Salt Lake City, UT	77	6.3	80	1,921	159.4
San Antonio–New Braunfels, TX	361	14.3	28	6,675	269.8
San Diego–Carlsbad, CA	346	10.3	54	12,973	390.1
San Francisco–Oakland–Hayward, CA ^e	626	13.2	34	23,167	491.8
Oakland Division	308	10.9	—	8,408	300.0
San Francisco Division	297	18.0	—	13,984	848.6
San Jose–Sunnyvale–Santa Clara, CA	167	8.4	69	3,170	159.0
San Juan–Carolina–Caguas, PR	330	16.3	19	8,826	419.4
Scranton–Wilkes-Barre–Hazleton, PA	33	5.9	83	470	84.6
Seattle–Tacoma–Bellevue, WA	395	10.0	57	9,307	239.6
Seattle Division	334	11.0	—	7,902	262.8
Tacoma Division	61	6.8	—	1,405	160.2
Spokane–Spokane Valley, WA	22	3.8	102	623	110.5
Springfield, MA	71	11.2	45	2,129	338.2
Stockton–Lodi, CA	65	8.6	66	1,281	172.5
Syracuse, NY	37	5.7	89	1,267	194.6
Tampa–St. Petersburg–Clearwater, FL	563	17.9	13	12,642	409.0
Toledo, OH	56	9.3	62	1,018	168.6
Tucson, AZ	125	12.0	40	2,509	244.2
Tulsa, OK	59	5.9	85	1,895	191.1
Virginia Beach–Norfolk–Newport News, VA–NC	243	14.1	29	5,711	331.1
Washington–Arlington–Alexandria, DC–VA–MD–WV	934	14.9	25	30,372	489.9
Silver Spring Division	151	11.5	—	3,744	288.2
Washington Division	783	15.8	—	26,628	543.3
Wichita, KS	43	6.7	79	900	139.5
Winston-Salem, NC	88	13.1	35	1,870	280.5
Worcester, MA–CT	46	4.9	97	2,073	220.0
Youngstown–Warren–Boardman, OH–PA	32	5.9	84	755	139.3
Subtotal for MSAs (population of ≥500,000)	30,381	13.5	—	811,765	363.7
Metropolitan areas (population of 50,000–499,999)	4,805	8.1	—	103,331	174.4
Nonmetropolitan areas	2,363	5.1	—	56,046	121.7
Total^f	37,815	11.4	—	1,019,757	310.5

Abbreviation: MSA, metropolitan statistical area.

Note. Because of the lack of U.S. census information for all U.S. dependent areas, table includes data for only the United States and Puerto Rico.

Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

MSA definitions for this report can be found at <http://www.census.gov/programs-surveys/metro-micro.html>.

^a Data are based on residence at time of diagnosis of HIV infection.

^b Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^c Rates are per 100,000 population.

^d Based on rate.

^e Counts of diagnoses of HIV infection for the metropolitan divisions do not sum to the MSA total. MSA total includes data from 1 metropolitan division with population of <500,000.

^f Includes persons whose county of residence is unknown.

Table 31. Stage 3 (AIDS), 2018 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico

MSA of residence	Diagnosis, 2018 ^b			Diagnosis, cumulative ^{a,b}			Prevalence of stage 3 (AIDS), year-end 2017 ^c	
	No.	Rate ^d	Rank ^e	Adults or adolescents No.	Children No.	Total No.	No.	Rate ^d
Akron, OH	14	2.0	96	1,006	1	1,007	430	61.0
Albany–Schenectady–Troy, NY	35	4.0	64	2,670	25	2,695	1,242	140.8
Albuquerque, NM	26	2.8	83	1,886	4	1,890	955	104.6
Allentown–Bethlehem–Easton, PA–NJ	24	2.8	81	1,802	18	1,820	438	52.3
Atlanta–Sandy Springs–Roswell, GA	784	13.2	4	35,505	153	35,658	17,504	298.0
Augusta–Richmond County, GA–SC	53	8.8	13	2,808	26	2,834	1,196	199.3
Austin–Round Rock, TX	111	5.1	43	6,583	26	6,609	3,046	144.0
Bakersfield, CA	49	5.5	36	2,195	9	2,204	854	96.1
Baltimore–Columbia–Towson, MD	263	9.4	9	26,355	229	26,584	8,479	303.0
Baton Rouge, LA	78	9.4	10	5,970	26	5,996	2,688	323.4
Birmingham–Hoover, AL	80	6.9	24	3,740	25	3,765	1,732	150.6
Boise City, ID	6	0.8	106	463	0	463	89	12.5
Boston–Cambridge–Newton, MA–NH ^f	202	4.1	60	17,517	167	17,684	7,620	157.3
Boston Division	111	5.5	—	10,807	98	10,905	4,477	221.9
Cambridge Division	87	3.6	—	6,319	68	6,387	3,004	125.7
Bridgeport–Stamford–Norwalk, CT	38	4.0	62	4,302	57	4,359	1,568	166.2
Buffalo–Cheektowaga–Niagara Falls, NY	29	2.6	89	3,082	20	3,102	1,297	114.8
Cape Coral–Fort Myers, FL	42	5.6	31	2,377	26	2,403	1,246	168.5
Charleston–North Charleston, SC	64	8.1	16	2,896	25	2,921	1,295	167.1
Charlotte–Concord–Gastonia, NC–SC	96	3.7	68	6,361	30	6,391	3,578	141.7
Chattanooga, TN–GA	22	3.9	65	1,389	3	1,392	631	113.5
Chicago–Naperville–Elgin, IL–IN–WI	537	5.7	30	39,680	265	39,945	14,430	151.6
Chicago Division	468	6.4	—	36,276	242	36,518	13,130	179.6
Elgin Division	11	1.7	—	830	9	839	214	33.6
Gary Division	32	4.6	—	1,492	9	1,501	584	83.3
Lake County Division	26	3.0	—	1,082	5	1,087	502	57.6
Cincinnati, OH–KY–IN	113	5.2	42	4,164	21	4,185	2,072	95.1
Cleveland–Elyria, OH	112	5.4	38	5,628	49	5,677	2,555	124.1
Colorado Springs, CO	21	2.8	82	777	5	782	386	53.2
Columbia, SC	93	11.2	7	4,804	25	4,829	2,205	267.2
Columbus, OH	112	5.3	40	5,091	25	5,116	2,513	120.7

Table 31. Stage 3 (AIDS), 2018 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, 2018 ^b			Diagnosis, cumulative ^{a,b}			Prevalence of stage 3 (AIDS), year-end 2017 ^c	
	No.	Rate ^d	Rank ^e	Adults or adolescents No.	Children No.	Total No.	No.	Rate ^d
Dallas–Fort Worth–Arlington, TX	536	7.1	23	28,830	66	28,896	13,578	183.3
Dallas Division	412	8.2	—	22,742	39	22,781	10,571	215.0
Fort Worth Division	124	4.9	—	6,088	27	6,115	3,007	120.7
Dayton, OH	37	4.6	53	1,706	14	1,720	814	101.3
Deltona–Daytona Beach–Ormond Beach, FL	49	7.4	20	2,184	18	2,202	1,091	168.3
Denver–Aurora–Lakewood, CO	135	4.6	52	8,883	24	8,907	3,918	135.4
Des Moines–West Des Moines, IA	13	2.0	97	806	4	810	463	71.8
Detroit–Warren–Dearborn, MI	212	4.9	47	14,077	79	14,156	4,919	113.8
Detroit Division	129	7.4	—	10,930	62	10,992	3,368	191.8
Warren Division	83	3.2	—	3,147	17	3,164	1,551	60.5
Durham–Chapel Hill, NC	35	6.1	28	1,736	10	1,746	875	154.5
El Paso, TX	34	4.0	63	2,233	10	2,243	1,143	135.2
Fayetteville–Springdale–Rogers, AR–MO	10	1.8	99	537	6	543	302	56.1
Fresno, CA	46	4.6	51	2,283	11	2,294	1,040	105.4
Grand Rapids–Wyoming, MI	28	2.6	87	1,270	6	1,276	586	55.3
Greensboro–High Point, NC	35	4.6	54	1,886	20	1,906	986	129.1
Greenville–Anderson–Mauldin, SC	49	5.4	39	2,195	7	2,202	1,069	119.4
Harrisburg–Carlisle, PA	18	3.1	75	1,686	9	1,695	288	50.4
Hartford–West Hartford–East Hartford, CT	45	3.7	69	5,941	46	5,987	2,083	172.6
Honolulu (Urban), HI	17	1.7	100	2,432	14	2,446	885	89.7
Houston–The Woodlands–Sugar Land, TX	635	9.1	11	36,252	182	36,434	15,193	220.0
Indianapolis–Carmel–Anderson, IN	120	5.9	29	5,684	28	5,712	2,739	135.1
Jackson, MS	78	13.4	3	3,794	31	3,825	1,585	272.5
Jacksonville, FL	146	9.5	8	8,651	79	8,730	3,824	254.1
Kansas City, MO–KS	104	4.9	48	6,164	17	6,181	2,510	118.0
Knoxville, TN	26	2.9	78	1,387	8	1,395	626	71.5
Lakeland–Winter Haven, FL	52	7.3	21	2,667	24	2,691	1,342	195.7
Lancaster, PA	7	1.3	102	931	23	954	143	26.4
Las Vegas–Henderson–Paradise, NV	180	8.1	18	6,923	28	6,951	3,839	175.8
Lexington–Fayette, KY	19	3.7	70	1,070	1	1,071	549	107.1
Little Rock–North Little Rock–Conway, AR	51	6.9	25	2,039	15	2,054	984	133.3

Table 31. Stage 3 (AIDS), 2018 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico (*cont*)

MSA of residence	Diagnosis, 2018 ^b			Diagnosis, cumulative ^{a,b}			Prevalence of stage 3 (AIDS), year-end 2017 ^c	
				Adults or adolescents	Children	Total		
	No.	Rate ^d	Rank ^e	No.	No.	No.	No.	Rate ^d
Los Angeles—Long Beach—Anaheim, CA	725	5.5	37	73,585	305	73,890	28,863	217.0
Anaheim Division	117	3.7	—	8,713	46	8,759	3,483	109.5
Los Angeles Division	608	6.0	—	64,872	259	65,131	25,380	250.8
Louisville/Jefferson County, KY—IN	72	5.5	32	3,467	30	3,497	1,680	129.9
Madison, WI	8	1.2	103	704	5	709	317	48.4
McAllen—Edinburg—Mission, TX	39	4.5	55	1,208	13	1,221	712	83.0
Memphis, TN—MS—AR	200	14.8	1	7,791	24	7,815	3,351	248.7
Miami—Fort Lauderdale—West Palm Beach, FL	859	13.9	2	71,019	1,011	72,030	27,967	454.8
Fort Lauderdale Division	291	14.9	—	21,766	266	22,032	10,132	523.8
Miami Division	437	15.8	—	37,140	514	37,654	13,119	477.9
West Palm Beach Division	131	8.8	—	12,113	231	12,344	4,716	320.7
Milwaukee—Waukesha—West Allis, WI	46	2.9	79	3,407	20	3,427	1,471	93.4
Minneapolis—St. Paul—Bloomington, MN—WI	96	2.6	86	6,162	24	6,186	3,191	88.8
Modesto, CA	21	3.8	66	940	6	946	458	84.0
Nashville—Davidson—Murfreesboro—Franklin, TN	69	3.6	72	5,357	26	5,383	2,490	131.0
New Haven—Milford, CT	43	5.0	45	5,176	74	5,250	2,092	243.9
New Orleans—Metairie, LA	164	12.9	5	11,641	78	11,719	4,024	316.7
New York—Newark—Jersey City, NY—NJ—PA ^f	1,617	8.1	17	228,974	2,998	231,972	77,985	389.9
Nassau County Division	100	3.5	—	9,570	117	9,687	3,486	122.7
New York Division	1,276	9.0	—	192,669	2,498	195,167	67,070	470.1
Newark Division	232	9.3	—	24,792	369	25,161	6,807	272.6
North Port—Sarasota—Bradenton, FL	31	3.8	67	2,541	29	2,570	1,109	137.7
Ogden—Clearfield, UT	7	1.0	105	345	4	349	189	28.4
Oklahoma City, OK	71	5.1	44	3,217	4	3,221	1,336	96.6
Omaha—Council Bluffs, NE—IA	26	2.8	85	1,469	5	1,474	194	20.8
Orlando—Kissimmee—Sanford, FL	297	11.5	6	12,518	96	12,614	6,089	242.3
Oxnard—Thousand Oaks—Ventura, CA	9	1.1	104	1,303	5	1,308	547	64.3
Palm Bay—Melbourne—Titusville, FL	33	5.5	33	1,912	12	1,924	911	154.9

Table 31. Stage 3 (AIDS), 2018 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico (cont)

MSA of residence	Diagnosis, 2018 ^b			Diagnosis, cumulative ^{a,b}			Prevalence of stage 3 (AIDS), year-end 2017 ^c	
	No.	Rate ^d	Rank ^e	Adults or adolescents No.	Children No.	Total No.	No.	Rate ^d
Philadelphia–Camden–Wilmington, PA–NJ–DE–MD	334	5.5	34	35,821	319	36,140	12,986	213.6
Camden Division	40	3.2	—	3,960	43	4,003	1,397	112.4
Montgomery County Division	44	2.2	—	2,982	12	2,994	458	23.2
Philadelphia Division	209	9.7	—	25,109	239	25,348	9,727	453.7
Wilmington Division	41	5.7	—	3,770	25	3,795	1,404	194.5
Phoenix–Mesa–Scottsdale, AZ	229	4.7	49	10,712	35	10,747	5,500	115.5
Pittsburgh, PA	58	2.5	91	4,185	22	4,207	683	29.3
Portland–South Portland, ME	10	1.9	98	764	2	766	411	77.2
Portland–Vancouver–Hillsboro, OR–WA	70	2.8	84	6,165	9	6,174	2,940	119.7
Providence–Warwick, RI–MA	56	3.5	73	4,891	44	4,935	2,104	130.1
Provo–Orem, UT	3	0.5	107	166	3	169	90	14.6
Raleigh, NC	71	5.2	41	3,238	20	3,258	1,763	132.1
Richmond, VA	102	7.8	19	4,696	35	4,731	1,367	105.7
Riverside–San Bernardino–Ontario, CA	201	4.3	58	11,533	63	11,596	7,195	157.4
Rochester, NY	32	3.0	77	3,733	17	3,750	1,647	153.7
Sacramento–Roseville–Arden–Arcade, CA	71	3.0	76	5,249	31	5,280	2,598	112.0
St. Louis, MO–IL	126	4.5	56	8,042	44	8,086	3,418	121.8
Salt Lake City, UT	28	2.3	95	2,091	9	2,100	948	78.7
San Antonio–New Braunfels, TX	154	6.1	27	7,337	32	7,369	3,429	138.6
San Diego–Carlsbad, CA	155	4.6	50	16,043	72	16,115	6,986	210.1
San Francisco–Oakland–Hayward, CA ^f	237	5.0	46	46,446	103	46,549	13,212	280.5
Oakland Division	105	3.7	—	12,223	54	12,277	4,828	172.2
San Francisco Division	129	7.8	—	32,515	44	32,559	7,921	480.7
San Jose–Sunnyvale–Santa Clara, CA	58	2.9	80	4,953	17	4,970	1,839	92.2
San Juan–Carolina–Caguas, PR	129	6.4	26	25,091	280	25,371	4,394	208.8
Scranton–Wilkes-Barre–Hazleton, PA	14	2.5	90	743	7	750	248	44.6
Seattle–Tacoma–Bellevue, WA	141	3.6	71	11,492	27	11,519	4,802	123.6
Seattle Division	118	3.9	—	10,118	18	10,136	4,070	135.3
Tacoma Division	23	2.6	—	1,374	9	1,383	732	83.4
Spokane–Spokane Valley, WA	8	1.4	101	704	1	705	344	61.0
Springfield, MA	26	4.1	61	2,622	28	2,650	1,195	189.8
Stockton–Lodi, CA	33	4.4	57	1,550	15	1,565	699	94.1
Syracuse, NY	17	2.6	88	1,634	10	1,644	711	109.2

Table 31. Stage 3 (AIDS), 2018 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence), year-end 2017, by metropolitan statistical area of residence—United States and Puerto Rico (*cont*)

MSA of residence	Diagnosis, 2018 ^b			Diagnosis, cumulative ^{a,b}			Prevalence of stage 3 (AIDS), year-end 2017 ^c	
				Adults or adolescents	Children	Total		
	No.	Rate ^d	Rank ^e	No.	No.	No.	No.	Rate ^d
Tampa–St. Petersburg–Clearwater, FL	262	8.3	15	15,271	117	15,388	6,986	226.0
Toledo, OH	33	5.5	35	1,137	15	1,152	490	81.1
Tucson, AZ	44	4.2	59	2,600	12	2,612	1,280	124.6
Tulsa, OK	24	2.4	93	2,087	12	2,099	951	95.9
Virginia Beach–Norfolk–Newport News, VA–NC	123	7.1	22	6,554	65	6,619	2,382	138.1
Washington–Arlington–Alexandria, DC–VA–MD–WV	538	8.6	14	40,185	330	40,515	15,284	246.5
Silver Spring Division	68	5.2	—	4,092	26	4,118	1,814	139.6
Washington Division	470	9.5	—	36,093	304	36,397	13,470	274.9
Wichita, KS	21	3.3	74	1,080	2	1,082	474	73.5
Winston-Salem, NC	60	8.9	12	1,519	11	1,530	775	116.2
Worcester, MA–CT	23	2.4	92	2,600	22	2,622	1,235	131.1
Youngstown–Warren–Boardman, OH–PA	13	2.4	94	790	0	790	354	65.3
Subtotal for MSAs (population of ≥500,000)	13,658	6.1	—	1,079,758	8,640	1,088,398	424,119	190.0
Metropolitan areas (population of 50,000–499,999)	2,218	3.7	—	127,228	862	128,090	53,682	90.6
Nonmetropolitan areas	1,256	2.7	—	67,822	441	68,263	29,811	64.8
Total^g	17,219	5.2	—	1,279,949	9,988	1,289,937	533,489	162.4

Abbreviation: MSA, metropolitan statistical area.

Note. Because of the lack of U.S. census information for all U.S. dependent areas, table includes data for only the United States and Puerto Rico.

Data for the year 2018 are considered preliminary because they are based on a 6-month reporting delay.

Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

MSA definitions for this report can be found at <http://www.census.gov/programs-surveys/metro-micro.html>.

^a From the beginning of the epidemic through 2018.

^b Data are based on residence at time of diagnosis of HIV infection.

^c Data are based on address of residence at the end of the specified year (i.e., most recent known address).

^d Rates are per 100,000 population.

^e Based on rate.

^f Counts of stage 3 (AIDS) classifications for the metropolitan divisions do not sum to the MSA total. MSA total includes data from 1 metropolitan division with population of <500,000.

^g Includes persons whose county of residence is unknown.

Web Addresses for Reports of State and Local HIV Surveillance

Alabama	http://www.alabamapublichealth.gov/hiv/publications.html
Alaska	http://epibulletins.dhss.alaska.gov/Bulletin/DisplayClassificationBulletins/46
Arizona	http://www.azdhs.gov/phs/edc/odis/hiv-epidemiology/reports/index.php?pg=annual
Arkansas	https://www.healthy.arkansas.gov/programs-services/topics/hiv-aids-sti-surveillance
California	https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OAsre.aspx
Chicago	https://www.cityofchicago.org/city/en/depts/cdph/provdrs/health_data_and_reports/svcs/get_sti_hiv_datainchicago.html
Colorado	https://www.colorado.gov/pacific/cdphe/sti-hiv-data
Connecticut	https://portal.ct.gov/DPH/AIDS--Chronic-Diseases/Surveillance/Connecticut-HIV-Statistics
Delaware	http://www.dhss.delaware.gov/dhss/dph/epi/disstatshiv.html
District of Columbia	https://dchealth.dc.gov/service/hiv-reports-and-publications
Florida	http://www.floridahealth.gov/diseases-and-conditions/aids/surveillance/index.html
Georgia	https://dph.georgia.gov/data-fact-sheet-summaries#SurveillanceSummaries
Guam	http://dphss.guam.gov/hiv-surveillance-program/
Hawaii	http://health.hawaii.gov/harmreduction/hiv-aids/data-and-statistics/
Houston	http://www.houstontx.gov/health/HIV-STD/
Idaho	http://healthandwelfare.idaho.gov/Health/FamilyPlanningSTDHIV/STDStatistics/tabid/393/Default.aspx
Illinois	http://dph.illinois.gov/topics-services/diseases-and-conditions/hiv-aids/hiv-surveillance/update-reports
Indiana	http://www.in.gov/isdh/23266.htm
Iowa	http://idph.iowa.gov/hivstdhep/hiv/data
Kansas	http://www.kdheks.gov/sti_hiv/hiv_std_update.html
Kentucky	https://chfs.ky.gov/agencies/dph/dehp/hab/Pages/reportsstats.aspx
Los Angeles	http://publichealth.lacounty.gov/dhsp/Reports.htm
Louisiana	http://new.dhh.louisiana.gov/index.cfm/newsroom/category/63
Maine	https://www.maine.gov/dhhs/mecdc/infectious-disease/hiv-std/data/index.shtml
Maryland	http://phpa.dhmm.maryland.gov/OIDEOR/CHSE/Pages/statistics.aspx
Massachusetts	https://www.mass.gov/lists/hiv-aids-epidemiologic-profiles
Michigan	http://www.michigan.gov/mdch/0,4612,7-132-2940_2955_2982_46000_46003---,00.html
Minnesota	https://www.health.state.mn.us/diseases/hiv/stats/index.html
Mississippi	https://msdh.ms.gov/msdhsite/_static/14,0,150.html
Missouri	http://health.mo.gov/data/hivstdaids/data.php
Montana	https://dphhs.mt.gov/publichealth/cdepi/diseases/HIV_HCV
Nebraska	http://dhhs.ne.gov/Pages/HIV-Prevention.aspx
Nevada	http://dpbh.nv.gov/Programs/HIV-OPHIE/dta/Publications/HIV/AIDS_Surveillance_Program_(HIV-OPHIE)_-_Publications/
New Hampshire	http://www.dhhs.nh.gov/data/index.htm
New Jersey	http://www.nj.gov/health/hivstdtb/hiv-aids/statmap.shtml
New Mexico	http://nmhealth.org/data/infectious/20/
New York	http://www.health.state.ny.us/diseases/aids/statistics/index.htm
New York City	http://www1.nyc.gov/site/doh/data/data-sets/hiv-aids-surveillance-and-epidemiology-reports.page
North Carolina	http://epi.publichealth.nc.gov/cd/stds/figures.html
North Dakota	https://www.ndhealth.gov/hiv/Data/
Ohio	https://odh.ohio.gov/wps/portal/gov/odh/know-our-programs/hiv-aids-surveillance-program/data-and-statistics
Oklahoma	https://www.ok.gov/health/Prevention_and_Preparedness/HIV_STD_Service/Fact_Sheets_-_OK_Data/
Oregon	http://public.health.oregon.gov/DiseasesConditions/CommunicableDisease/DiseaseSurveillanceData/HIVData/Pages/index.aspx
Pennsylvania	https://www.health.pa.gov/topics/programs/HIV/Pages/Annual-Summary.aspx
Philadelphia	http://www.phila.gov/health/AACO/AACODataResearch.html
Puerto Rico	http://www.salud.gov.pr/Estadisticas-Registros-y-Publicaciones/Pages/Publicaciones-sobre-la-salud.aspx
Rhode Island	http://health.ri.gov/publications/bytopic.php?parm=HIV
San Francisco	http://www.sfdph.org/dph/files/reports/default.asp
South Carolina	http://www.dhec.sc.gov/Health/DiseasesandConditions/InfectiousDiseases/HIVandSTDs/DataandReports/
South Dakota	http://doh.sd.gov/diseases/infectious/HIV-AIDS/Prevention.aspx
Tennessee	https://www.tn.gov/health/health-program-areas/statistics/health-data/hiv-data.html
Texas	http://www.dshs.state.tx.us/hivstd/reports/default.shtm
U.S. Virgin Islands	https://doh.vi.gov/programs/communicable-diseases
Utah	http://health.utah.gov/epi/diseases/hiv-aids/surveillance/index.html
Vermont	http://www.healthvermont.gov/immunizations-infectious-disease/hiv/surveillance
Virginia	http://www.vdh.virginia.gov/disease-prevention/disease-prevention/hiv-aids-sexually-transmitted-disease-std-hepatitis-reports/
Washington	http://www.doh.wa.gov/DataandStatisticalReports/DiseasesandChronicConditions/HIVAIDSData.aspx
West Virginia	https://oeps.wv.gov/hiv-aids/Pages/hiv-aids_data.aspx
Wisconsin	http://dhs.wisconsin.gov/aids-hiv/Stats/index.htm
Wyoming	https://health.wyo.gov/publichealth/communicable-disease-unit/hiv-aids-surveillance-program/

Note. Electronic reports are not available for the following areas: American Samoa and the Northern Mariana Islands.